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   I 
ABSTRACT 
Hepatitis C virus (HCV) is a global health problem with over 150 million 
individuals infected worldwide. Many of these patients will develop end-stage 
liver diseases, such as cirrhosis and hepatocellular carcinoma (HCC), and will 
require liver transplantation.  
HCV exists as a heterogeneous population in infected individuals, however, 
the processes which maintain this genetic complexity are unknown. Recent 
observations suggest that HCV transmits between hepatocytes via a cell-to-
cell route of infection, supporting a “demic” model of evolution where HCV 
diversity arises from independent evolution in small isolated hepatic 
populations.  
To investigate the distribution of HCV within the liver we sampled eight 
segments of the liver explant from 22 HCV infected subjects undergoing liver 
transplant and measured viral RNA burden and sequence diversity. 
Comparable HCV RNA levels were observed across all 8 samples from a 
single liver, however, between patients we observed a 100-fold range in the 
hepatic viral load that was independent of hepatic expression of anti-viral and 
pro-viral interferon stimulated genes (ISGs). Sequence analysis of the viral 
envelope E1E2 region, obtained from PCR generated single molecules or 
ultra-deep sequencing approaches, showed minimal evidence of genetic 
compartmentalisation between hepatic sites or between the liver and plasma. 
Modelling the HCV population structure in infected patients will have a major 
impact on our understanding of how HCV escapes host immune responses 
and anti-viral therapies.  
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IFI27   α-inducible protein (IFI) 27  
IFN   Interferon 
IRF   IFN regulatory factor  
ISRE   Interferon-stimulated response element 
ISG   Interferon stimulated gene 
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IU   International unit 
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qPCR   Quantitative PCR 
qRT-PCR  Real-Time qPCR 
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SGA   Single genome amplification 
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1.1 A brief introduction to viral hepatitis 
Epidemic jaundice was first mentioned in the Babylonian Talmud in the 5th 
century B.C. Since then epidemic jaundice has been recognised as an 
important military disease, especially linked to times of war, without anyone 
knowing the cause. In the 1930’s several doctors noticed an increase in the 
number of soldiers with hepatitis following yellow fever immunisation with 
glycerinated human lymph-node preparation. Often these incidents were 
blamed on other drugs being administrated and not on the human serum 
inoculum. However, accumulating transmission and epidemiology studies 
during the Second World War lead to the discovery of two different types of 
hepatitis caused by the ultra-filterable agents hepatitis type A (infectious) and 
type B (serum) (Krugman, 1976; MacCallum, 1972; Reuben, 2002). Several 
studies documented that hepatitis type A is transmitted through the faecal/oral 
transmission route and that hepatitis B is transferred via blood and blood 
products, making the later the source of hepatitis following immunisation 
(MacCallum and Bradley, 1944; Neefe et al., 1944).  
 
In 1965, Blumberg and Alter set out to investigate the immune-reactivity of 
plasma proteins, without any particular interest in viral hepatitis. During their 
experiments they discovered a unique protein in the serum of Australian 
aborigines, which was soon after named  “Australian antigen” (Au) (Blumberg 
   2 
et al., 1965). A few years later it was reported that the Au had a strong link to 
acute hepatitis and that the antigen in fact was the surface protein of what 
became known as the hepatitis B virus (HBsAg) (Dane et al., 1970; London et 
al., 1969; Prince, 1968). Screening of blood and blood products decreased the 
incidence of post-transfusion and immunisation associated hepatitis 
dramatically, however about 10% of patient having received HBsAg-negative 
blood-products were still developing hepatitis, suggesting that the individuals 
had contracted a non-A, non-B (nA/nB) viral hepatitis (Alter et al., 1975a; Alter 
et al., 1975b; Feinstone et al., 1975). 
 
1.2 Hepatitis C virus discovery 
Extensive research was carried out from the 1950’s throughout the 1980’s to 
identify the causative behind nA/nB viral hepatitis, but it wasn’t until the late 
1980’s that Houghton and colleagues at Chiron and Bradley at the Centre for 
Disease Control and Prevention made a breakthrough (Choo et al., 1989). 
These researchers performed a “blind” immune-screening of a cDNA 
expression library previously generated from total plasma DNA and RNA 
collected from nA/nB viral hepatitis infected chimpanzees with high viral titer 
(Bradley and Maynard, 1986). The library was screened against serum 
deriving from a patient with chronic nA/nB viral hepatitis with an unusually high 
serum alanine aminotransferase (ALT) level and from thousands of cDNA 
clones they identified and sequenced a single immuno-reactive clone, labelled 
as 5-1-1 (Choo et al., 1989). This 5-1-1 clone and subsequent overlapping 
clones encoded a positive single-stranded RNA molecule of about 10,000 
nucleotides that was closely related to the viral genomes of the Flavivridae 
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family members (Choo et al., 1991). The virus was named hepatitis C virus 
(HCV), following the alphabetical labelling system introduced by MacCallum in 
1944 (MacCallum and Bradley, 1944) and was classified within a separate 
genus (Hepacivirus) of the Flavivridae family.  
 
The origin of HCV is unclear; it could either have originated from a single 
emergence in humans followed by diversification or by several cross-species 
transmissions from a currently unidentified source. Recent identification of 
several HCV-like viruses in different species of wild rodents and bats strongly 
support the latter hypothesis (Drexler et al., 2013; Kapoor et al., 2013). In 
addition, a HCV homolog, later named non-primate hepacivirus (NPHV), has 
been identified in the respiratory tract of domesticated dogs (also called canine 
hepacivirus (CHV)) (Burbelo et al., 2012; Kapoor et al., 2011) and in plasma 
from horses (Lyons et al., 2012). Detailed phylogenetic investigation of the 
human and canine strains suggest that the HCV and CHV clades diverged 
within the past 500 - 1000 years, well after the domestication of canines. Close 
contact with dogs (and potentially horses (Lyons et al., 2012)) may therefore 
have played an important role in the emergence of the human hepacivirus, 
HCV (Kapoor et al., 2011).  
 
1.3 HCV epidemiology  
According to WHO 2013, approximately 150 million people are chronically 
infected with HCV worldwide and there are about 3 - 4 million new cases every 
year. The sero-prevalence varies for different geographical regions and the 
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latest estimates predict that approximately 4% of the populations in Central, 
East, South and Southeast Asia, North Africa and Middle East are infected, 
whereas 2% of the North America, Western and Central Europe populations 
are infected (Mohd Hanafiah et al., 2013; Sharma and Feld, 2014). The virus 
is commonly transmitted directly through blood or blood products and is often 
associated with injectable therapy and intra-venous drug-use (Chisari, 2005). 
Another, less considered, route is mother-to-child transmission (MTCT), which 
occurs in approximately 5% of cases and is the leading route for HCV infection 
in children (Abdel-Hady et al., 2011; Yeung and Roberts, 2010).  
 
HCV is divided into seven genotypes (1, 2, 3, 4, 5, 6 and 7), which differ by 
approximately 30 - 35% over the complete viral genome, corresponding to 
between 22 – 31 amino acids. Each of the six genotypes can further be 
divided into more closely related subtypes with 20 - 25% genetic differences 
(Bostan and Mahmood, 2010; Irshad et al., 2010; Simmonds, 1995, 2004). 
The geographic distribution varies for the genotypes; 1a, 1b and 3a are mainly 
found in Europe and North America, whereas genotypes 2, 4, 5 and 6 are in 
Central, East, South and Southeast Asia, North Africa and the Middle East 
(Bruggmann, 2014; Irshad et al., 2010; McOmish et al., 1994; Simmonds, 
1995, 2004). 
 
Most patients are unaware they have been infected and can be asymptomatic 
for decades until signs of liver damage appear (Sharma and Feld, 2014). Of 
the people infected about 70% will develop chronic infection, despite the 
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presence of a humoral and cellular immune response against the virus (Bowen 
and Walker, 2005a) (see section 1.6). Once chronic infection is established 
approximately 20% will develop cirrhosis and 2.5% hepatocellular carcinoma 
(HCC). Both of these conditions are linked with end-stage liver disease and 
these patients may require liver transplantation (Afdhal, 2004; Hoofnagle, 
2002; Sharma and Feld, 2014). Today, HCV related diseases are the leading 
indication for liver transplantation in the Western world. Following 
transplantation the new liver graft becomes re-infected by circulating virions in 
100% of the cases and the patient has an increased risk of requiring a second 
liver transplantation. HCV is therefore the biggest burden on the liver 
transplantation lists (Brown, 2005; Charlton et al., 2004).  
 
1.4 HCV in children 
Viral hepatitis is estimated to be the most important cause of liver diseases in 
children and affects between 0.05% and 5% of children worldwide 
(Schwimmer and Balistreri, 2000). Since the introduction of blood and blood 
product screening for HCV in the early 1990s, MTCT has become the leading 
course for paediatric HCV infection in developed countries (Mok et al., 2005). 
Dependent on the geographic area, about 0.1 to 8% of pregnant women are 
infected with HCV (Abdel-Hady et al., 2011; Arshad et al., 2011) and between 
5 to 10% of these will transmit the virus to their children (Resti et al., 1998; 
Yeung and Roberts, 2010). Mothers co-infected with HIV have a 5-10% higher 
risk of transmitting HCV (Marine-Barjoan et al., 2007; Thomas et al., 1998), 
but apart from HIV co-infection, associations between transmission rate and 
host / viral factors has proven controversial. Some studies claim an increased 
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risk of MTCT when the maternal viral loads are above 106 HCV RNA copies 
per ml (Lin et al., 1994b; Thomas et al., 1998), while others have shown that 
there is a broad overlap in viral loads between transmitting and non-
transmitting mothers (Gibb et al., 2000; Indolfi and Resti, 2009; Steininger et 
al., 2003). Furthermore, contradictory results have been found for vaginal 
delivery versus caesarean section (Boxall et al., 2007; Gibb et al., 2000; Inui et 
al., 2002; Zanetti et al., 1995) and there is currently no guideline for the mode 
of delivery for HCV positive mothers. In addition, small-scale studies have 
suggested that genotype 3 and 1 are more frequently transmitted (Gibb et al., 
2000; Zuccotti et al., 1995), however investigation of larger cohorts of infected 
children have suggested that the genotype is irrelevant for the transmission 
rate (Abdel-Hady et al., 2011).  
 
Spontaneous clearance rate in children is strongly dependent on the mode of 
infection. Children infected vertically have a clearance rate comparable with 
adults (25 – 30%), whereas children infected following blood transfusion have 
35% – 45% chance of spontaneously clearing the virus (Abdel-Hady et al., 
2011; Bortolotti et al., 2008; Iorio et al., 2005). Those children who progress to 
chronic infection will usually have a milder disease progression than adults, 
indicated by low serum ALT levels and minimum or mild histological evidence 
for liver fibrosis (Jonas, 2002; Kage et al., 1997; Murray et al., 2005). This is 
further supported by the observation that only 0.09% of all liver 
transplantations performed on children in North America are the result of HCV-
related liver damage (Mack et al., 2012).  
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1.5 Treatment and outcome for HCV infection: 
At the time of writing the standard-of-care HCV therapy consists of pegylated 
Interferon-α (PEG-IFN-α) and ribavirin for up to 48 weeks. This combined 
treatment will lead to a cure for more than half the patients, but the individual 
treatment outcome may depend on the infecting virus genotype; patients 
infected with genotype 1 will clear the virus in 40% to 64% of the cases, 
whereas those with genotype 2 and 3 infections have a 76% to 86% clearance 
rate following treatment (Davis et al., 2003; Di Bisceglie and Hoofnagle, 2002; 
Fried et al., 2002; Lawitz et al., 2013; McHutchison et al., 2009).  
 
In 2009, two independent studies reported an association between HCV 
genotype 1 treatment-response and polymorphisms on chromosome 19, at 
locations rs12979860 and rs8099917 (Ge et al., 2009; Tanaka et al., 2009). 
Interestingly, these sites are in close proximity to the cytokine IFN-γ gene 
(Interleukin (IL) 28-β) and frequently referred to as the IL28-β genotype. A 
cytosine at position rs12979860 predicts a higher chance (76%) of achieving 
sustained viral response (SVR) following anti-viral therapy for 24 weeks, 
compared to a non-cytosine (35%) (Tanaka et al., 2009). A thymine at position 
rs8099917 results in SVR for 80% of the patients compared to 35% for the 
patients with non-thymine genotypes (Ge et al., 2009). The exact mechanism 
of action for the IL28-β genotypes are not known, however reports have shown 
that the favourable IL28-β may be associated with higher IL28-β expression 
(Dill et al., 2011). Although the IL28-β genotype may be a reliable predictor for 
genotype 1 infected patients, it is less reliable for genotype 3a (Gupta et al., 
2014; Mangia et al., 2013) and has no association to treatment response for 
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genotype 2 patients (Rauch et al., 2010). Researchers have now turned their 
attention to the intra-hepatic specific gene expression, especially the intra-
hepatic interferon stimulated genes (ISGs) as better predictors of treatment 
response.  
 
ISGs are usually expressed in large quantities just a couple of days after 
experimental HCV infection of chimpanzees (Bigger et al., 2001) and acutely 
infected humans (Dill et al., 2012), demonstrating that HCV induces an innate 
immune response (see section 1.7). About half of chronically infected patients 
continue to have a high hepatic ISG expression during chronic infection, 
whereas others have no detectable expression (Chen et al., 2005; Dill et al., 
2011; Sarasin-Filipowicz et al., 2008). Administrating PEG-IFNα to patients 
with high levels of hepatic ISG mRNA will not further increase the expression 
levels and as a consequence these patients are less likely to respond to 
treatment than patients with low pre-treatment ISG levels (Chen et al., 2005; 
Dill et al., 2011; Honda et al., 2010; Sarasin-Filipowicz et al., 2008). Recently 
Dill et al. reported that the combined expression pattern of ISG15, α-inducible 
protein (IFI) 27 and radical S-adenosyl methionine domain containing (RSAD) 
2, together with the HIV-tat interactive protein (HTATIP) 2; a ubiquitously 
tumour suppressor gene, can accurately predict the treatment outcome to an 
error rate of 15% (Dill et al., 2011). These 4-gene classifiers were also 
reported to be a better predictor than the IL28-β genotype (Dill et al., 2011).  
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To this date, it is not fully understood why some patients have a higher ISG 
expression then others. Low intra-hepatic ISG expression has previously been 
associated with the favourable IL28-β genotype (Honda et al., 2010; Urban et 
al., 2010). In contrast, Dill et al. observed an association between the 
favourable IL28-β genotypes and high intra-hepatic IL28-β mRNA level, which 
may prime ISG expression (Dill et al., 2011). Other studies have reported 
correlations between high ISG expression and HCV genotype 1 (Broering et 
al., 2010; Sarasin-Filipowicz et al., 2008), which may explain why genotype 1 
patients are less likely to respond to treatment.  
 
Of note, the cellular origin of ISG expression may be important in predicting 
treatment outcome. Immunohistochemical staining for ISG15 and IFN-
regulated resistance GTP-binding protein (MxA) in needle biopsies prior to 
treatment has revealed a link between immune-positive Kupffer cells (liver 
recident macrophages) and treatment response, whereas expression by 
hepatocytes has been associated with non-responders (Chen et al., 2010; 
McGilvray et al., 2012).  
 
Researchers are now more than ever trying to find a more successful cure 
against HCV infection and a new generation of directly acting anti-viral (DAA) 
treatments are under development and in late stage clinical trials (Asselah and 
Marcellin, 2011; Scheel and Rice, 2013). These new DAA drugs are designed 
to directly inhibit the viral encoded NS3-NS4A protease, the multi-functional 
role of NS5A in viral replication and assembly and the NS5B RNA polymerase 
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activity (see section 1.12). At the time of writing the NS3-NS4A protease 
inhibitors Telaprevir, Boceprevir (U.S. Food and Drug Administration (FDA) 
approved in 2011) and Simeprevir (FDA approved in 2013), together with the 
NS5B polymerase inhibitor Sofosbuvir (FDA approved in 2013), are the only 
clinically approved DAAs. The new drugs are currently given in combination 
with ribavirin and PEG-IFN-α. Triple combination with the first generation 
DAAs, Telaprevir and Boceprevir resulted in SVR for up to 75% of patients 
infected with genotype 1 compared to the PEG-IFN/ribavirin therapy 
(Jacobson et al., 2011; Poordad et al., 2011). Nevertheless, the second 
generation of DAAs have reported even higher rates of SVR for the difficult to 
treat genotype 1 patients; triple therapy with Simeprevir showed SVR for 91% 
of patients following 12 weeks of treatment and combination therapy with 
Sofosbuvir has been reported to clear the virus for 89% of genotype 1 infected 
patients (Lawitz and Gane, 2013).  
 
Although the new generation DAAs have promising effect in the clinic, HCV 
escape mutations have been detected for the three NS3-NS4A protease 
inhibitors in vivo and in vitro (Fried et al., 2013; Imhof and Simmonds, 2011; 
Lenz et al., 2013; Wu et al., 2013). HCV escape mutants have also been 
detected for the NS5B polymerase inhibitor Sofosbuvir In vivo (Tong et al., 
2014).  
 
One strategy to avoid HCV escape mutants is to design drugs against host 
factors instead of viral. One of the drugs that are currently being evaluated in 
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the clinic is the small molecule SR-BI antagonist ITX5061, which has shown to 
inhibit HCV entry in vitro (Syder et al., 2011). Recent reports have found that 
this drug is well tolerated, but that administrating the antagonist alone does not 
have a significant reduction in viral load (Sulkowski et al., 2013). Instead 
ITX5061 may be a strong candidate in the liver transplantation setting to 
prevent reinfection of the allograft (Rowe, unpublished data).  
 
The standard-of-care treatment for children between 3 and 17 years of age is 
PEG-IFNα-2a/b in combination with ribavirin (Wirth, 2012). The treatment will 
continue for 24 to 48 weeks and results in SVR in more than 90% of the 
genotype 2 and 3 cases and between 44 and 57% of genotype 1a infected 
children (Baker et al., 2007; Ghany et al., 2009; Jara et al., 2008; Schwarz et 
al., 2011; Wirth et al., 2005; Wirth et al., 2010). The use of different dose 
concentrations and treatment times makes it difficult to directly compare adult 
and child response rates. However, despite overlapping values, HCV 
genotype 2 and 3 infected children do tend to have a higher response rate 
than adults, whereas the SVR rate is comparable between genotype 1 infected 
children and adults (Davis et al., 2003; Di Bisceglie and Hoofnagle, 2002; 
Fried et al., 2002; Lawitz et al., 2013; McHutchison et al., 2009). Predicting the 
response rate for children is still a largely unexplored area and so far only the 
pre-treatment serum/plasma viral load seems to be a reliable predictor (low 
viraemia being an indicator of a higher chance of SVR (Sokal et al., 2010; 
Wirth et al., 2010)). Interestingly the IL28-β genotype, which is predictive for 
genotype 1 infected adults, does not have any predictive value for children 
(Domagalski et al., 2013; Komatsu et al., 2013). The notion that intra-hepatic 
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ISG expression prior to treatment can be predictive for adults makes it an 
attractive predictor for paediatric patients as well, however to date no one has 
investigated this area and our study will therefore be the first to explore 
hepatic ISG expression in HCV infected children.  
 
1.6 Immunity  
During the initial infection the plasma viral load will usually stay below the level 
of detection for 7 to 21 days. Over the following 8.2 to 21 days the level of 
detectable plasma HCV RNA accelerate exponentially, with a HCV RNA 
doubling-time of 7.4 to 17 hours, resulting in a viral peak of 105 - 107 
International Units (IU)/ml blood (Busch, 2001; Glynn et al., 2005; Ribeiro et al., 
2012). After the initial viremic burst the viral titer stays constant for the 
following 4-8 weeks and then decline with the onset of an adaptive cellular 
immune response (Farci et al., 1991; Heim, 2013a; Major et al., 2004; Thimme 
et al., 2001). Towards the end of the high viral titer phase, anti-HCV antibodies 
can be detected in the serum, however this sero-conversion is not required to 
clear the acute infection (Farci et al., 1991; Thimme et al., 2001) (Figure 1.1). 
A clear example of this is seen for immune-compromised patients who 
spontaneously resolve HCV infection (Christie et al., 1997). Furthermore, 
presence of antibodies (Ab) against the hypervariable region 1 (HVR1) in the 
5’UTR of E2 (section 1.9.2) and anti-E2 sero-conversion has previously been 
linked with persistent infection in chimpanzees and humans (Major et al., 
2004; Prince et al., 1999). However, the function of the detected Abs was not 
evaluated in these studies and it is therefore impossible to rule out that they 
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potentially were non-functional. Other studies have found that early induction 
of cross-reactive anti-E2 nAbs is associated with viral clearance in humans 
(Dowd et al., 2009; Osburn et al., 2014; Pestka et al., 2007). These data 
suggest that that the mere presence of Abs does not eliminate the virus, but 
that the width and affinity of the Ab spectrum may be important.  
 
During the humoral immune response, nAbs against the HCV antigens are 
constantly being produced. However the high viral mutation rate means that 
the virus may evolve escape mutants that are not recognised by nAbs, leading 
to viral persistence (Dowd et al., 2009; Kato et al., 1994; von Hahn et al., 
2007). The presence of nAbs may form a selective pressure on the HCV 
population complexity and indirectly influence the evolutionary path (Farci et 
al., 2000; Ray et al., 1999) (see section 1.14). 
 
An early strong adaptive immune response is important for successful 
clearance of the HCV infection. Studies have show that patients with a broadly 
directed, vigorous and sustained activation of the CD8+ T cells, together with a 
strong intra-hepatic IFN-γ expression tend to have a higher clearance rate 
(Billerbeck et al., 2013; Gruner et al., 2000; Lechner et al., 2000; Thimme et al., 
2001). However, the CD8+ T cells require the CD4+ T cells for the initial HCV-
priming and a broad-spectrum CD4+ T cell population is associated with an 
increased chance of clearing the virus as well (Day et al., 2002; Grakoui et al., 
2003; Schulze zur Wiesch et al., 2005). The initial detection of HCV specific 
CD8+ and CD4+ T cells is strongly linked to a decline in viral load within the 
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first 4-8 weeks of infection, and to a significant increase in liver-associated 
serum ALT, which is associated with immune-mediated liver injury  (Figure 
1.1). The serum ALT level will usually decline after a few months and for some 
patients the level will return to the normal range (Hoofnagle, 2002).  
 
For patients with persistent infection the number and function of responding 
CD8+ T will often decline. This reduction in T cells has previously been linked 
with an increase in inhibitor receptors such as programmed death-1 (PD-1) 
(Cox et al., 2005; Sumida et al., 2013). The increase in PD-1 may be the result 
of CD8+ T cell exhaustion, which is often the feature of infections with early 
and high replication rate and persistent high viral burden (Moskophidis et al., 
1993; Wherry et al., 2003). T cell exhaustion is believed to increase the risk of 
viral persistence and may in part explain why 70% of infected individuals do 
not clear the virus (McMahan et al., 2010). In addition, identification of epitope 
escape HCV variants may also play a part in the progression to chronic 
infection (Bowen and Walker, 2005b; Neumann-Haefelin et al., 2008).  
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Figure 1.1 Natural course of HCV chronic infection.  
In the early stage of HCV infection the serum viral load (red) is un-detectable. After 7-
21 days the HCV serum level accelerate up to 107 IU/ml, but declines with the onset 
of the cellular and humoral immune response (anti-HCV antibodies are indicated with 
the transparent box). During the chronic infection the viral kinetics remain relatively 
stable. Detection of serum alanine aminotransferase (ALT, blue) is associated with 
the high hepatic infiltrate of CD8+ T cells. Following the initial burst of serum ALT the 
level will decline and in some cases return to normal (lower blue line), whilst for other 
patients the ALT level will remain elevated (top blue line). The dashed line indicates 
the detectable level of serum HCV RNA and the upper limited of normal serum ALT. 
The graph is made from modified data in Heim et al. 2013 (Heim, 2013b) and 
Hoofnagle et al. 2002 (Hoofnagle, 2002).  
 
 
0 2 4 6 8 12 24 1 5 10 20 40
Weeks Years
































   16 
1.7 Interferon and Interferon stimulated genes 
The type I interferons (IFN-α and IFN-β) are usually detected during the early 
stages of infection regardless of infection outcome (Bigger et al., 2001; 
Thimme et al., 2001) and have been found to correlate with viral load during 
the acute infection of experimentally inoculated chimpanzees (Su et al., 2002). 
The main source of IFN-α and IFN-β is unknown. However a recent study 
have reported ISG mRNAs in association with HCV RNA positive cells in vivo 
(Wieland et al., 2013), suggesting that the hepatocytes may be the main site of 
type I IFN expression. Alternatively it has been suggested that the type I IFN 
may derive from plasmacytoid dendritic cells (pDCs) located in close proximity 
to infected hepatocytes (Dreux et al., 2012).  
 
Activation of type I and type III IFN expression in infected hepatocytes is a 
result of cellular viral sensors reacting to the HCV pathogen-associated 
molecular patterns (PAMPs). The two major pathways for IFN production are 
the retinoic acid inducible gene-I (RIG-I) and Toll-like receptor (TLR) cascades. 
Both pathways leads to the downstream activation of nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and the IFN regulatory factor 
(IRF) 3 and IRF7. The activated transcription enhancers translocate to the 
nucleus and bind the interferon-stimulated response element (ISRE) in the IFN 
promotor to stimulate type I and III IFN expression  (Heim, 2013a, b; Rosen, 
2013; Sharma and Feld, 2014; Thimme et al., 2012). More detailed 
descriptions of the pathways can be found in Figure 1.2. The secreted type I 
and III IFN bind to their respective receptors on the membrane surfaces of 
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infected cell and naïve neighbouring cells, leading to the activation of the Jak-
STAT pathway and downstream ISG expression (Figure 1.2) (Akira and 
Takeda, 2004; Heim, 2013a).  
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Figure 1.2 Activation of the innate immune response.  
A. During the RIG-I pathway the cytosolic HCV double stranded (ds) RNA is recognised by the RNA helicases RIG-I and melanoma 
differentiation-associated protein 5 (Mda5). These activated helicases will bind and activate the mitochondrial anti-viral signalling 
molecule (MAVS) on the mitochondria, which in turn leads to the activation of the IκB kinase (IKK)-related kinases (IKKε) and TANK-
binding kinase-1 (TBK-1). This activation will result in the phosphorylation of IFN regulatory factor (IRF) 3 and IRF7, leading to homo-and 
hetero-dimerization and the activation of the transcription regulator nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB). These transcription factors will then translocate to the nucleus and stimulate the expressions of type I IFN-α, -β and type III IFN-λ. B. 
In the TLR pathway the TLR3, TLR7 and TLR9 endosome residential proteins recognise the intruding virus by the presence of viral 
dsRNA or single stranded (ss) RNA. Following stimulation, TLR3 initiates a signalling cascade through the TRIF proteins and the kinase 
TBK1, which translocate and form an active complex with IKKε. TLR7 and TLR9 signal through the MyD88 protein, which in turn leads to 
the association of TNF receptor associated factor 6 (TRAF6) and the Interleukin-1 receptor-associated kinases 4 and 1 (IRAK4/1). 
Activation of the IRAK4/1-TRAF6 complex results in the phosphorylation of IRF3 and 7, which lead to dimerization and activation of the 
IFN transcription. C. The secreted IFN-α, -β and -λ will bind their receptive receptors on the cell surface, here shown for IFN-α. Following 
ligand binding the Janus Kinase (Jak) 1 and tyrosine kinase (Tyk) 2 will initiate phosphorylation of the intra-cellular IFN-α receptor 
(IFNAR) domains, which in turn recruits the signal transducers and activators of transcription (STATs). The phosphorylated STAT1 and 
STAT2 will form the IFN-stimulated gene factor 3 (ISGF3) complex together with IRF9, which translocate to the nucleus and initiates the 
expression of interferon stimulated genes (ISGs), e.g. ISG15, IFI27 and RSAD2 (Akira and Takeda, 2004; Heim, 2013a, b; Rosen, 2013; 
Sharma and Feld, 2014; Thimme et al., 2012). 
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The ISG proteins can have either anti-viral or pro-viral properties (Schoggins 
and Rice, 2011). Among the anti-viral effectors are RSAD2 (also called 
Viperin) and IFI27. RSAD2 is located on the endoplasmic reticulum (ER) and 
associates with the HCV replication complex on the lipid droplets (see section 
1.12.2). Here RSAD2 is capable of inhibiting the HCV replication by interacting 
with the viral protein NS5A (Helbig et al., 2011; Hinson and Cresswell, 2009). 
Another example of an anti-viral protein is IFI27, which has been shown to limit 
HCV replication in vitro. The exact method of anti-viral action remains 
unknown, but the evidence suggests that IFI27 may regulate HCV replication 
indirectly by being involved in cellular anti-viral responses (Itsui et al., 2006).  
 
One of the most intensely studied ISGs is ISG15, however scientists are still 
discussing its function during viral infection. ISG15 functions as ubiquitin-like 
protein modifier and conjugates its target proteins through the action of the E1 
activating protein Ube1L (Yuan and Krug, 2001), the E2 conjugating enzyme 
UbcH8 (Yuan and Krug, 2001) and E3 ligase HERC5 (Wong et al., 2006). ISG 
can be conjugated (ISGylation) to more than 150 cellular proteins and is 
involved in various cellular functions including signalling transduction and 
immune/stress responses (Kim and Zhang, 2003; Zhao et al., 2005). The 
effect of ISGylation during viral infection has proven to be controversial. 
Several studies have reported an anti-viral effect for DNA and RNA viruses. 
For example ISGylation of the HIV Gag protein in vitro will inhibit its interaction 
with host Tsg101 protein and block viral release (Okumura et al., 2006). 
Moreover, ISG15 knock-out mice have been found to be more susceptible to 
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influenza Sinbis virus and herpes simplex virus 1 infections (Lenschow et al., 
2007). Controversially, ISG15 seems to have the opposite effect during HCV 
infection. For instance, over-expression of ISG15 has been reported to 
promote replication of HCV strain J6/JFH in hepatoma cell lines, whereas 
silencing led to decreased viral replication (Broering et al., 2010; Chua et al., 
2009), suggesting a positive regulatory role in the viral life cycle. In addition, 
intra-hepatic ISG15 has been reported up-regulated in HCV infected patients 
who do not respond to treatment compared to those who do (Broering et al., 
2010; Chen et al., 2005; Dill et al., 2011; Urban et al., 2010). The exact 
mechanism for this pro-viral effect is unknown, but evidence suggests that 
ISG15 may control the RIG-I activity through ISGylation, (Arnaud et al., 2011). 
Conjugation with ISG15 may inhibit the HCV dsRNA inducted activation of 
RIG-I, leading to an reduction in IFNβ expression and an increase in the 
accumulation of the HCV structural protein NS3 (Arnaud et al., 2011).  
 
Acute HCV infection leads to an activation of IFN and subsequently ISG 
expression (Bigger et al., 2001; Su et al., 2002; Thimme et al., 2001), however 
in 70% of cases the virus is not cleared and persists. This paradox can partly 
be explained by the ability of the viral encoded NS3/4A to manipulate the RIG-I 
and TLR pathways in infected cells. This HCV protease is capably of blocking 
the phosphorylation of IRF3 (Foy et al., 2003) and can cleave and release the 
mitochondrial antiviral-signalling protein (MAVS) from the mitochondria 
(Bellecave et al., 2010; Meylan et al., 2005). Both actions lead to inactivation 
of the target protein and inhibition of the RIG-I pathway. In addition NS3/4A 
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has been found to cleave the adaptor protein TRIF, leading to abolishment of 
the TLR3-pathway in infected cells (Li et al., 2005). It is not known to what 
extent HCV is capable of inhibiting the PAMP sensing pathways, however 
recent studies using new methods for ISG mRNA detection reveals a 
correlation between HCV RNA and ISG mRNA expression, suggesting that 
that the infected cells are the major source of ISG expression and that HCV 
inhibition of the sensing pathways therefore only have a minor role (Wieland et 
al., 2013). 
 
1.8 HCV genome 
The viral genome is a 9.6 kilobase (kb) long uncapped positive single RNA 
strand. The 5’- and 3’-untranslated regions (UTRs) of the genome consist of 
control elements required for translation and replication. The 5’-UTR contains 
an internal ribosome entry site (IRES), which binds the 40S ribosomal subunit 
and initiates translation of the virus RNA-strand in a cap-independent manner 
(Penin et al., 2004). The 3’UTR include a poly(U/UC) tract, which is believed to 
be important for viral replication and translation of the viral genome (Friebe 
and Bartenschlager, 2002; Friebe et al., 2005; Tuplin et al., 2012).  The two 
UTRs are separated by a single uninterrupted open reading frame (ORF), 
which encodes a single polyprotein of approximately 3,011 amino acids (aa). 
After co- and post-translational modifications, this polyprotein is processed into 
3 structural (core, E1, E2) and 7 non-structural proteins (p7, NS2, NS3, NS4A, 
NS4B, NS5A and NS5B) (reviewed in (Ashfaq et al., 2011; Lindenbach and 
 23 
Rice, 2005). A cartoon of the HCV genome, polyprotein and cleaved 




Figure 1.3 HCV genome and proteins.  
The 9.6kb long ssRNA genome contains several secondary structures in both the 5’ 
and 3’-non-coding regions (NCR) or UTR. Following transcription and translation of 
the HCV polyprotein, individual proteins become separated by host encoded ER 
signalling peptidases and peptide peptidases (rhombi), and by viral encoded cis- or 
trans-acting proteases (arrows). The key functions of the 3 structural genes (core, E1, 
E2) and 6 of the 7 non-structural proteins (p7, NS2, NS3, NS4A, NS4Band NS5B) are 
listed underneath their sequence location. The exact mechanism of NS5A is not 
known (indicated by a question mark). It has been suggested that the protein is 
involved in viral assemble by interaction with core and the ssRNA genome. Green 
dots underneath the E1 and E2 proteins indicate glycosylation sites (Kim and Chang, 
2013; Moradpour et al., 2007; Ogawa et al., 2009; Suzuki et al., 2007). Illustration 




1.9 The HCV particle and the viral structural proteins  
HCV particles comprise the structural proteins core, E1 and E2 (Figure 1.4). 
The 191aa core protein forms the icosahedral capsid around the viral genome. 
This highly conserved non-mature protein can be divided into 3 domains 
according to their hydrophobicity. Domain I (aa 1-117) is hydrophilic, and 
thought to bind and stabilise the RNA genome, domain II (aa 118-171) 
mediates the interaction with the lipid droplets in the viral replication complex 
(section 1.12.2) and finally domain III (aa 172-191) correspond to the signal 
sequence for E1, which leads to E1 translocation to the ER lumen 
(McLauchlan, 2000; Rouille et al., 2006; Santolini et al., 1994). Following 
insertion of E1 into the ER membrane, signal peptidases will release the 
signalling sequence from the envelope protein. The signalling sequence is 
further processed by a signal peptide peptidase  located in the ER membrane 
(Pene et al., 2009) which leads to the release of the mature core from the 
signalling sequence (McLauchlan et al., 2002). A high-resolution structure of 
core and its topology in the capsid remains to be discovered.  
 
The nucleocapsid is surrounded by a cell-derived lipid envelope bilayer. The 
viral type-I transmembrane proteins E1 and E2 are associated with the 
envelope where they form non-covalent hetero-dimers, which stabilise the viral 
particle and interact with viral entry factors on permissive cells (Bartenschlager 
et al., 2011). Density gradient analyses of infected patient serum have shown 
that the HCV particles may have variable densities and that only the low-
density particles are infectious (Bradley et al., 1991; Hijikata et al., 1993). It 
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was later found that the infectious fraction contains high content of triglycerol, 
and the apolipoproteins (Apo) B and E, which leads to the current model that 
the HCV particle resembles the very-low-density lipid-proteins (VLDL) (Andre 
et al., 2002; Hishiki et al., 2010).  
 
It has previously been reported that the E2-p7 cleavage by the ER signalling 
peptidases is incomplete, resulting in both E2 and E2-p7 species (Lin et al., 
1994a). Later investigation of HCV pseudo-particles (HCVpp) (see section 
1.10) generated from E1E2p7 transient expressing 293Ts (instead of only 
E1E2), revealed that p7 may become incorporated into the HCV envelope, 
suggesting that p7 may function as a structural protein as well. The 
incorporation, however, had no effect on the infectivity of the HCVpp particle 
(Flint et al., 2004).  The role of p7 is still not fully understood and most reports 
suggests that p7 may have both structural and non-structural features during 
the HCV life cycle (Khaliq et al., 2011). A description of the non-structural 
feature can be found in section 1.12.3.  
 
The viral envelope proteins E1 and E2 are type-I transmembrane proteins, 
which consist of three domains; (i) the transmembrane domain, which is 
responsible of anchoring the proteins to the viral particle and to the ER during 
protein maturation, (ii) the membrane proximal domain, involved in 
dimerization and (iii) the ecto-domain which interacts with entry factors on the 
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cell surface (Ashfaq et al., 2011; Dubuisson, 2007; Suzuki et al., 2007). A 
detailed description of the envelope proteins can be found below.  
 
1.9.1 Envelope protein 1 (E1) 
The E1 protein is encoded by amino residues 192 – 383 (length 181aa) and 
contains five sites for the addition of asparagine-linked glycans (N-linked 
glycosylation) labelled E1N1 to E1N5 (Meunier et al., 1999). Site-directed 
mutation studies of the glycosylation sites in the HCVpp envelope proteins 
have revealed that E1N1 and E1N4 are important for dimerization of E1E2 in 
the viral particle and that E1N1, E1N2 and E1N4 are required for successful 
HCVpp entry (Goffard et al., 2005). Unlike observations for E2, glycosylation of 
E1 does not seem to have an impact on the secondary structure of the protein 
(Lorent et al., 2008). The glycosylation sites may instead have an effect on the 
di-sulphide bonds and interactions with E2 in the particle. Furthermore, E1 has 
proven to be far less antigenic than E2, with only 10 - 50% of HCV chronically 
infected patients having reactivity against E.coli  expressed E1, compared to 
70%-73% for E2 (Hussy et al., 1997; Lorenzo et al., 2000).  
 
1.9.2 Envelope protein 2 (E2) 
The E2 protein is encoded by amino residues 384 -746 (length 362aa). Over 
the years, E2 has been the main focus of many research studies because of 
its high antigenicity and its direct interaction with entry factors on the cell 
surfaces (see section1.11). However, it was not until recently that the crystal 
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structure of the E2 core domain was published (Kong et al., 2013). In this 
study Kong et al. strategically truncated and/or replaced regions of E2 before 
co-crystallisation with a high affinity antibody, to achieve an E2 crystal 
structure (Kong et al., 2013). The crystal structure revealed a general globular 
shape of E2 with multiple loops, short helices and beta-sheets. Furthermore, 
the E2 surface featured a highly glycosylated face, a neutralising face, 
containing strain-restricted and cross-reactive epitopes, and several regions, 
which are believed to be concealed in the viral protein (Ball et al., 2014; 
Fauvelle et al., 2014). The globular E2 structure reported by Kong et al. 
contradicts the previously suggested model of the E2 having a class II 
membrane fusion protein structure (Keck et al., 2005; Krey et al., 2010).  
 
The E2 ecto-domain encodes three highly variable regions, termed 
hypervariable region 1 (HVR1, residues 384-410) hypervariable region 2 
(HVR2, residues 460-485) and the intergenotopic variable region (igVR, 
residues 570 - 580). Additional HVRs have been identified exclusively in 
genotype 3a viruses; HVR495 and HVR575 (Humphreys et al., 2009). The 
most variable of these is HVR1, which appears to be highly tolerant to aa 
substitutions (Cocquerel et al., 2000), however there seems to be a strong 
selective pressure to maintain a length of 27aa (Casino et al., 1999). This 
region is highly antigenic and contains key neutralising epitopes (Bankwitz et 
al., 2010; Farci et al., 1996; Kato et al., 1994; Manzin et al., 1998; Ray et al., 
1999; von Hahn et al., 2007). Despite the antigenic properties of HVR1, 
studies have shown that HCV cell culture particles (section 1.10) lacking HVR1 
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are more prone to neutralisation by both E2-specific monoclonal antibodies 
and patient serum (Bankwitz et al., 2010), which suggests that HVR1 may 
shield neutralising epitopes outside HVR1 in the E2 configuration. Further 
studies have shown that only one out of five anti-HVR1 antibodies were able to 
neutralize HCVpp entry, whereas antibodies against E2 aa regions outside 
HVR1 (412-423aa, 432-443aa and 436-447aa) completely neutralized 
infection (Hsu et al., 2003a). These observations suggest that the Ab epitopes 
identified in HVR1 may not lead to neutralisation. Instead it has been 
suggested that HVR1 may function as a immune decoy, which lead the 
attention away from the functional nAb sites in E2 (Ray et al., 1999).  
 
The HVR1 and part of HVR2 are located in the receptor-binding domain (RBD: 
residues 384 – 661 aa), however neither region has been reported to directly 
bind receptor CD81, an essential receptor for HCV entry. Instead, deletion of 
the HVR1 region may result in increased binding of soluble E2 (sE2) to cell 
lines expressing CD81. Furthermore, studies have shown that deleting or 
replacing the HVR1 region in the HCVpp lead to increased affinity to CD81 
(Bankwitz et al., 2010; Roccasecca et al., 2003) and neutralisation by anti-
CD81 antibodies (Bankwitz et al., 2010), suggesting that HVR1 may act to 
shield the CD81 binding region in E2 (Roccasecca et al., 2003). In support of 
this, mutagenesis analyses have revealed that the direct interaction between 
CD81 and E2 residues are found outside HVR1 and HVR2 at positions W420, 
W437, L438, L441, F442, Y527, W529, G530, D535 and at a region spanning 
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613 – 618aa (Drummer et al., 2006; Owsianka et al., 2006; Roccasecca et al., 
2003).  
 
Although it has been reported that HVR1-deleted HCV particles may have 
increased recognition of CD81, deletion of the region has also been reported 
to decrease the viral entry (Bankwitz et al., 2010; McCaffrey et al., 2011; 
Prentoe et al., 2014). Interestingly, viral particles generated from HCV 
genomes lacking HVR1 have increased particle density, suggesting alteration 
of the lipid composition in the viral particle (Bankwitz et al., 2010). Recent, 
reports have further shown that HVR1-deleted HCV cell culture particles 
(section 1.10) have decreased dependency of low density lipoprotein receptor 
(LDLr) and SR-BI during entry (Bankwitz et al., 2010; McCaffrey et al., 2011; 
Prentoe et al., 2014), however the receptor independency were not associated 
with variable incorporation of apolipoprotein E (ApoE) into the envelope. It is 
therefore thought that HVR1 instead directly or indirectly binds to LDLr and 
SR-BI during the early stages of viral entry (Prentoe et al., 2014).  
 
The HCV E2 envelope protein contains eleven sites for N-linked glycosylation 
(E2N1-E2N11). Of these, ten are highly conserved between genotypes 
(Goffard et al., 2005). Site-directed mutagenesis studies in the HCVpp 
systems have revealed that E2N6, E2N8 and E2N10 are involved in viral 
assembly (Goffard et al., 2005; Helle et al., 2007). Goffard and colleagues also 
reported that the E2N8 and E2N10 are involved in binding CD81 and 
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mediating virus entry (Goffard et al., 2005). Interestingly Helle et al. found that 
mutation of the E2N1, E2N6 and E2N11 significantly increased the sensitivity 
of virus neutralisation by anti-E2 mono- and polyclonal antibodies and 
increased the affinity for CD81 both in the HCVpp and HCVcc system (Helle et 
al., 2007; Helle et al., 2010). The presence of glycans at these 3 sites is 
believed to result in conformational changes that will shield important 
neutralising sites and the CD81 binding site (Helle et al., 2007; Helle et al., 
2010). Similar observations have been made for the HIV gp120 protein, where 
the heavy glycosylation of the envelope protein provides a “glycan shield” 
making the protein completely immunological silent (Wei et al., 2003).  
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Figure 1.4 HCV particle. 
The viral particle consists of the viral genome, the capsid and the envelope. The 
icosahedral capsid is made up of the viral encoded core protein, which binds and 
stabilises the RNA genome. The nucleocapsid is surrounded by a cell-derived lipid bi-
layer (also called the envelope) into which the envelope proteins E1 and E2 are 
incorporated. These proteins form non-covalent hetero-dimers that stabilise the viral 
particle and interact with viral entry factors on the permissive cells (Bartenschlager et 




1.10 Model systems for studying HCV life cycle 
Since the discovery of HCV in 1989 different in vitro models have been 
developed for studying the HCV life cycle. The first in vitro system of 
significance was the HCV replicon system, which was developed in 1999 by 
Lohmann and his colleagues (Lohmann et al., 1999). In the original HCV 
replicon the structural genes were replaced by a neomycin 
phosphotransferase gene followed by an IRES sequence deriving from the 
encephalomyocarditis virus (EMCV). This IRES lead to the synthesis of HCV 
non-structural proteins required for HCV replication, whereas the HCV IRES 
mediated the translation of the selective marker. In this setting only cells 
supporting HCV replication would express sufficient amount of neomycin 
phosphotransferase to become resistant against G418 treatment and thereby 
allow the studies of the HCV RNA replication (Lohmann and Bartenschlager, 
2014; Lohmann et al., 1999).  
 
In 2003 the HCV pseudo-particle (HCVpp) system was developed, which 
provided an important tool for studying viral entry (Bartosch et al., 2003; 
Drummer et al., 2003; Hsu et al., 2003b). The HCVpp consist of an envelope 
made up of HCV E1 and E2 glycoproteins, which surrounds a capsid 
consisting of retro-viral core proteins. The capsid contains a packed lenti-viral 
genome with a luciferase gene insertion. Following successful entry, the 
HCVpp genetic material becomes integrated into the host cell genome, 
wherefrom the reporter gene is expressed. The level of entry is evaluated 
indirectly by quantifying the activity of the luciferase in the cell lysate. The 
 33 
HCVpp envelope is the only part of the particle that has derived from an 
authentic HCV particle and the HCVpp system can therefore only be used for 
studying HCV entry (Bartosch et al., 2003; Drummer et al., 2003; Hsu et al., 
2003b). 
 
In 2005 another milestone was reached in HCV research, when an authentic 
HCV particle was reported to replicate and release infectious particles within a 
cell culture system (HCVcc) (Kato and Wakita, 2005; Lindenbach et al., 2005; 
Zhong et al., 2005). The strain was generated by transfecting HCV genotype 
2a clonal RNA from a Japanese patient with fulminant hepatitis-1 into producer 
cell lines and the strain is therefore termed Japanese fulminant hepatitis-1 
(JFH1) (Lindenbach et al., 2005). The HCVcc system has been further 
developed and chimeric JFH1 strains have been created by replacing the core, 
E1, E2, p7 and NS2 of JFH1 with genotype specific sequences for genotype 
1a, 1b, 3a, 4a and 5a (Gottwein et al., 2007; Jensen et al., 2008; Pietschmann 
et al., 2006; Scheel et al., 2008; Yi et al., 2007). The advantage of the HCVcc 
system is that it allows the full HCV life cycle to be studied in hepatocyte 
derived cell lines and cultured primary hepatocytes (Ploss et al., 2010). 
  
1.11 HCV entry factors and the internalisation process 
The complex process of HCV entry into hepatocytes is thought to be initiated 
by the interaction of low-affinity attachment factors, such as heparin sulphate 
glycosaminoglycans and low-density lipoprotein receptors with the E2 protein, 
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ApoB and ApoE in the viral envelope (Barth et al., 2003; Hishiki et al., 2010; 
Owen et al., 2009). Internalisation of the HCV particle requires a series of 
interactions with the four essential HCV entry receptors and entry factors; The 
tetraspanin CD81 (Flint et al., 1999; Pileri et al., 1998), scavenger receptor 
class B type I (SR-BI) (Scarselli et al., 2002) and the tight-junction proteins 
Claudin-1 (CLDN1) (Evans et al., 2007) and Occludin (OCLN) (Ploss et al., 
2009) (Figure 1.5). A description of each entry factor can be found below.  
 
1.11.1 CD81 
CD81 is a member of the tetraspanin superfamily and is ubiquitously 
expressed on most nucleated cells. The protein contains 4 transmembrane 
domains, which create 2 extracellular loops defined as EC1 and EC2 (Hemler, 
2005). CD81 was the first HCV entry factor to be identified and was discovered 
by screening a human cDNA expression library with soluble E2 (sE2) (Pileri et 
al., 1998). Further proof of the role of CD81 as an entry factor came when the 
non-permissive hepatoblastoma cell line (HepG2) was found to support 
infection following the exogenous expression of CD81 (McKeating et al., 2004; 
Zhang et al., 2004). In addition, HCVpp entry can be inhibited by anti-CD81 
monoclonal antibodies, by si-RNA mediated CD81 silencing (Zhang et al., 
2004) and by soluble forms of the CD81 EC2 domain (Bartosch et al., 2003; 




1.11.2 Scavenger receptor B type I 
 
Scavenger receptor B type I (SR-BI) is primarily expressed in liver and 
steroidogenic tissues, where it selectively takes up the cholesterol by binding 
high cholesterol ligands such as high-density lipoprotein (Acton et al., 1996). 
SR-BI was identified as a putative HCV receptor as sE2 was shown to bind the 
CD81-negative HepG2 (Scarselli et al., 2002). Furthermore, siRNA silencing of 
SR-BI reduces HCVcc infection in vitro (Zeisel et al., 2007), while over-
expression of SR-BI enhances virus infection (Grove et al., 2007). E2 HVR1 is 
thought to interact with SR-BI since the deletion of the HVR impaired sE2-SR-
BI binding (Scarselli et al., 2002). In addition, deletion of HVR1 has been 
reported to decrease SR-BI dependency of the virus, but increase the affinity 
for E2-CD81 interaction (Bankwitz et al., 2010; McCaffrey et al., 2011; Prentoe 
et al., 2014).  This observation suggests that HVR1 may interact directly or 
indirectly with SR-BI, leading to conformational change of E2 exposing the 
CD81 binding site (Bankwitz et al., 2010).  
 
1.11.3 Claudin-1 
Claudin-1 (CLDN1) plays a key role in the formation of cellular tight junctions 
(Krause et al., 2008). The entry factor was identified as a HCV entry co-
receptor when introducing the cDNA library generated from a highly 
permissive huh-7.5 hepatoma cell line into the non-permissive 293T cell line 
(Evans et al., 2007). Residues required for HCV entry have been mapped to 
the first extracellular loop of CLDN1, particularly to the highly conserved CLDN 
motif W30-GLW51-C54-C64 (Cukierman et al., 2009). Fluorescent resonance 
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energy transfer (FRET) studies from the McKeating laboratory have shown 
that CLDN1 associates with CD81 to form a complex on the cell surface 
(Harris et al., 2010; Harris et al., 2008). This association appears essential for 
endocytosis of the receptor complex and for later fusion with Rab5a 
expressing endosomes (Farquhar et al., 2012). 
 
1.11.4 Occludin 
Occludin (OCLN) is an additional tight junction protein, which is required for 
HCV entry. Ploss et al., confirmed OCLN as a HCV receptor via screening of a 
huh7.5 cDNA library in mouse embryonic fibroblasts. Briefly, transduction of 
human OCLN into non-permissive murine fibroblasts transduced to express 
human CD81, SRBI and CLDN1 enabled HCVpp entry. Furthermore, silencing 
OCLN would abolish the entry of both HCVpp and HCVcc (Ploss et al., 2009). 
The mechanism of HCV-OCLN interaction remains uncertain. Although OCLN 
has been reported to interact with the E2 glycoprotein, it is unknown whether 
this interaction is direct, or indirect via CD81/CLND1 (Meredith et al., 2012).  
 
1.11.5 Additional entry receptors 
Recently, the transferrin receptor (TfR) 1 (Martin and Uprichard, 2013), 
Niemann-Pick C1-like 1 cholesterol absorption receptor (NPC1L1) (Sainz et al., 
2012), the epidermal growth factor receptor (EGFR) and ephrin receptor A2 




The most recently identified entry factor is TfR1. The receptor was initially 
found down-regulated in huh7 cells infected with HCVcc, however further 
characterisation of the receptor protein revealed that HCVcc and HCVpp 
infection could be inhibited by TfR1 silencing and in the presence of anti-TfR1 
antibodies. Furthermore, adding the antibodies after HCV attachment would 
inhibit viral entry, suggesting that TrF1 acts at the post-binding step (Martin 
and Uprichard, 2013). The NPC1L1 is a cholesterol sensing receptor 
expressed on the apical surface of hepatocytes. Blockage of the receptor by 
the FDA-approved NPC1L1 antagonist ezetimbe (used to treat 
hypercholesterolemia) potently prevented HCV uptake in a cholesterol-
dependent manner (Sainz et al., 2012). The EGFR and EphA2 were identified 
as HCV entry factors by RNAi kinase screening. Inhibiting the receptor kinase 
activity resulted in impaired HCV infection in vitro and in vivo. In addition, the 
receptors are believed to have a regulatory role in the formation of CD81-
CLDN1 co-receptor complexes after the initial attachment of the virus 






Figure 1.5: HCV entry factors.  
The initial binding of the viral particle is believed to be initiated by low-affinity 
interactions between the surface proteins heparin sulphate glycosaminoglycans 
(GAGs) and low-density lipoprotein receptors (LDL-R), and the particle components 
E2 and ApoB and ApoE (here represented in the form of very-low density lipoprotein 
(VLDL) (Barth et al., 2003; Hishiki et al., 2010; Owen et al., 2009). Following the initial 
attachment, the viral envelope interacts with SR-BI, CD81, CLDN1 and OCLN, 
leading to clathrin-mediated endocytosis (Blanchard et al., 2006; Meertens et al., 





The HCV particle enters the cell via clathrin-mediated endocytosis driven by 
dynamin (Blanchard et al., 2006; Meertens et al., 2006). By using inhibitors of 
vascular acidification, researchers demonstrated that the release into the 
cytoplasm of the HCVpp (Hsu et al., 2003b) or HCVcc (Tscherne et al., 2006) 
nucleic acid contents is highly pH-dependent. In other enveloped viruses, such 
as influenza, lowering the pH in the endosome will lead to conformational 
changes of the glycoproteins, which expose fusion peptides, also called fusion 
loops. These domains then trigger the fusion process between the endosomal 
membrane and the glycoproteins, leading to the cytosolic release of the viral 
genome (Thorley et al., 2010). Identification of 3 classical fusion loop motifs at 
positions 270 to 284aa, 416 to 430aa and 600 to 620aa in the E1 and E2 
proteins, suggests that the HCV genome may be released by fusion  (Lavillette 
et al., 2007). The biological importance of these regions was confirmed by 
generating mutant HCVpps by site-directed mutagenesis and testing them in 
liposome/HCVpp fusion assays (Lavillette et al., 2007). The initial model of the 
E2 ecto-domain structure confirmed the presence of fusion loops and 
predicted that the loops were positioned close to anti-parallel beta-sheets in 
the N-terminus and thereby resembles the flavivirus and alphavirus encoded 
class II fusion proteins (Krey et al., 2010). However, the recently published E2 
crystal structure show no signs of classical class II fusion protein folds and 
thereby differ markedly from the previous predicted model (Khan et al., 2014; 
Kong et al., 2013). In addition, the new E2 model does not undergo significant 
conformational changes when exposed to low pH (Khan et al., 2014). It 
therefore remains unknown how the viral genome is released into the cytosol.  
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1.12  HCV non-structural proteins and their role in viral replication, 
assembly and release 
The roles of the various HCV non-structural proteins are described below in 
the context of the intracellular viral life cycle. This life cycle can be viewed in 
Figure 1.6 
 
1.12.1 Translation and polyprotein maturation 
The translation occurs by the rough ER and yields a single polyprotein 
precursor of about 3000 amino acids in length. At the ER surface the structural 
proteins and the non-structural p7 become cleaved by host signal peptidases. 
Studies on the E1 and E2 maturation have suggested that the C-terminal 
trans-membrane domains of E1 and E2 form hairpin structures, which go 
through the ER membrane twice. Upon separation of these proteins the C-
terminal will translocate to the cytoplasm in order to form the type I membrane 
topology of mature E1 and E2, leaving the proteins retained in ER (Dubuisson, 
2007; Joyce and Tyrrell, 2010; Kim and Chang, 2013; Moradpour et al., 2007; 
Suzuki et al., 2007). The final glycosylation and di-sulphide rearrangement of 
the envelope proteins is believed to occur in the Golgi apparatus (Vieyres et al., 
2010) (section 1.12.3). The NS2-NS3 junction is cleaved by a zinc-dependent 
cysteine proteinase activity found at the C-terminus of NS2 and the N-terminus 
of NS3 (Dubuisson, 2007; Joyce and Tyrrell, 2010; Kim and Chang, 2013; 
Moradpour et al., 2007; Suzuki et al., 2007). The cleavage of the remaining 
polyprotein is performed by a serine protease activity in the N-terminus of NS3 
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in association with the NS4A co-factor protein. In addition, to the serine 
protease, NS3 contains an RNA helicase/NTPase activity, which is required for 
eliminating RNA secondary structures, separation of the dsRNA replication 
intermediates and removal of nucleic acid binding proteins from the genome. 
RNA unwinding occurs in a 3’ to 5’ direction and requires energy from NTP 
hydrolysis. The NS4A protein functions as a co-factor for both the protease 
and RNA helicase/NTPase activity and facilitates the location of the highly 
hydrophobic NS3 by anchoring it to the ER membrane (Dubuisson, 2007; 
Joyce and Tyrrell, 2010; Kim and Chang, 2013; Moradpour et al., 2007; Suzuki 
et al., 2007).  
 
1.12.2 Viral replication 
HCV replication processes occur at sponge-like inclusions of the ER 
membrane, also termed the membranous web. The formation of this 
membranous web is believed to be initiated by the viral NS4B proteins, which 
may play an essential role in gathering the non-structural proteins together at 
the replication site, including the RNA-dependent RNA polymerase (RdRp) 
NS5B (Elazar et al., 2004). The HCV replication proceeds through NS5B 
synthesising a complementary negative strand RNA directly from the positive-
stranded genome. The viral RdRp afterwards rely on this intermediate RNA 
template to generate the positive strand genome (Gu and Rice, 2013; Kim and 
Chang, 2013; Moradpour et al., 2007; Suzuki et al., 2007). NS5B initiates the 
synthesis of the negative and positive strand genomes in a primer dependent-
manner, where structures in the 3’UTR are thought to create a cis-acting “copy 
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back loop”, in which the secondary structures leads to the priming for the 
complementary strand. The NS5B RdRp is highly error-prone and will 
generate multiple mistakes during the replication process. The mistakes are 
incorporated as mutations in the viral genome and the positive-stranded 
replicons are often not 100% complementary to the template (Behrens et al., 
1996; Elazar et al., 2004; Friebe et al., 2005; Tuplin et al., 2012) (see section 
1.14). Interestingly, the polymerase activity of NS5B is able to copy both 
homogenous and heterogeneous RNA templates in a primer-dependent 
manner (Behrens et al., 1996), however is it not well understood how HCV 
template specificity is achieved. It is believed that the organisation of the NS5B 
domains may be important (Gu and Rice, 2013). Alternatively, precipitation 
studies reported that NS5A binds both negative and positive strand 3’UTR 
(Huang et al., 2005) and could potentially play a role in the delivery of HCV 
specific genomes to the NS5B polymerase. 
 
The exact function of NS5A in the HCV lifecycle is largely unknown, however 
identification of both viral and host interaction partners strongly indicates that 
this serine phosphoprotein may have multiple functions. Besides binding both 
negative and positive strand RNA prior to replication (Huang et al., 2005), 
NS5A has been reported to interact with the viral core protein, leading to an 
increase in HCV particle production (Masaki et al., 2008). It has also been 
reported to bind host proteins, such as the cellular chaperon cyclophilin A, 
which functions in protein folding and trafficking (Lim and Hwang, 2011) and 
with the phosphatidylinositol 4-kinase III α, which is involved in the formation of 
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the phospholipid PIP2 (Foster et al., 2011). These interactions are believed to 
be dependent on the phosphorylation status of NS5A, which can either be 
hypo- or hyper-phosphorylated (Shulla and Randall, 2012).  
 
1.12.3 Assembly and release 
In recent years researchers have started to uncover the mechanisms behind 
HCV assembly and release. Although more research is required, current data 
suggests that the newly synthesised RNA and the structural proteins are 
assembled on ER-derived lipid droplets in association with the original ER 
membranous web. During the assembly process the core becomes 
concentrated on the lipid droplets and becomes surround by membranous 
structures containing the non-structural proteins (Miyanari et al., 2007). 
Transfection studies using full-length viral genomes lacking core have shown a 
reduced recruitment of the replication complex and viral RNA to the lipid 
droplets, suggesting that core play an essential role in the initial assembly 
process (Miyanari et al., 2007). In addition, the lack of core will lead to a 
reduction in infectious HCV particle being released and an increase in the ratio 
of high-density non-infectious virus particles compared to the wild-type viral 
genome (Miyanari et al., 2007).  
 
During the genome packing process, NS2 is believed to interact with the viral 
p7 protein, which stabilises the structure of NS2. The association of these two 
proteins are essential for the interaction of NS2 with the NS3/4A complex 
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(Lindenbach, 2013; Lindenbach and Rice, 2013; Stapleford and Lindenbach, 
2011), which in turn leads to the trafficking of core protein from lipid droplets 
(Coller et al., 2012).  The exact relationship between core and NS3-4A is 
unknown, but the fact that one is the capsid protein and the other an RNA-
helicase suggests that NS3/4A assists in the packaging of the HCV genome 
into the nucleocapsid (Lindenbach, 2013; Lindenbach and Rice, 2013). In 
addition, NS2 has been shown to recruit the ER-resident E1E2 complex to the 
assembly site (Stapleford and Lindenbach, 2011). A further essential 
requirement for viral assembly is the interaction of NS5A with core on the lipid 
droplet. This interaction is believed to assist genome packaging and formation 
of the icosahedral capsid (Miyanari et al., 2007). In addition, NS5A is 
associated with the host Apo E protein, which is often incorporated into the 
envelope (Benga et al., 2010).  
 
The full details on the HCV assembly mechanism is not yet clear, however it is 
believed that the HCV particle forms via budding into the ER, where the final 
maturation of the particle is closely linked with the VLDL secretion pathway. 
This prediction is supported by the high levels of immature intracellular HCV 
particles following treatment of infected huh7 cells with an inhibitor of the 
microsomal triglyceride transfer protein; a key regulator of VLDL precursor 
synthesis (Gastaminza et al., 2008). In the same study Gastaminza and 
colleagues also found evidence for translocation of the HCVcc particle from 
the ER to the Golgi apparatus (Gastaminza et al., 2008), where the final 
maturation of the particle is believed to occur, notably E2 glycosylation by the 
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Golgi glycosidases and glycosyltransferases (Vieyres et al., 2010). Following 
maturation in the Golgi the viral particles are sorted into endosome 
compartments, which are subsequently released at the plasma membrane 
(Coller et al., 2012).  The viral p7 has previously been shown to form ion 
channels in artificial lipid bi-layers and is believed to be essential for 
preventing acidification of the endolysosomal compartments during the 




Figure 1.6: HCV life cycle.  
A. The viral particle interacts with surface receptors on the hepatocytes, which initiate clathrin-mediated endocytosis. Of note, only the 
entry factors SR-BI and CD81 are represented in the illustration, however claudin 1 and occludin are equally important for HCV 
internalisation. B.  Following endocytosis the HCV particle un-coats in response to a reduction in endosomal pH level. C. The HCV 
genome is translated into a single polyprotein by the host ribosomal complex and transferred to the surface of the ER membrane. Here 
the polyprotein undergoes post-translational modifications leading to the processing of three structural and seven non-structural proteins. 
The viral proteins remains directly linked to the ER membrane where non-structural proteins direct viral replication. D. Prior to replication 
NS4B initiates the formation of the membranous web where the RNA-dependent RNA polymerase, NS5B, syntheses a complementary 
negative strand RNA directly from the positive-stranded HCV genome. This intermediate RNA template is subsequently used by NS5B 
to generate numerous positive strand HCV genomes. E. The newly synthesised genomes are packaged into icosahedral capsid. The 
capsids bud into the ER lumen creating an ER-derived envelope surrounding the nucleocapsid. F. From the ER lumen the completed 
viral particles translocate to the Golgi, where the final maturation of the E1 and E2 glycoproteins occurs. The particles are sorted into 
endosomal compartments that are trafficked to the cell surface, resulting in viral release from the infected cell (Ashfaq et al., 2011; 
Dubuisson, 2007; Kim and Chang, 2013; Lindenbach, 2013; Moradpour et al., 2007; Ogawa et al., 2009; Suzuki et al., 2007). Illustration 
from (Ke and Chen, 2012). 
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1.13 HCV transmission routes between hepatocytes 
The main site for HCV replication is the hepatocytes in the liver. By 
determining the viral kinetics researchers estimate that it takes approximately 
6 hours for the hepatocyte to generate a viral particle starting from the 
negative HCV RNA-strand (Ribeiro et al., 2012).  During the chronic infection 
approximately 1 x 1012 RNA copies are being produced every day and the half-
life of the viral particle is about 3 – 5 hours in the blood (Layden et al., 1999; 
Neumann et al., 1998). Even though most (if not all) circulating HCV particles 
arise from infected hepatocytes, it has proven difficult to accurately determine 
the fraction of infected cells and the number of HCV RNA copies within each of 
them. Recent reports using highly sensitive in situ hybridisation and single cell 
laser capture micro-dissection suggest that between 1-54% of the hepatocytes 
are infected during chronic infection (Kandathil et al., 2013; Wieland et al., 
2013). In addition, Kandathil and colleagues found that a single HCV positive 
cell contain 1 - 50IU HCV RNA molecules (Kandathil et al., 2013), a 
quantification that correlates well with previous estimations (Chang et al., 
2003; Stiffler et al., 2009) and suggests significantly lower viral burden in vivo 
compared with in vitro studies.  
 
The intra-hepatic replication of HCV will lead to the production of virions, which 
in turn may infect new hepatocytes. Most of the studies published to date have 
focused on the HCV particle being released into a peri-cellular (cell-free) 
environment before infecting naïve hepatocytes. However, recent data has 
demonstrated that HCV is also capable of direct cell-cell transmission between 
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adjacent cells in the presence of nAbs (Brimacombe et al., 2011; Meredith et 
al., 2013a; Timpe and McKeating, 2008; Witteveldt et al., 2009) (Figure 1.7). 
The fraction of virions being transmitted through cell-free and cell-cell routes is 
unknown, but in vitro data from Brimacombe et al. shows that all genotypes 
utilise both transmission pathways to differing degrees; genotype 3a 
transmission is dominated by cell-cell, whereas genotype 6a mainly transmits 
through a cell-free route (Brimacombe et al., 2011). The cell-cell transmission 
route has been reported dependent on SR-BI expression (Brimacombe et al., 
2011; Meredith et al., 2013b; Xiao et al., 2014), NPC1L1 (Barretto et al., 2014), 
occludin and claudin-1 (Ciesek et al., 2011; Timpe et al., 2008; Xiao et al., 
2014), but independent of CD81 (Timpe et al., 2008; Witteveldt et al., 2009) 
and TrF1 (Martin and Uprichard, 2013).  
 
The exact mechanism for HCV cell-cell transmission is at the time of writing 
not fully understood. Studies on HIV have shown that infection induces 
activation of the actin cytoskeleton, leading to the formation of filopodia that 
may carry HIV-particles towards the recipient cell (Aggarwal et al., 2012). A 
similar route of transmission has been suggested for HCV, since hepatocytes 
form multiple cell contacts, however a recent publication have reported that 
filopodia express limited levels of the essential entry receptor SR-BI in vitro, 
making it unlikely that the virus is transmitted to naïve cells via these 
filamentous contacts (Meredith et al., 2013a). Reports of HCV cell-cell 
transmission being resistance to monoclonal and polyclonal anti-HCV Ig 
isolated from infected individuals (Brimacombe et al., 2011; Meredith et al., 
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2013a; Timpe et al., 2008; Zhong et al., 2013) and to the DAAs Telaprevir, 
Boceprevir and Simeprevir (Xiao et al., 2014) suggests that HCV may transmit 
through synapses or ”pockets” between adjacent hepatoma cells. However, 
recent observations that heavy-chain antibodies (also referred to as 
nanobodies) raised in HCV E2 immunized alpacas (Tarr et al., 2013) and 
polyclonal anti-E1E2 sera from immunized guinea pigs (Chmielewska et al., 
2014) can limit cell-cell transmission, suggest that the viral particle is not 
transmitted via a synopsis that is protected from Ab access.   
 
In 2013 researchers reported that exosomes isolated from HCVcc transduced 
human hepatoma cell lines contained full-length HCV RNA and viral particle 
proteins and that these were capable of transmitting productive infection in a 
process that were partly resistant to IgGs isolated from chronically infected 
patients and rat antisera raised against CD81, SR-BI and CLDN1 
(Ramakrishnaiah et al., 2013). The observation that the sub-genomic replicon 
cell line were capably of transmitting HCV RNA by exomes as well, suggests 
that the transmission is independent of E1E2 and explains why the antisera 
did not lead to full neutralisation of the exosomes containing full length HCV 
RNA (Cosset and Dreux, 2014; Ramakrishnaiah et al., 2013). The report of 
HCV transmission via exosomes stands in contrast to previous observations 




The presence of a cell-cell transmission route for HCV in vivo has been difficult 
to prove, however recent studies using high-sensitive imaging techniques, 
such as two-photon microscopy and in situ hybridization with individually 
designed probes against the infecting HCV variant have demonstrated the 
presence of HCV antigen expressing foci in histologically stained needle 
biopsies from chronically infected patients (Liang et al., 2009; Wieland et al., 
2013). In addition, single cell laser capture micro-dissection followed by HCV 
qRT-PCR, reported a similar focal distribution of HCV positive cells in hepatic 
biopsies (Kandathil et al., 2013; Stiffler et al., 2009). These observations 
strongly support the existence of cell-cell dissemination in vivo and highlight 
the importance of considering multiple transmission routes when designing 




Figure 1.7: Modes of HCV transmission.  
Following HCV entry, un-coating and genome translation, the RNA-dependent RNA 
polymerase (NS5B) initiates replication. The NS5B is highly error-prone and will 
generate genetically distinct, but closely related progeny strands (indicated with 
different colour strands) (see section 1.14). Following viral assembly the particles may 
disseminate through cell-free or cell-cell transmission. During cell-free transmission 
the virions are released to the extracellular environment. Here the virus will encounter 
neutralising anti-HCV antibodies (Y), which may prevent the virus from entering new 
target cells. (Brimacombe et al., 2011; Timpe et al., 2008; Witteveldt et al., 2009). 
(CLDN1: Claudin 1, OCLN: Occludin).   
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1.14 HCV quasispeices   
Longitudinal studies have shown that HCV accumulates between 1.11 and 
1.44 x 10-3 nucleotide substitutions per site per year over the whole genome 
(Gomez et al., 1999; Gray et al., 2011; Simmonds, 2004). This is the 
equivalent of 0.1% -10% of the daily virus production having at least one 
nucleotide change (Gregori et al., 2014; Guedj et al., 2013). As a result HCV 
sequence diversity evolves rapidly and the patient becomes infected with a 
group of closely related variants, rather than a clonal population. Each variant 
in the heterogeneous population is represented at a different quantity, also 
referred to as the major/dominant and minor variants, the major being the 
variant with the highest number of detectable copies.  
 
In 1971, Eigen developed the quasispecies model, which has proven to be a 
useful tool for looking at general evolutionary modelling of error-prone self-
replicative systems (Eigen, 1971). The term is often used to define a 
population of genetically variable sequences where natural selection acts on 
the group rather than the individual (Holmes, 2010a, b; Holmes and Grenfell, 
2009). In 2006, Vignuzzi et al. set out to challenge the quasispeices 
hypothesis by generating laboratory poliovirus variants with high- (wild type) 
and low-fidelity (mutant) polymerases. In support of the quasispecises model 
they found that the wild type poliovirus polymerase lead to a lower viral 
diversity in inoculated animal models and a more attenuated pathogenic 
phenotype compared to the mutant (Vignuzzi et al., 2006). This observation 
has been described as proof that quasispecies variants function as an 
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interactive unit, which together contribute to the phenotype of the whole 
population. HCV is often described as a quasispecies population with similar 
properties as the poliovirus mutant. However, Holmes challenges the proof 
that HCV or any other RNA viruses form quasispecies in vivo (Holmes, 2010a). 
Instead, Holmes et al. suggests that all previous in vivo studies merely studied 
HCV variability and phenotype in transit, which is necessary for demonstrating 
quasispecies behaviour, but not sufficient. Most studies investigating natural 
selection, such as immune escape, drug resistance or co-receptor affinity for 
individual HCV variants, have failed to show natural selection on the whole 
group. According to Holmes et al. natural selection at the group level can only 
occur if the mutation rates are high enough to generate an effective 
“mutational coupling” between the variants, so that they evolve as a unit. 
However it is unlikely that the mutation rates of RNA viruses are high enough 
to form this “coupling”, thereby reinforcing Holmes’ contention that RNA 
viruses do not form quasispecies (Holmes, 2010a, b; Holmes and Grenfell, 
2009; Jenkins et al., 2001).  
 
In contrast to Holmes, other researchers argue that quasispecies dynamics do 
exist for error-prone asexually-replicating organisms (e.g. RNA viruses). The 
argument is that RNA viruses follow a concept of “mutation-selection balance”, 
where the quasispecies dynamics rely on mutation-fitness and replication rate. 
In a situation where the mutation rate is low or zero, the homogenous 
replicator with a high replication rate will quickly take over the population, but 
this homogenous population will be less robust to external factors, which may 
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change the population structure (survival of the fittest model). However, if the 
mutation rate is high, the resulting heterogeneous population will have higher 
mutational robustness, where the population is less sensitive to external 
selection against individual variants (the concept of quasispecies population) 
(Sardanyes et al., 2008; Wilke, 2005; Wilke et al., 2001). This latter criterion is 
also called “survival of the flattest”, with a strong reference to Darwin’s survival 
of the fittest concept. In this model the heterogeneous population covers a 
wide range of fitness values, including some with very high individual fitness 
(Mas et al., 2010; Sardanyes et al., 2008; Wilke, 2005; Wilke et al., 2001). 
Most studies today, including those from the McKeating group, consider HCV 
as a quesispecies-forming virus that follows the concept of “survival of the 
flattest” during persistent infection. The term quasispecies will therefore be 
used in our study to describe the swarm of genetically distinct, but closely 
related HCV variants isolated from the study subjects. 
 
1.15 HCV quasispecies and persistent infection  
Analyses of the E2 HVR1 have previously shown proportionally higher 
accumulation of non-synonymous (dns) than synonymous (ds) substitutions 
per site over time (Farci et al., 2000; Liu et al., 2010; Manzin et al., 1998; Ray 
et al., 1999; Wang et al., 2007b). For protein-coding genes this suggests 
positive selection on the mutation rate. The observation that HCV establishes 
persistent infection in the presence of cellular and humoral responses strongly 
suggests that positive selection is being driven by the host immune response, 
leading to the evolution of HCV “escape” variants capable of evading the 
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immune response. This is further supported by the observations that  (i) HVR1 
sequences diverge around the time of sero-conversion (Bowen and Walker, 
2005a), (ii) major HVR1 variants are not neutralised by autologous nAbs 
present in simultaneously collected serum samples, but are neutralised when 
testing against later collected sera (Kato et al., 1994; von Hahn et al., 2007) 
and (iii) that patients with hypogammaglobulinemia, (lack of a functional 
humoral immune system) and co-infected HIV patients have significantly lower 
nucleotide substitution rates for HVR1 compared to immuno-competent HCV 
infected individuals (Booth et al., 1998; Canobio et al., 2004).  
 
Studies evaluating the HCV HVR1 dn/ds ratio in patients who subsequently 
resolve their infection and in those that progress to chronic diseases have 
shown contradicting results. Farci and colleagues found that resolving patients 
had higher HVR1 dn/ds ratios than progressing patients, favouring the model 
that a strong immune selection pressure towards the antigenic HVR1 is 
required to eliminate the virus (Farci et al., 2000). In contrast Ray et al. found 
high HVR1 dn/ds ratios linked to persistent infection and so argued that HVR1 
may function as an immunological decoy, stimulating a strong immune 
response that is unsuccessful in clearing the infection. Instead HVR1 may 
distract the humoral immune response from the effective nAb epitopes (Ray et 
al., 1999) (section 1.9.2).  
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A potential association of HCV quasispecies complexity with hepatic diseases 
has also proven controversial. While some studies have reported that high 
HCV sequence divergence is associated with cirrhosis (Hayashi et al., 1997; 
Honda et al., 1994; Koizumi et al., 1995) and HCC (El-Shamy et al., 2013), 
others have found no significant differences in HVR1 diversity for patients with 
mild or severe liver disease (Duffy et al., 2002; Naito et al., 1995). Most 
studies on this topic have been cross-sectional and have not taken into 
account the fluctuation of the HCV genetic population over time, which may 
explain the reported disagreements. 
 
More recent studies have looked at the longitudinal dynamics of HCV 
quasispecies during hepatic disease progression. Interestingly, most published 
papers have found that patients who, will later develop severe liver disease, 
have a lower level of sequence diversity than patients with mild progression 
(Curran et al., 2002; Li et al., 2011; Sullivan et al., 2007; Wang et al., 2007b). 
A high HVR1 genetic diversity prior to liver transplantation has also been 
linked to a milder disease progression following transplantation (Li et al., 2010). 
In addition, patients with mild disease progression accumulate a higher dn/ds 
ratio over time than those with more aggressive disease (Curran et al., 2002; 
Li et al., 2011; Wang et al., 2007b), suggesting that a high selective immune 
pressure will lead to milder disease progression. Interestingly, the 
observations listed above contrast with the immune-pathogenesis theory that 
strong HCV-specific immunity (leading to high selective pressure on the HCV 
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particles) is the major contributor to liver injury (Spengler and Nattermann, 
2007).  
 
1.16 Analyses of HCV quasispecies variability 
Over the years several different approaches have been made to measure the 
genetic distance between the identified HCV sequences (diversity) and the 
number and distribution of each HCV genetic variant (complexity) within the 
quasispecies population. Two of the most popular methods, when HCV was 
first discovered, were single strand conformation polymorphism (SSCP) and 
Heteroduplex mobility analysis (Gomez et al., 1999; McCaughan et al., 2003). 
The results from SSCP analyses only provided information about the 
quasispecies complexity and not diversity (Peters et al., 1997). That said, 
SSCP is still widely used for analysing changes in the quasispecies population 
during PEG-IFN-α and ribavirin treatment (Caraballo Cortes et al., 2012; 
Salmeron et al., 2008). Unlike the SSCP approach, heteroduplex mobility 
analysis is capable of measuring both quasispecies complexity and diversity 
(McCaughan et al., 2003). However, heteroduplex mobility analysis has 
proven to be less sensitive at differentiating single nucleotide substitutions and 
detecting HCV minor sequences than molecular cloning followed by Sanger 
sequencing (Wilson et al., 1995). Today, heteroduplex mobility analysis is 
mainly used to distinguish between HCV genotypes and to detect super-
infection (Li et al., 2008; White et al., 2000).  
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Sanger sequencing of PCR amplified cDNA has been the preferred route to 
investigate HCV quasispecies populations. Often the investigator will generate 
a bulk PCR product and perform direct sequencing to generate an initial 
consensus sequence of all the viral polymorphisms in the sample. Using the 
consensus sequence to assess viral heterogeneity offers an easy and low cost 
overview of the sequence polymorphisms in the sample (Rodrigo et al., 2001) 
However, many scientists are sceptical about the approach, claiming that the 
method is less sensitive to detect minor sequences and that it does not 
provide sufficient information about the population structure (Forns et al., 
1999; Gomez et al., 1999; Rodrigo et al., 2001). Results presented in this 
thesis show that the approach is also less sensitive than single molecule 
amplification (SGA) and Next generation deep-sequencing (NGS) (see 
Chapter 6).   
 
A more desirable, but labour intensive approach is to bulk PCR amplify desired 
regions of the viral genome, followed by cloning and Sanger sequencing of 
individual clones (Fishman and Branch, 2009; Forns et al., 1999; Gomez et al., 
1999; Rodrigo et al., 2001). Although this approach provides an overview of 
the different variants it may be subject to several technical errors, leading to 
over- or under-estimation of the population variability and divergence. For 
instance, Forns et al. reported that transformation of the DH5 competent E. 
coli would favour HCV sequences with mutations or frame-shift mutations, 
resulting in an under-estimation of the genetic diversity (Forns et al., 1997). 
Furthermore, over-estimation of the diversity may be a consequence of low-
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fidelity polymerase creating artificial stop codons, frame-shifts and/or 
substitutions during PCR amplification. These errors can be minimised by 
using proof-reading high-fidelity polymerases, such as Phusion (Qin et al., 
2011). Amplifying closely related sequences may result in a phenomena called 
“PCR bridging”, where the PCR polymerase “jumps” from one template 
molecule to another, creating a chimeric sequence that does not exist in the 
true population (Liu et al., 2002). To eliminate PCR bridging, Simmonds et al. 
developed a highly sensitive PCR method that is able to detect a single 
molecule of target DNA (single molecule amplification, SGA) (Simmonds et al., 
1990). Another advantage of amplifying from a single copy of target molecule 
is that the PCR product will be homogeneous and can be directly sequenced, 
saving time and limiting the risk of non-random cloning (Simmonds et al., 
1990).   
 
HCV genome heterogeneity occurs throughout the genome, however the 
mutation rates vary in different regions. The non-structural genes (p7, NS2, 
NS3, NS4, NS5A and NS5B) have an estimated mutation rate of 1 x 10^-3 
nucleotide substitutions/site/year, whereas the envelope proteins are 
estimated to have up to 2.7 x 10^-3 nucleotide substitutions/site/year and core 
0.28 x 10^-3. Unsurprisingly, the HVR1 has the highest rate of mutations 
ranging from 2.5 – 6.9 x 10^-3 substitutions/site/year (Gray et al., 2011). As a 
consequence HVR1 has become the most extensively analysed region of the 
HCV genome for quasispecies population studies (Jacka et al., 2013). Sub-
genomic sequence analysis offers a less expensive alternative to the full-
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sequence analysis, but the disadvantage is the risk of creating false 
monophyletic groups of HVR1 identical variants, which potentially could have 
heterogeneity outside this region (Fishman and Branch, 2009; Forns et al., 
1999; Gomez et al., 1999). A clear example of this is highlighted in the study 
reported in this thesis (see Chapter 6).  
 
In recent years NGS approaches have been developed, enabling coverage of 
96% and an accuracy of 99.96% for Mycoplasma genitalium (580kb); the first 
organism ever to be sequenced by NGS (Margulies et al., 2005). NGS has 
proven to be more reliable and more sensitive to detect minor viral variants 
than SGA detection followed by Sanger sequencing (Fonseca-Coronado et al., 
2012; Gregori et al., 2014; Wang et al., 2007a) and the technique has become 
a popular tool for studying HCV and HIV population dynamics (Bull et al., 
2011; Caraballo Cortes et al., 2013; Hoffmann et al., 2007; Wang et al., 2007a; 
Wang et al., 2010). One of the limitations with NGS is the manual filtering of 
reads; depending on where the threshold for quality score is set (e.g. calling 
an incorrect base), there may be a risk of filtering out true viral variants (non-
errors) together with the sequencing errors (Cabanski et al., 2012; Ramirez et 
al., 2013). 
 
1.17 Viral compartmentalisation  
In this study viral compartmentalisation is defined as the existence of viral sub-
populations in different tissues within a single host or in different 
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compartments of the same tissue, between which movement of viral variants is 
restricted (Beerli et al., 2001). The most widely analysed virus in terms of 
genetic compartmentalisation is HIV. Compartmentalised HIV sub-populations 
have been observed between PBMC and the CNS (i.e. brain, spinal cord and 
surrounding meninges) (Hughes et al., 1997; Lamers et al., 2011), the female 
genetic tract (Philpott et al., 2005), semen (Anderson et al., 2010), breast milk 
(Becquart et al., 2002) and most recently between PBMCs and the liver 
(Blackard et al., 2012; Penton and Blackard, 2013).  
 
In addition, HIV-1 is reported to form intra-splenic compartmentalisation 
between the white pulps. In this study, Delassus et al. found that HIV proviral 
variable regions in the gp120 envelope protein (V1 an V2) had identical 
dominant sequences, but different minor sequences between splenic white 
pulps isolated from a patient with AIDS (Delassus et al., 1992). It is thought 
that the spatial HIV distribution in the spleen is the result of a few initial 
(founder) viruses being transferred to different periarteriolar lymphoid sheaths 
(PALS) in the spleen. The antigen-depended T cell activation in the PALS will 
afterwards result in an error-prone HIV replication, leading to an independent 
HIV evolution at the specific sites (Cheynier et al., 1992; Gratton et al., 2000). 
The spleen will eventually be infected with a large number of small HIV 
populations (meta-populations), which over time undergo genetic drift and 




1.18  HCV compartmentalisation between tissues  
HCV genetic diversity has previously been reported between several tissue 
compartments. In 2004, Forton et al. who found statistical support for HCV 
genetic divergence between brain, serum and lymph node for one out of two 
patients, using cloning and Sanger sequencing methods (Forton et al., 2004). 
In addition, several studies have reported genetic compartmentalisation 
between PBMC and serum/plasma for different HCV genomic regions; NS5A 
(Blackard et al., 2012), HVR1 (Blackard et al., 2007; Navas et al., 1998; 
Ramirez et al., 2009) and the 5’UTR (Roque-Afonso et al., 2005; Vera-Otarola 
et al., 2009).  
 
HCV compartmentalisation studies are often focused on either viral RNA 
quantity or genetic sequence divergence between serum and liver tissue. 
Comparative studies on the viral load between the two sites in a single host 
are often difficult as different approaches are used to isolate and measure viral 
RNA copies at each site. Serum and/or plasma loads are measured as either 
HCV copies or international unit (UI) per ml serum/plasma, whereas the liver 
burden is usually expressed as copies per amount of total hepatic RNA, 
making the two challenging to compare directly. Instead, studies have 
compared the ratio of the two parameters between multiple study objects. 
Whereas some have reported positive correlation between the serum/plasma 
and the liver viral RNA load for humans and chimpanzees (Bigger et al., 2004; 
Cabot et al., 2000; Descamps et al., 2012; Idrovo et al., 1996; Sakai et al., 
1999; Vona et al., 2004) others have reported no correlation between the viral 
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burden in the two compartments (Ballardini et al., 1997; Fanning et al., 2001; 
Yuki et al., 2006). It should be mentioned that the majority of ‘between’ tissue 
compartmentalisation studies do not consider the disease stage of the study 
subjects. Of the studies mentioned above, only one has investigated the 
impact of fibrosis staging (Cabot et al., 2000). In this study, only patients with 
mild fibrosis showed correlation between the plasma and hepatic HCV RNA 
loads, however the correlation was lost for patients with cirrhosis (Cabot et al., 
2000).  
 
In addition to studying viral burden between the periphery and liver, reports 
have assessed the genetic diversity between these sites. Fan et al. showed 
that the liver has a higher number of non-identical sequences, which failed to 
correlate with the peripheral sequence set (Fan et al., 1999) and Li et al. has 
reported that 11 out of 14 patients showed statistical evidence for genetic 
divergence for HVR1 clones deriving from liver and plasma (Li et al., 2010). 
Others have found correlation in the level of sequence diversity and complexity 
between the compartments (Cabot et al., 2000; Sakai et al., 1999) and 
furthermore that 46 to 53% of patients have identical HVR1 dominant clones 
between the two compartments together with a unique set of minor (Cabot et 
al., 2000; Ramirez et al., 2009; Sakai et al., 1999). In this thesis an in depth 
investigation of the HCV genetic distribution between liver and plasma 
provides new insight to the topic (see Chapter 6).  
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The observation that the viral load and genetic pool differs between different 
compartments in one patient could potentially be the result of either excess 
hepatic replication, poor hepatic release of some HCV variants or a stronger 
immune selective pressure on systemic circulating virions (Cabot et al., 2000). 
Under high immune selective pressure, nAbs may define the clearance rate for 
some strains in the circulation, leading to an overrepresentation of escape 
mutants (Cabot et al., 2000; Fan et al., 1999; Ramirez et al., 2009). Another 
possibility is that extra-hepatic viral replication may contribute to the circulating 
population. This is supported by detection of HCV negative strands in PBMCs 
(Natarajan et al., 2010; Willems et al., 1994), lymph nodes (Pal et al., 2006) 
and in the CNS (Maggi et al., 1999). These extra-hepatic sites have been 
suggested to act as viral reservoirs and could be involved in the formation of 
viral variants capably of re-infecting the liver-graft after transplantation (Brown, 
2005; Gray et al., 2011).  
 
1.19 HCV intra-hepatic compartmentalisation  
The liver is the main site of HCV replication, however several in vivo studies 
have shown that not all hepatocytes in the liver are infected. Techniques such 
as two-photon microscopy with antibodies specific for HCV have shown that 7-
20% of hepatocytes express HCV antigens and are inferred to be infected 
(Liang et al., 2009). More recently, in vivo studies using single cell laser 
capture micro-dissection of individual hepatocytes followed by qRT-PCR 
(Kandathil et al., 2013) and in situ hybridisation with patient-specific HCV 
probes (Wieland et al., 2013) have estimated that between 1 and 50% of 
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hepatocytes are infected and that the number of infected cells correlates with 
the plasma viremia (Wieland et al., 2013). A further interesting observation 
from these studies is that infected hepatocytes are not randomly distributed 
across the liver, but exist in clusters of 5-10 infected cells (foci) (Kandathil et 
al., 2013; Liang et al., 2009; Wieland et al., 2013), similar to what has been 
observed in vitro (Brimacombe et al., 2011; Meredith et al., 2012).  
 
The formation of foci supports a model where cell-cell infection is the dominant 
mode of HCV transmission in vivo, however it is not known what prevents the 
virus from expanding the infected foci beyond the 5-10 infected cell. Wieland 
et al. reported higher levels of IFI27 mRNA in hepatocytes expressing HCV 
antigens and neighbouring naïve cells, compared to more distant ones 
(Wieland et al., 2013). This suggests that the Jak-STAT pathway is initiated by 
endogenous IFN production, which in turn may limit viral transmission. In 
contrast, Kandathil and colleagues failed to observe a similar distribution of 
another ISG, the IFITM3 (Kandathil et al., 2013). Although the observation of 
non-random virus distribution is convincing, it should be mentioned that other 
studies have claimed uniform distribution of HCV across the liver. In 2004, 
Vona et al. found random distribution of HCV infected hepatocytes when using 
a fluorescein-conjugated serum-derived polyclonal Ab against viral NS5A on 
hepatic needle biopsies (Vona et al., 2004). However the antibodies used in 
this study are believed to have low sensitivity and the uniform detection of 
HCV antigens may be the result of high background staining. Nevertheless, a 
uniform distribution of infection would support previous reports on comparable 
 67 
levels of HCV copies in needle biopsies taken from 2 – 7 individual sites in the 
liver (Fanning et al., 2001; Idrovo et al., 1996; Sakai et al., 1999; Terrault et al., 
1997).  
 
Information on HCV genetic intra-hepatic compartmentalisation is limited. The 
most extensive study to be published included 10 hepatic specimens taken 
from two explanted livers with end-stage liver disease. In that study 
heteroduplex mobility revealed that the 10 hepatic sites contained close to 
identical viral diversity, leading the authors to conclude that the viral diversity is 
uniform at end-stage liver disease, however the study did not include 
sequence analyses (Li et al., 2010).   
 
As far as is known, only two reports have studied the HCV sequence diversity 
across distant sites of the liver. Sakai et al. studied 3 samples taken from 
unidentified sites in the livers of 8 patients with earlier stage liver disease and 
compared the HVR1 sequence diversity between those patients who 
progressed to advance disease and those that did not. The data showed 
correlation between the degree of sequence heterogeneity across the liver, but 
left out any phylogenetic or compartmentalisation testing for the HVR1 
sequences obtained (Sakai et al., 1999). In a second study, Cabot et al. 
analysed liver biopsies taken from 3 different sites in one patient. In this study, 
comparison of the 5’UTR region and the E2-NS2 junction revealed identical 
dominant and sub-dominant sequences, together with a set of unique minor 
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sequences. Cabot and colleagues’ concluded that HCV does not form genetic 
compartmentalisation, based on the fact that the intra-hepatic compartments 
shared major HCV sequences (Cabot et al., 1997).  
 
The limitation of the studies described above is that most do not include 
statistical evidence of intra-hepatic compartmentalisation. As far known, the 
HCV genetic compartmentalisation study by Sobesky et al. is the only study to 
have included statistical testing (Mantel’s test) of the isolated sequences from 
each hepatic site (Sobesky et al., 2007). In this study researchers found 
statistical evidence of compartmentalisation of HCV core sequences between 
micro-dissected sections from chronically infected individuals with HCC 
(Sobesky et al., 2007). In addition they reported evidence for 
compartmentalisation between non-tumorous and HCC tissue within the same 
biopsies, indicating that HCV may have evolved independently at different 
histological sites (Sobesky et al., 2007).   
 
Performing single cell HCV sequencing would provide a new insight into HCV 
genetic compartmentalisation in the microenvironment. However amplifying 
and sequencing the quasispecies at a single cell level would require highly 
sensitive systems. As far known proviral HIV is the only viral genome to be 
sequenced in a single cell in vivo (Balfe et al., 1990; Josefsson et al., 2011; 
Simmonds et al., 1990) and single cell sequencing studies are yet to be 
performed for viral RNA genomes. Interestingly, a recent study has showed 
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that the NS5B sequences from single huh7 cells supporting sub-genomic 
JFH1 HCV replication, displayed ds and dn changes between cells in the 
same culture after 6 days incubation (McWilliam Leitch and McLauchlan, 
2013). This observation suggests that HCV evolve independently in individual 
cells, leading to potential genetic compartmentalisation. It should be 
mentioned that the study by McWilliam Leitch et al. does not take into account 
viral transmission, since the replicon cells lack structural protein and do not 
assemble infectious particles. Repeating this study with a full-length infectious 
virus could potentially lead to less diversity between cells due to the presence 
of both cell-free and cell-to-cell transmissions. 
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2 PROJECT OPJECTIVES 
The overall goal of this study was to gain a better understanding of the HCV 
quasispecies distribution within the liver and between the liver and plasma, 
and to evaluate potential markers, which may predict the intra-hepatic and 
plasma viral RNA burden.  
The hypothesis was that the level of HCV RNA load and the diversity of 
quasispecies population would vary between different sites within the liver and 
between liver and plasma, and that intra-hepatic markers would reflect this 
variation.  
 
The result chapters address the following objectives:  
 To quantify the HCV RNA burden across 8 different sites in the livers of 
22 patients with end-stage liver disease and to ascertain whether an 
association exists between hepatic and peripheral HCV RNA levels.  
 
 To measure the expression levels of the 4-gene classifiers (ISG15, 
IFI27, RSAD2 and HTATIP2) across the 8 hepatic sites and compare 
the level with hepatic and plasma viral RNA loads and other clinical 
parameters, such as previous response to PEG-IFN-α + ribavirin 
treatment, disease diagnosis and infecting viral genotype.  
 
 To investigate HCV sequence diversity across the 8 hepatic sites and 
plasma collected from patients with end-stage liver disease and to 
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determine whether genetic compartmentalisation exists between 




3 MATERIALS AND METHODS 
 
 
3.1 Clinical samples 
3.1.1 Adult samples 
This project is part of a clinical trial for the SR-BI antagonist ITX5061 in a liver 
transplantation setting. The clinical trial was managed by Dr Ian Rowe (HCV 
Research Group, University of Birmingham). In total 23 patients were recruited 
to the study. The first 13 received placebo treatment and the remaining 10 
patients received one dose of ITX5061 12 hours pre-transplantation and then 
daily for 7 days post-transplantation. Less than 24 hours after liver 
transplantation, pathologist Dr. Gary Reynolds  (Liver Research Group, 
University of Birmingham) sampled 150mg specimens from each of the 8 
Couinaud’s segments in the liver explants. Parts of these were snap-frozen for 
later RNA extraction and the adjacent sections were fixed in formalin for 
histology. An overview of the 8 liver segments is illustrated in Figure 3.1A. The 
Couinaud’s segments indicated on the patient 1 liver in Figure 3.1B.  
 
In addition to the liver specimens, each of the transplanted patients donated 
5ml plasma at the time of transplantation. The plasma viral load was quantified 
by the Heartlands Hospital, Birmingham, UK, using the Roche Cobas Amplicor 
2.0 assay and expressed as International Unit (IU) / ml. To compare the HCV 
copies per sample, all IU were converted to HCV copy numbers by using the 
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guidelines on the Hepatitis C Support Project (HCSP) Fact Sheet for the 
Cobas Amplicor HCV monitor v2.0 (1 IU/ml = 2.7 HCV copies/ml).  
 
Information about the patient age, indication for liver transplantation, previous 
response to IFN treatment, plasma viral load at time of transplantation and the 
time between the explanted liver was removed from the patient and processed 
in the laboratory can be found in Table 3.1. Further information regarding the 
trial is available at www.clinicaltrials.gov (NCT01292824).  
 
Total hepatic RNA from six normal livers, six livers with alcoholic liver disease 
(ALD), six non-alcoholic steatohepatitis (NASH), six auto-immune hepatitis 
(AIH) and six non-A, non-B, non-C viral hepatitis (nA/nB/nC) were provided by 




Figure 3.1 Anatomy of the liver. 
A. Illustration of the Couinaud’s segmental anatomy of the human liver. The main 
portal vein is divided into right and left branches, followed by further division into four 
vessels, which supply each of the 8 Couinaud segments with portal blood. In addition 
the segments have individual arterial blood supply and bile drainage. Segment 1 is 
the equivalent of the caudate lobe, which is separate from the other segments. 
Segments 2 and 3 are located on the left lateral liver section, segment 4 on the left 
medial sector, segment 6 and 7 on the right anterior sector and 5 and 8 on the right 
posterior sector (Dooley et al., 2011). In this study specimens were taken from the 
surface of each of the 8 sections (illustration from (Bornman and Beckingham, 2001)). 
B. Liver explant from patient 1. The numbers indicate where the specimens were 
taken. Sample 4 was dissected from the dorsal side.  
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3.1.2 Children samples 
Frozen hepatic needle biopsies from 11 chronically infected children were 
provided by the Birmingham Children’s Hospital Biobank. Information on the 
pediatric patients can be found in Table 3.2.  







3.2 Histology  
3.2.1 Sectioning 
Hepatic specimens from patient 2, 7 and 9 were snap frozen in liquid nitrogen 
prior to cryo-sectioning (Leica Biosystems, Germany). The frozen tissue was 
embedded within Jung Tissue Freezing Medium (Leica Biosystems) and 
placed on a chuck in the cryostat (– 20°C). All 20µm sections were transferred 
to pre-chilled sterilised eppendorf tubes, which were placed back into liquid 
nitrogen. The 2 x 5µm sections for each patient were placed on glass-slides 
and allowed to air-dry before being fixed in 10% formal saline solution (Adam’s 
Healthcare Ecolabs, UK) for 24 hours at room temperature. Following fixing, 
the tissue was stained with H&E using the standard protocol (Bancroft et al., 
2013). All reagents for the H&E were provided by Leica Biosystems.  
 
3.2.2 Microscope imaging 
The 5µm sections from patients 2, 7 and 9 were scanned at 10 x magnification 
by the Leica DM6000 microscope (Leica Biosystems). The images were 
afterwards analysed using ImageJ 1.48b (Wayne Rasband, National Institute 
of Health, USA).  
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3.3 RNA extraction  
3.3.1 Adult hepatic samples 
Total RNA was extracted from the HCV infected hepatic specimens (weight 
~150mg) using the RNeasy Midi-kit with the manufacturer’s provided 
instructions for “Isolation of total RNA from animal cells” (Qiagen, Germany). 
Briefly, the snap frozen hepatic sample was placed in separate gentleMACSTM 
M-tubes (Miltenyi Biotec, UK) together with 4ml of Buffer RLT (all buffers were 
provided with the kit) + 1% β-Mecaptoethanol (Sigma-Aldrich, USA). The M-
tubes were placed on the gentleMACSTM Dissociator (Miltenyi Biotec), which 
homogenised the liver tissue during the manufacture’s default program 
RNA02.01. The homogenised lysate were added 4ml of 70% ethanol and 
transferred to RNeasy Midi-columns. The columns were centrifuged for 5 
minutes at 12,500 x g and the flow-through discarded. Four ml of washing 
buffer RW1 was added to the column prior to centrifugation for 5 minutes at 
12,500 x g. This was followed by two washes with 2.5ml buffer RPE followed 
by 2 minutes centrifugation at 12,500 x g between each wash step. The 
Rneasy Midi-columns were transferred to sterile15ml Falcon tubes (Fisher 
Scientific, UK) and 250µl of the provided RNase-free H2O added. The 
membrane was allowed to soak for 5 minutes before the RNA was eluted 
during a 5-minute centrifugation at 12,500 x g. The eluted RNA was stored in 
50µl aliquots at -80°C.    
 
All samples from one adult liver were processed on the same day and only 
one liver processed per day, in order to decrease the risk of potential cross 
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contamination between patients. Plasma specimens were processed on 
separate days for the same reasons. Phylogenetic analyses of the plasma- 
and liver derived sequences showed no evidence of cross-contamination, 
validating this approach.   
 
3.3.2 Children hepatic samples and adult liver sections 
The paediatric hepatic samples (about 27mm3) and the 12 sections of the 
adult liver specimens (about 0.72mm3) were considerably smaller than the 8 
hepatic adult specimens (about 256mm3) and therefore required the RNeasy 
Micro-kit (Qiagen) for RNA extraction. The capacity of the RNeasy column is 
300µl lysate, however the gentleMACSTM M-tubes requires a minimum volume 
of 600µl for a complete homogenisation. The lysates were therefore split into 2 
x 300µl after being homogenised on the gentleMACSTM Dissociator (program: 
RNA02.01) in the presence of 600µl buffer RLT + 1% β-Mecaptoethanol + 4 
ng/µl carrier RNA. The RNA extraction was done according to the 
manufacture’s instructions for “Purification of total RNA from fibrous tissue”. In 
short, 300µl of lysate were added to 300µl Protease K solution (0.33mg/ml) 
(Qiagen) and incubated at 55°C for 10 minutes followed by 3 minutes 
centrifugation at 20,000 x g. The supernatant was transferred to a new 
eppendorf tube and 500µl of 100% ethanol gently added. This mixture was 
transferred to the RNeasy Micro-column and the sample centrifuged for 30 
seconds at 20,000 x g, followed by a 350µl buffer RW1 wash step. The flow-
through was discarded and 80µl of DNAse I (0.34 Kunitz units/µl) added to the 
membrane. The column was incubated for 15 minutes at room temperature 
 80 
before 350µl buffer RW1 was applied and the sample centrifuged for 30 
seconds at 20,000 x g. The flow-through was discarded and 500µl of buffer 
RPE added prior to an additional centrifugation step. A volume of 500µl 80% 
ethanol was added to the RNeasy Micro-column, followed by a 7-minutes spin 
at 20,000 x g. The column was then transferred to a sterile eppendorf tube and 
the RNA eluted in 15µl of RNase-free H2O by centrifugation at 20,000 x g for 2 
minutes. The elutes from the duplicate RNA extractions were pooled and 
stored at -80°C.   
 
3.3.3 Adult plasma samples 
RNA was extracted from 500µl of plasma by the QIAamp MinElute virus spin 
kit (Qiagen, UK), using the provided protocol for “Purification of viral nucleic 
acids from plasma, serum or cell free body fluids”. The viral RNA was 
extracted according to the manufacture’s instruction without any alterations. 
The extracted viral RNA, was eluted in 30µl RNase-free water and stored at   -
80°C.  
 
3.4 Optimising HCV detection  
3.4.1 RNA heat denaturation 
Investigation of the optimal temperature for dsRNA denaturation was 
performed with 1µg dsRNA ladder (New England Biolabs, UK) as the template. 
The dsRNA ladder was mixed with 1x SYBR-green jumpstart Taq ReadyMix 
(Sigma-Aldrich) and incubated at increasing temperatures going from 37 to 
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99°C over 30 minutes or decreasing temperatures going from 99 to 37°C over 
1 hour, using the melting-curve setting on the Stratagene Mx3000P QPCR 
machine, (Stratagene, UK). The fluorescence intensity from the SYBR-green 
oligos binding dsRNA were analysed by the qPCR software provided by the 
manufacture (Stratagene Mx3000P QPCR machine system). 
 
The compounds betain, trehalos dihydrate and dimethyl sulfoxide (DMSO) 
have previously shown to reduce secondary RNA structure during qRT-PCR 
and it was therefore decided to test these within our melting curve assay. The 
optimal effect of DMSO is usually found within a narrow range of 
concentrations (Masoud et al., 1992) and we therefore compared 
concentrations of 5 and 10% DMSO in the assay. The final concentrations of 
the remaining compounds were based on previous experience in the 
McKeating lab (Peter Balfe, unpublished data). 
 
The assays were set up with the addition of either 10% betain (Sigma-Aldrich), 
1% D-(+) trehalos dihydrate (Sigma-Aldrich), 5 or 10% DMSO (Fisher 
Scientific, UK) to the 1x SYBR-green jumpstart Taq ReadyMix and 1µg dsRNA 
ladder. The melting curve program on the Stratagene qPCR machine was set 
to reach 99°C within 30 minutes and the SYBR-green fluorescence was 
measured for each second. As a result of these data, HCV quantification in the 
hepatic RNA extractions was performed in the presence of 5% DMSO (Fisher 
Scientific) (see section 3.5). 
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The dsRNA denaturation rate was determined by incubating the dsRNA ladder 
at 85°C for 30 minutes on the Stratagene qPCR machine. The fluorescence 
intensity was measured every second. Heating up the samples to 85°C 
resulted in a rapid 1.25-log reduction in fluorescence intensity within the first 
few seconds. By 15 seconds all of the samples had reached plateaus of 
minimum fluorescence (Figure 3.2, here shown for the first 30 seconds). The 
fluorescence did not decrease further during the 30-minute incubation. These 
data suggest that the RNA remained single stranded for an extensive period 
and it was therefore decided to incubate RNA samples with 5% DMSO for 2 
minutes at 85°C immediately prior to target-specific HCV cDNA synthesis (see 





Figure 3.2 Heat-treatment of dsRNA. 
One µg of the dsRNA ladder (New England Biolabs, UK) was used as template for the 
melting curve assay. The amount of dsRNA was indirectly detected by quantifying the 
SYBR-green (Sigma-Aldrich) bound to the dsRNA. Different compounds were mixed 
with the RNA-SYBR green mixtures and the samples incubated at 85°C for 30 
minutes and the SYBR-green fluorescence measured every second. The 
fluorescence intensity was unchanged after 15 seconds of heat incubation.  
 
  
Melting curve - 1! g RNA
25C (5min) - 85C (15min) -  37C (5min)































3.4.2 HCV cDNA efficiency 
HCV RNA was synthesised from the full-length genotype 1a vector, H77 
(pcDNA3.1 Directional TOPO expression vector (Life Technologies, UK)). 
Firstly the vector was restriction digested with 5U/µl XbaI in the provided buffer 
(New England Biolabs Inc, UK), followed by RNA transcription of 2000ng 
vector DNA using the RiboMAX Large Scale RNA production system –T7 
according to the manufacture’s instructions (Promega). The RNA product was 
purified using manufacture’s “RNA clean-up” protocol provided with the 
RNeasy Kit (Qiagen) and the RNA concentration measured by the GeneQuant 
Spectrophotometer (Amersham Biosciences). For the spiking assay increasing 
amounts of total liver RNA (18.75ng; 37.5ng; 75ng; 150ng; 375ng; 750ng; 
1500ng; 2250ng and 3000ng) from a HCV negative ALD liver were spiked into 
a constant amount of HCV RNA (8.3 x 105 copies) followed by cDNA synthesis 
in the presence 10nmol v3463a-1a primer (Table 3.3) (SuperScript® VILO™ 
cDNA synthesis kit according to the manufacture’s recommendations (Life 
Technologies)). The HCV and GAPDH content were measured by qPCR (see 
section 3.5.1).  
 
3.4.3 Detection of minor HCV RNA in vitro 
Using the same protocol as for the HCV spiking experiment (see section 3.4.1), 
RNA was generated from 1600ng of the patient-derived P1-B6.H3-1.6 and P5-
B3.F3-B9 clones, followed by RNA purification with the RNeasy kit. The RNA 
concentration was quantified by spectrophotometry and decreasing amounts 
of P4-B3.F3-B9 (0.5log dilutions starting at 5000ng) was spiked into a constant 
 85 
solution of 5000ng P1-B6.H3-1.6 RNA and 1500ng total ALD RNA. HCV 
specific cDNA synthesis (primer: v3471a-3a (10nmol)) was carried out using 
the Superscript III Reverse Transcriptase kit according to the manufacturer’s 
instructions (see also section 3.6.1).  
 
This cDNA was used as the template in bulk amplifications (see section 3.6.2) 
and the PCR products purified using the QIAquick PCR purification kit 
according to the manufacturer’s recommendations (Qiagen). Consensus 
sequencing of the purified product was done by Sanger sequencing using the 
v1293s primer (see section 3.8).   
 
3.5 Real time quantification PCR (qRT-PCR) 
Absolute and relative quantifications of target RNA were measured in the 
presence of the CellsDirect One-Step qRT-PCR reagents (Life Technologies, 
UK); 1 x Reaction Mix, 0.225 x SuperScript® III RT/Platinum® Taq Mix 
together with 1 x human GAPDH (VIC) reference primer-set (Applied 
Biosystems) and 5% DMSO (Fisher Scientific). The total volume for the qRT-
PCR was 15µl per well in 96 well plates and 10µl for 384 well plates. The 
content of target RNA was quantified by either the ABI 7500 Real Time PCR 
system (96 well plate) or the ABI 7900HT Real Time PCR system (384 well 
plate) (Applied Biosciences). All measurements were performed as duplicates 
in two technical repeats.  
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3.5.1 Quantification of HCV RNA 
For the detection of HCV RNA, 0.015µl HCV 5’UTR specific primer/probe 
mixture (FAM) (PrimerDesign, UK) were added per 1µl CellDirect PCR 
reaction mixture (see section 3.5). Quantification of the HCV copies in adult 
specimens was performed for 0.5µl template in 384 well plates and 96 well 
plates. The viral burden in the children samples was evaluated in 96 well 
plates using 1.5µl of template.  
 
A dilution series of HCV positive control standards were included on each 
qRT-PCR and qPCR plate (100 to 107 copies/µl, PrimerDesign) to generate a 
standard curve from which the absolute HCV copy numbers could be 
calculated. The following thermo-cycling protocol was used for HCV qRT-
PCRs:  
30 min 50°C  
5 min   95°C 
15 sec 95°C                 
60 sec  60°C 
 
The results were analyzed by manually setting the threshold values at the 
exponential phase of the FAM (HCV content) and VIC (GAPDH content) 
sigmoidal amplification curves. The HCV quantity for the 8 hepatic specimens 
were normalised to the concentration of total liver RNA measured by 
spectrophotometry. The HCV copy numbers in the children needle biopsies 
50 cycles 
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and the adult 20µm hepatic sections were normalised to the internal GAPDH 
expression (2^∆ Ct).  
 
3.5.2 Evaluation of hepatic expression 
The expression patterns of DDX3 (Hs00606179_m1), albumin 
(Hs00910225_m1), ISG15 (Hs00192713_m1), IFI27 (Hs00271467_m1), 
RSAD2 (Hs00369813_m1) and HTATIP2 (Hs01091727_m1) were evaluated 
by target-specific qRT-PCR. The probes were obtained from Life Technologies 
TaqMan® Gene Expression Assay library, all with FAM-dye. The probes were 
diluted 1 in 3 with the CellDirect qRT-PCR reaction mix. DDX3, ISG15, IFI27, 
RSAD2 and HTATIP2 mRNA levels were measured in 0.5µl template from the 
8 hepatic specimens. The gene expressions were quantified in duplicate in two 
independent qRT-PCR assays.  
 
The 20µm sections from patients 2, 7 and 9 were evaluated for albumin, 
ISG15, IFI27, RSAD2 and HTATIP2 expressions in 96 well plates. A volume of 
0.02µl total liver RNA were used for quantifying albumin mRNA and 0.5µl used 
for the quantification of the remaining gene mRNAs. The expressions of ISG15, 




The relative expressions of the target genes were evaluated by normalising 
the Ct-values with the internal GAPDH expression (2^∆ Ct).  
 
3.5.3 Evaluation of housekeeping genes 
Evaluation of the housekeeping gene’s mRNA levels was performed with the 
PerfectProbe geNorm 12 gene kit (PrimerDesign). The probes were prepared 
according to the manufacturer’s instructions, and used together with the 
previously described protocol for CellsDirect One-Step qRT-PCR kit in a 96 
well plate. The volume of hepatic specimens was 0.25µl / measurement.  
 
Threshold values were set manually in the exponential phase of the FAM 
(housekeeping gene content) and VIC (GAPDH content) sigmoidal 
amplification curves. Calculation of the 2^∆ Ct was performed by using the Ct-
value for each gene to normalise the Ct levels for the remaining 11 gene 
measurements for the sample template RNA. 
 
3.5.4 Anti-viral gene-array 
Biopsy 1 total hepatic RNA extraction collected from patient 4 (5.3ng RNA), 
patient 5 (16.9ng RNA), patient 6 (14.3ng RNA) and patient 13 (14.2ng RNA) 
were used as templates for cDNA synthesis using reagents from the RT2 First 
Strand Kit (SABiosciences, USA) together with the manufacturer’s instructions. 
The total volume of cDNA synthesis for each specimen was applied to 96 wells 
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on a 384 well Human antiviral Response PCR Array (SABiosciences, USA) 
and the gene expression measured according to the provided protocol (RT2 
Profiler PCR Array, using the Absolute Quantity RT-qPCR program). Data 
analyses were done in the web-based RT2 Profiler PCR Array Data Analysis 
Program  
(www.sabiosciences.com/pcrarraydataanalysis.php, SABiosciences). Gene 
expressions of the candidate genes were normalised to the mean expression 
of the housekeeping genes; actin, B2M, GAPDH, HPRT1 and RPLP0 (2^∆ Ct).  
 
Comparative analyses between patients with high and low hepatic HCV loads 
were performed by calculating the 2^∆∆ Ct levels for each candidate gene and 
the fold-difference displayed on heat-maps.   
 
3.6 Generation of patient-derived HCV sequences 
3.6.1 cDNA synthesis 
Recent studies show that cis-interactions between core, E1, E2, p7 and NS2 
from the same virus variant are important in the assembly of the infectious 
HCVcc particles (Stapleford and Lindenbach, 2011). We therefore aimed at 
generating the 3.4kb cDNA fragment from the RNA extractions using reverse 
primers binding at the N-terminal of the NS3 junction (see Table 3.3). For 
unknown reasons it was not possible to generate the 3.4kb fragment for HCV 
genotype 1a and instead the E1 and E2 fragment was obtained (1.7kb).  
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In addition, we found that the cDNA genesis efficiency varied between HCV 
genotype 1a and 3a and we therefore used different kits in order to obtain high 
cDNA yields from both genotypes. The “High capacity cDNA reverse 
transcription” (Applied Biosystems, ABI) were used for HCV genotype 3a 
variants and the SuperScript® reverse transcriptase kit (Life Technology) for 
genotype 1a. The cDNA syntheses were either used directly for nested PCR 
amplification or stored at -20°C.      
 
Optimization for viral positive strand RNA availability (see section 3.4.1), 
resulted in the following cDNA synthesis protocols for the two kits:  
 High capacity cDNA reverse transcription kit (Applied Biosystems, ABI): 
7µl RNA were heat-treated for 2 minutes at 85°C before being added 
10µM HCV specific reverse primer (v3471a-3a, see Table 3.3), 1 x 
Reverse transcriptase buffer, 1 x Reverse Transcriptase Mixture and 
5% DMSO (Fisher Scientific) in a total volume of 20µl. The cDNA 
synthesis was carried out at 37°C for 2 hours, followed by heat-
treatment at 95°C for 10 minutes to deactivate the reverse transcriptase.  
 
 SuperScript® III Reverse Transcriptase kit (Life Technology): 11µl RNA 
were pre-heat treated for 2 minutes at 85°C before being added to 
10nmol HCV specific reverse primers (v2616a-1a, see Table 3.3), 
10mM dNTPs and 5% DMSO (Fisher Scientific) to a total volume of 
13µl. The mixture was heated to 65°C for 5 minutes followed by a 1 
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minute incubation on ice. The template mixture was then added to 1 x 
First-Strand Buffer, 5mM DTT, 200 units of Superscript™ III Reverse 
Transcriptase and 40 units of RNaseOUT™ Recombinant Ribonuclease 
Inhibitor (Life Technologies) in a total volume of 20µl. The mixture was 
allowed to rest for 5 minutes at room temperature. The cDNA synthesis 
was carried out at 50°C for 2 hours followed by heat-treatment at 70°C 
for 15 minutes to inactivate the reaction.  
 
3.6.2 Polymerase chain reaction (PCR) 
The cDNA syntheses were used as templates for amplifying HCV cDNA 
sequences in the sample. Nested PCR reactions were set-up on ice using 
reagent for GC-rich templates (New England Biolabs): 1x GC buffer, 4% 
DMSO, 0.2µM HCV specific forward primer, 0.2µM HCV specific reverse 
primer, 40units/µl Phusion High-Fidelity DNA polymerase and 0.3µM dNTP 
mixture (Invitrogen). Amplifications were performed on the Mastercycler 
gradient thermocycler (Eppendorf), with the following program:  
2 min   95°C  
15 sec  94°C 
15 sec  60°C          30 cycles 
150 sec  72°C 
∞   4°C 
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One µl of the 1st round PCR product was used as template in the 2nd round 
PCR. The 2nd round PCR products were evaluated on 1% agarose gels (1% 
molecular grade agarose (Bioline, UK), 1x bionic buffer (Sigma-Aldrich), 1x 
SYRB Safe DNA gel stain (Invitrogen)) by gel electrophorese (100V). The 
sizes of the amplified fragments were verified by running 100ng of the 1kb 
Plus DNA ladder (Invitrogen) along side the PCR products on the gel. The 
amplified products were purified using the QIAquick PCR purification kit 
(Qiagen) according to the manufacturer’s protocol before direct sequencing.  
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3.6.3 End-stage limit dilution 
Simmonds et al. previously described the technique for single genome 
amplification (SGA) (Simmonds et al., 1990). Here, modifications were made 
to the original protocol for estimating the quantity of the 3.4kb and 1.8kb HCV 
cDNA fragments in the hepatic and plasma samples. A volume of 1.5µl cDNA 
was added to 100µl of 1st round Phusion PCR mixture, which were afterwards 
split into 20µl aliquots. The fifth aliquot was added to 80µl of new Phusion 
PCR mixture (dilution 1/5) and the mixture divided into 20µl aliquots. This 
procedure was repeated until the quadruplicate samples had reached a 
dilution factor of 1/125. The schematic overview of the end-stage limit dilution 
assay can be viewed in Figure 3.3. After the 1st round PCR amplification, 1µl 
of each 1st round PCR products were transferred to 20µl of 2nd round Phusion 
PCR reaction mixture and re-amplified using the PCR program for the nested 
HCV amplicons (see section 3.6.2).  
 
The nested PCR products were separated on 1% agarose (Bioline) gels and 
the number of negative reactions noted for each dilution. The fraction of 
negative reactions were used in the equation for the null class of the Poisson 
distribution to estimate the concentration of HCV cDNA copies that had been 
synthesised (µ = -ln(F0), where µ is the number of HCV copies and F0 the 
fraction of negative reactions) (Figure 3.4). Calculation of the cDNA 
concentrations for samples collected from patient 1, 2, 4, 5, 7 and 9 can be 




Figure 3.3 End-stage limit dilution PCR. 
A limited dilution of the patient-derived HCV cDNA was made for the 1st round of 
PCR; 1.5µl of the template solution was transferred to 100µl 1st round PCR mixture. 
Volumes of 20µl PCR-template mixture were then split into 4 tubes and the remaining 
20µl mixture transferred to 80µl fresh 1st round PCR mixture, making up 100µl 
(dilution 1:5). The procedure was repeated 3 times. The dilution step for the template 
cDNA can be viewed below the tubes. 
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Figure 3.4 Estimation of HCV cDNA copies. 
End-point template dilution by nested PCR was set-up for selected biopsies. All 
dilutions were performed in quadruplicate. Here the PCR products are shown for 
patients 1 (3.4kb fragment, indicated with a black arrow). Underneath the calculation 
of cDNA copies is performed for patient 1, biopsy 5 (P1-B5, red), as an example of 
the null class of Poisson distribution (µ = -ln(F0,  where F0 is the fraction of negative 




Table 3.4: Quantification of HCV cDNA copies synthesised (HCV copies/µl) 
 
 
3.6.4 Single Genome Amplification (SGA) 
The number of HCV cDNA copies (Table 3.4) were used for calculating the 
volume of cDNA template required for generating 20% HCV positive 
amplifications in a 96 well plate (~20 HCV cDNA copies). The required amount 
of cDNA was mixed into 2000µl of 1st round Phusion PCR master mix before 
transferring 20µl aliquots to the 96-well plate. Nested PCR was performed 
according to the protocol stated above (section 3.6.2). Positive amplifications 
were sequenced across the highly variable 5’-region of E2 to reveal any 
ambiguities in the template. Only PCR products that generated monotypic 
chromatograms were carried forward for cloning  (see section 3.7).  
 
3.7 Molecular cloning  
Plasmids carrying the 3.4kb genotype 3a fragment or the 1.8kb genotype 1a 
fragment were generated for the patient-derived SGA sequencens in order to 
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stably store the amplified HCV fragment and for future biological 
characterisation of their phenotypes.  
 
3.7.1 Ligation 
The purified PCR products were ligated into the pcDNA™3.1D/V5-His TOPO® 
vector using the reagents provided in the pcDNA3.1 Directional TOPO™ 
Expression Kit (Invitrogen). The ligation reaction was carried out in a total of 
6µl including 1µl of salt solution, 1µl of the pcDNA™3.1D/V5-His TOPO® 
vector (15-20ng/µl) and 4µl of purified PCR product. The mixture was allowed 
to ligate for 10 minutes at room temperature.    
 
3.7.2 Transformation 
Chemically competent cells were thawed on ice for 5 minutes and kept on ice 
during the whole transformation procedure. For each transformation reaction 
25µl of the One Shot® TOP10 Chemical Competent E. coli (Invitrogen) and the 
6µl ligation reaction were carefully mixed and incubated on ice for 30 minutes.  
Subsequently, DNA uptake was enabled by heat shocking the E. coli for 45 
seconds in a 42°C water bath. The cells were incubated on ice for 5 minutes 
before adding 75µl of the provided super optimal broth (S.O.C medium, 
Invitrogen). The cells were allowed to recover for 1 hour at 37°C with 300rpm 
before the 100µl cell suspension was spread on 2% Luria Broth Base (LB, 
Invitrogen) + 1% agarose (Bioline) plates supplemented with ampicillin 
(100ng/ml) (Sigma-Aldrich).  
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3.7.3 PCR colony screening 
Overnight colonies of transformed One Shot® TOP10 Chemical Competent E. 
coli were PCR screened for the desired insert by using primers targeting the 
HCV insert and the pcDNA™3.1D/V5-His TOPO® plasmid backbone (see 
Table 3.3). The PCR master mixture was made from the reagents in the 
GoTaq® DNA Polymerase kit (Promega) and consisted of 1x Go Taq Buffer, 
8% MgCl2, 0.13µM forward and reverse primers and 0.75U/µl Go Taq Flexi 
polymerase, together with 0.1µM dNTPs (Invitrogen). Single colonies were 
picked up with sterile toothpicks and spread on to 2% LB plates supplemented 
with ampicillin (100ng/ml) (Sigma-Aldrich). After the spread plating the 
toothpicks were dipped into wells containing 15µl of GoTaq® PCR master 
mixture. The screening plates were incubated at 37°C overnight to allow 
colonies to form. The PCR reactions containing the matching colonies were 
screened using the following program:  
5 min   95°C  
15 sec  94°C 
30 sec 57°C 15 cycles 
2 min  72°C   
∞   4°C 
The PCR products were separated on 1% agarose gels and positive PCR 
amplifications evaluated by the size of the amplified product.  
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3.7.4 Plasmid purification and restriction digestion 
Two HCV positive colonies from each transformation were transferred from the 
PCR screening plate to 5ml of 2% LB medium, supplemented with ampicillin 
(100ng/ml) and the suspension incubated at 37°C with 300rpm overnight. The 
following day the plasmid DNA was isolated using the Qiaprep Spin Miniprep 
Kit (Qiagen) according to the manufacture’s instructions. Briefly, the 5ml 
bacterial culture was pelleted by 5 minutes centrifugation at 12.500 x g. The 
supernatant was discarded, 250µl Suspension Buffer P1 (containing LyseBlue) 
added and the mixture vortexed thoroughly until the pelleted bacterial cells 
were completely re-suspended. A volume of 250µl ice-cold Lysis Buffer P2 
were added and the tube inverted gently until the suspension had turned blue. 
The homogenously coloured lysate then had 350µl of Neutralising Buffer N3 
added and the tube was inverted until the blue colour had disappeared. The 
lysates were transferred to 1.5ml sterile eppendorfs, centrifuged for 10 minutes 
at 20,000 x g and the supernatant transferred to the Qiaprep spin column. The 
spin column was centrifuged for 1 minute at 20,000 x g, the filtrate discarded 
and 750µl of Washing Buffer PE applied to the filter. The column was 
centrifuged again and the filtrate removed before a further centrifugation step 
for 1 minute at 20,000 x g. Subsequently, the Spin Column was transferred to 
a Collection Tube and the filter allowed soaking for 1 minute in 40µl of Elution 
Buffer EB. The plasmid DNA was eluted by spinning the column for 1 minute 
at 20,000 x g. The purified plasmids were quantified by spectrometry before 
storing at -20°C. 
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The correct size of the inserted fragment was evaluated by digesting in the 
multiple restriction sites on each side of the insert, followed by gel 
electrophoresis. The restriction digestions were performed on 1µg plasmid in 
the presence of 10 units of XbaI (Promega), 10 units of BamHI (Promega), 
0.1µg/µl acetylated bovine serum albumin (BSA, Promega) together with the 
buffer recommended by the manufacture (1 x Buffer D), making up a total 
volume of 20µl. The digests were performed for 60 minutes at 37°C.   
 
In total 120 HCV clones were generated from liver and plasma samples 
collected from patients 1, 2, 4, 5, 7 and 9 (Table 3.5). In average 20 clones 
were generated per patient. The naming system for the clones is based on the 
well they were identified in. The first 2 characters refer to the initial positive 
well during the end-point dilution PCR and the last 2 characters derive from 
the colony screening PCR. This way all clones can be traced back to the day 
of amplification and the initial E2 sequencing. A few clones are giving numeric 
first characters, these refers to the dilution of the cDNA template from which 
they where amplified. 
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3.8 Sanger sequencing 
All sequencing was performed by the Functional Genomics Lab at the School 
of Biosciences, University of Birmingham, UK, who used a 3730 DNA Analyzer 
(Life Technologies). For each sequencing assay 500ng template was used 
together with 1nmol HCV specific primer.  
 
3.8.1 Sequencing sensitivity assay 
The concentration of the patient 1 and patient 4 nested bulk PCR products 
were quantified by spectrophotometry. Patient 1 biopsy 8 and Patient 4 biopsy 
4 had comparable DNA concentrations (560ng/µl) and were directly mixed at 
ratios of 0:10, 1:9, 2:8, 5:5, 8:2, 9:1 and 10:0. The mixtures were sequenced 
with the v1293s-3a primer (Table 3.3) to identify ambiguities within the HVR1. 
 
3.9 454 ultra-deep sequencing 
The 454 ultra-deep sequencing were performed and analysed by our 
collaborators, Damien Tully, Karen Power ad Todd Allen from the Ragon 
Institute of MGH, MIT and Harvard at Harvard University, USA. In brief, cDNA 
was generated using a one-step RT-PCR for the core, E1, E2, p7 and NS2 
fragment. The amplified cDNA sequences were digested into smaller 
fragments (300-600bp) and ligated to adaptor sequences with individual 
barcodes (Nextera Tagmentation), allowing the HCV cDNA sequence to bind 
agarose beads whose surfaces carried oligonucleotides complementary to the 
ligated adaptors in the cDNA library. Each bead was associated with a single 
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fragment. The bead complexes were subsequently isolated in oil:water 
micelles containing PCR reagents. Thermal cycling (emulsion PCR) of the 
micelles resulted in the formation of thousands of clonal sequences on the 
surfaces of each bead, which were afterwards transferred to individual wells 
on a PicoTiterPlate where the sequencing reaction could be performed. During 
the sequencing reaction the Roche 454 genome sequencer introduces the 
nucleotides in a step-wise manner, allowing the DNA polymerase to 
incorporate one nucleotide at a time. Once incorporated, the nucleotide 
releases a pyrophosphate, which initiates a series of downstream reactions 
leading to the production of light. The emitted light is recorded by a charge-
coupled device (CCD) camera and translated into the genetic code of the 
sequenced fragment. The nucleotide sequences were used for generating a 
de novo HCV consensus genome using the Assemble Viral 454 (Henn et al., 
2012) and VICUNA de novo assembler (Yang et al., 2012) and the detection of 
intra-host HCV variations was assessed by aligning the individual reads 
against the de novo assembled consensus sequence. The validation of true 
polymorphisms was done by ReadClean 454 and V-phaser algorithms 
(Macalalad et al., 2012), which detect any processing errors such as 
homopolymers and carry-forward-incomplete-extensions (CAFIE) miscalls by 
considering the frequency of the polymorphisms compared to the coverage. 
Information about the number of reads and sequence coverage for each 
sample can be found in Table 3.6. The 454 ultra-deep sequencing process 
information was provided by Dr. Damien Tully and from Mardis et al. (Mardis, 
2008) and Schuster et al. (Schuster, 2008).  
 105 




3.10 Sequence analysis  
3.10.1 Phylogenetic analysis 
The CLC Main Workbench 6 (CLC Bio) software was used for analysing the 
genetic distances for the HCV variants. Phylogenetic Neighbour joining 
modelling was performed with 1000 bootstraps and the Hasegawa-Kishino-
Yano (HKY) substitution model with a transition/transversion ratio of 2.0. 
Phylogenetic tree were generated in FigTree version 1.3.1. (Andrew Rambaut, 
Institute of Evolutionary Biology, University of Edinburgh).  
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The Slatkin-Maddison tree-based statistical model was used for estimating the 
minimum number of migration events required to predict the observed spatial 
distribution of sequences between sites (Beerli et al., 2001). The Slatkin-
Maddison modelling were performed with the HyPhy 2.220130723beta(MP) 
software, created by S. Pond, A. Poon and S. Frost, Antiviral Research Centre, 
University of California, USA, and S. Muse, Statistical Genetics, North Carolina 
State University, USA. The analyses were performed with the maximum 
number of unique permutations available. P-values below 0.05 were 
considered statistically significant evidence that the sequences were 
compartmentalised (Beerli et al., 2001). 
 
3.10.2 Shannon entropy 
Shannon Entropy is the most widely used informational theory to quantitatively 
measure uncertainties in a data set. The entropy measure can be used as a 
strategy to calculate sequence variability for a single column of nucleotides in 
a sequence alignment (one-way entropy) or between two sequence 
alignments (two-way entropy). The model considers both nucleotide 
frequencies (e.g. 50% G and 50% C will have a higher entropy than 80% G 
and 20% C) and the number of nucleotide possibilities (e.g.. 80% T, 10% A 
and 10% C will have a higher entropy than 90% T and 10% A) (Sherwin, 2010). 
This gives each position an individual entropy score from 0 (no variability) to 1 
(maximum variability).  
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One-way and two-way entropies were found for each nucleotide in the SGA 
alignments using the Shannon Entropy software on the http://hcv.lanl.gov 
website.     
 
3.10.3 Synonymous and non-synonymous changes 
The number of synonymous (ds) and non-synonymous (dn) changes were 
found for each codon in the SGA-derived HCV sequence alignments using the 
SNAP v1.1.1 program on the  
http://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html website.  
 
3.10.4 BLOcks SUbstitution Matrix (BLOSUM) 
In nature amino acid substitutions do not occur randomly, some are more likely 
to happen than others. For instance, tryptophan (W) will only on very rare 
occasions mutate, whereas histidine (H) more often changes to arginine (R). 
The BLOSUM will weigh these substitutions according to the likelihood of them 
occurring and give a similarity score between the analysed sequences. As a 
result BLOSUM matrices are not based on explicit evolutionary modelling, but 
instead on counting the relative frequency and the substitution probabilities 
between protein families. The BLOSUM62 matrixes for the SGA-derived HCV 
sequences were generated in the ClustalW2 program 
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(https://www.ebi.ac.uk/Tools/msa/clustalw2, European Bioinformatics Institute, 
UK).  
 
3.11 Statistics  
Most statistical analyses were performed using the Prism 5.0 software 
(Graphpath, USA) and the results expressed as mean ± standard deviation, 
unless otherwise stated in the figure legends. Tests were performed using the 
two-tailed paired or unpaired t-test with a confidence interval of 95% and 
corrected for multiple comparison by the Bonferroni method. The Boniferroni 
calculation for multiple comparisons was also used in the post-test for the one-
way and two-way ANOVA. Calculations of the parametric Pearson’s 
correlation were applied to all correlation analyses.  
 
The multiple component linear regression modelling was performed in the R 
commander 3.0.2 software (The R Foundation for Statistical Computing 2012, 
USA) and scatter plot matrixes generated and exported.  
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4 HCV RNA BURDEN IN THE CHRONICALLY INFECTED 
LIVER AND PLASMA. 
 
Previous studies have shown that HCVcc can disseminate to naïve cells via 
cell-free and cell-cell routes in vitro. Cell-cell transmission results in direct viral 
transfer to adjacent cells without an extracellular stage, leading to the 
formation of infected foci in the presence of nAbs (Brimacombe et al., 2011; 
Timpe et al., 2008). Confocal imaging of liver biopsies has demonstrated 
similar foci of HCV antigen presenting cells consistent with the hypothesis that 
cell-to-cell route of virus dissemination occurs in vivo (Liang et al., 2009; 
Wieland et al., 2013). HCV cell-cell transmission in the infected liver may 
support a distribution model where a founder virus infect the hepatocyte 
followed by the dissemination of the virus progeny to adjacent cells, forming 
defined foci across the liver. Formation of HCV positive foci in the liver would 
imply that not all hepatocytes are permissive to HCV infection and that the 
virus may form replication hot spots in distinct areas of the liver.  
 
Clinical monitoring of HCV replication is usually performed with RNA isolated 
from plasma and only rarely performed on liver biopsies. As a result most 
studies on viral burden have been conducted on plasma samples. Of those 
studies which have investigated liver biopsies, most have only included one 
single needle biopsy (Ballardini et al., 1997; Cabot et al., 2000; Descamps et 
al., 2012; Idrovo et al., 1996; Sugano et al., 1995) and only in a few cases 
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have the investigators looked at more than 2 sites in the liver (Cabot et al., 
1997; Sakai et al., 1999; Terrault et al., 1997). For this study we investigated 
the distribution of HCV RNA copies across 8 anatomical segments in 22 
subjects undergoing liver transplantation for HCV associated end-stage liver 
disease (Table 4.1) and compared these hepatic viral burdens with the plasma 
load. 





In this thesis, the 8 hepatic specimens will be referred to as biopsies and in 
some cases be shortened to B1, B2, … B8 and the patients they were 
collected from will be referred to as P1, P2, … P23.  
 
4.1 Optimising detection of HCV in human specimens 
Although HCV is a single stranded RNA virus, double stranded RNA (dsRNA) 
structures, such as hairpin loops, occur both in the coding and non-coding 
regions (Tuplin et al., 2012). Moreover, RNA duplexes of negative and positive 
strands are generated during the HCV replication.  
 
Quantification of the HCV RNA requires that a specific HCV probe bind to its 
ssRNA target (in this study a 88nt conserved region in the 5’UTR). Any dsRNA 
structures in the HCV genome may inhibit this binding and underestimate the 
amount of HCV RNA present. Previous studies on dsRNA reovirus indicate 
that high temperatures increase the formation of viral ssDNA (Gomatos and 
Tamm, 1963a, b). In addition, researchers at the Mount Sinai Medical Centre, 
NY, USA, observed an increase in PCR detectable HCV RNA (up to 2-logs) 
following 106°C heat-treatment of total liver RNA from chronically infected 
individuals (unpublished data, presented at the Annual HCV meeting, 2011)..  
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The one-step HCV qRT-PCR assay used in this thesis requires several 
different temperature steps ranging from 50 to 95°C (see section 3.5). It was 
therefore decided to evaluate dsRNA denaturation during these different 
temperatures. A melting-curve was made using 1µg of a commercial dsRNA 
ladder together with SYBR-green fluorescence probes. As the temperature of 
the mixture increased from 37 to 99°C the SYBR-green fluorescence declined, 
indicating denaturation of dsRNA (Figure 4.1A). At 52°C the fluorescent 
intensity reached 50% of the maximum, indicating that half the dsRNA had 
denatured (Tm50 = 52°C). A plateau of minimum fluorescence was reached at 
85°C (~3700 fluorescent intensity), suggesting complete dsRNA denaturation 
at this temperature. Decreasing the temperature for the same samples to 37°C 
resulted in limited RNA re-annealing, and at 37°C 26% of the original dsRNA 
formations were reformed (Figure 4.1A). These data show that maximum 
denaturation occurs within the temperature range of the one-step HCV qRT-
PCR assay and that only limited re-denaturation occurs at the 50°C cDNA 
synthesis step.  
 
Several compounds have been reported to improve the efficiency of the 
enzymes used in cDNA synthesis, PCR amplification and qRT-PCR 
quantification by reducing secondary RNA (or DNA) structures in the template. 
These compounds include the disaccharide trehalose (Spiess et al., 2004), 
betaine (Schwinefus et al., 2013) and DMSO (Mamedov et al., 2008). The 3 
compounds were tested in our melting curve assay with the aim to optimise 
the dsRNA denaturation assay further. Each compound was added to a 
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SYBR-green solution containing 1µg of a dsRNA ladder, which were then 
incubated at increasing temperatures going from 25 to 99°C over 30 minutes 
(Figure 4.1B). Samples containing DMSO showed a reduction in fluorescent 
intensity of approximately 44% at 25°C compared to the control sample 
contained dsRNA. In comparison betaine and trehalose had 4% and 6% lower 
levels of fluorescence intensity at 25°C, respectively. This observation may 
suggest that the compounds result in dsRNA denaturation even at room 
temperature. Alternatively the compound could have a negative effect on the 
SYBR, resulting in reduced fluorescent independent on denaturation.  
 
Increasing the temperature towards 99°C showed that samples containing 
DMSO reached the minimum intensity plateau (approximately 3100 
fluorescent intensity) at a lower temperature (85-90°C) than any of the other 
solutions (94 to 98°C) and also had a lower Tm50 (Figure 4.1B). These melting 
assays led us to investigate the effect of DMSO on the quantification of HCV 
RNA by qRT-PCR. Since the 5 and 10% DMSO only showed minor difference 
in Tm50, we chose 5% DMSO to limit any potential toxicity effects on the 
enzyme activity.  
 
HCV specific qRT-PCR master mixes were made with or without 5% DMSO 
together with total hepatic RNA isolated from patient 1 (P1-B1 and P1-B5) and 
patient 5 (P5-B1 and P5-B7). The assay included total RNA from a HCV 
negative liver with alcoholic liver disease (ALD) and the full-length HCV H77 
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RNA genome, which had been transcribed from a vector (Figure 4.1C). The 
presence of 5% DMSO resulted in a higher mean HCV RNA detection for the 
patient derived samples (patient 1: 1.9-fold, patient 5: 2.6-fold). However, the 
difference was only statistical significant for P1-B5 (two-tailed unpaired t-test p 
= 0.03). The laboratory strain H77 was included as a negative control for the 
presence of positive-negative HCV RNA strand formations. The lack of 
increased H77 RNA detection in the presence of DMSO indicates that the H77 
genome, and potentially also patient-derived HCV, may not contain any 
dsRNA folds in the amplified region (Figure 4.1C). This supports our 
conclusion that the small changes in viral load seen for the hepatic RNA 
extractions may be the result of RNA duplex denaturation.  
 
Although the effect of 5% DMSO in the qRT-PCR only had a small effect on 
the amount of HCV RNA detected, it did not have any toxic effect and it was 




   
Figure 4.1 Optimisation of ssRNA detection. 
One µg of a commercially obtained dsRNA ladder (Promega) was used as template 
for the melting curve assay. The amount of dsRNA was detected by the intercalation 
of SYBR-green fluorescent dye into dsRNA. The Stratagene qPCR machine was set 
to record SYBR-green fluorescence every second over 30 minutes. A. The dsRNA 
ladder was incubated at increasing temperatures over a 30-minute period (blue line). 
Following heat denaturation the template was re-cooled towards 37°C (-1°C/minute, 
red line), allowing the RNA to re-anneal. B.  Different additives were tested for their 
ability to accelerate dsRNA denaturation during heat-treatment. The dsRNA templates 
were either mixed with betaine (10%, purple line), DMSO (10%, orange line), DMSO 
(5%, red line), trehalose (1%, green line) or water (blue line) before being heated from 
37 to 99°C over a 30-minutes period. H2O with SYBR-green master mix were 
included as an RNA negative control (black line). The coloured boxes indicate the 
melting temperature when 50% denaturation occurred (Tm50).  C. HCV specific qRT-
PCRs with or without 5% DMSO were performed with total hepatic RNA from patient 
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1 (P1), biopsy 1 (B1) and 5 (B5) and patient 5 (P5), B1 and B7 in duplicates (data 
represented as a mean). Total hepatic RNA was included from alcoholic liver disease 
(ALD) together with the full-length HCV H77 RNA genome. The absolute 
quantification of HCV copies were interpolated from an internal standard curve 
(Primer Design Ltd.) in the assay (data not shown) and the viral load normalised to 
the total amount of RNA in the samples.  
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4.2 Identification of stable housekeeping genes in HCV related end-
stage liver disease  
Investigation of HCV between specimens requires a stable reference for 
normalisation. In most of this chapter, the amount of total liver RNA (ng) was 
used as a reference, but in a few cases an internal mRNA reference had to be 
used. Waxman and Wurmback have previously shown that HCV positive 
patients with HCC exhibit a large variation in the expression of housekeeping 
genes compared to patents with early stage fibrosis or cirrhosis (Waxman and 
Wurmbach, 2007). It was therefore important to establish an optimal reference 
gene to enable HCV normalisation between samples obtained from our patient 
cohort. 
 
The expression of 12 common reference genes was measured with the 
GeNorm assay. For this experiment, biopsy 1 from three subjects with HCC 
(patients 4, 7 and 14) and two with cirrhosis (patient 2 and 17) were chosen as 
templates. The expression of the 12 candidate genes in the GeNorm panel 
was measured by target-specific qRT-PCR. For the five hepatic samples 
evaluated, only candidate genes with Ct-values between 15 and 25 were 
considered to have reliable expression patterns. Initial analysis of the raw Ct-
values indicated high expression of 18-sRNA (Ct-value <15) and low 
expressions of RPL13A, CYC1 and TOP1 (Ct-value > 25). These genes were 
therefore excluded from further investigation (data not shown). Eight genes, 
ATCB, GAPDH, UBC, B2M, YWHAZ, EIFA2, SDHA and ATP58 remained in 
the analysis. The expression of each of these 8 genes was afterwards used as 
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internal references for normalising the expression levels for the other 11 genes 
included in the array (Figure 4.2). Normalising all genes with the same internal 
reference revealed large variation in the 2^Δ Ct values. However, comparing 
the values between patient samples normalised with the same reference gene 
did not reveal any significant differences in expression levels (One-way 
ANOVA for each reference gene, p = 0.35). In addition, two-way ANOVA of 
the entire data set did not reveal any systemic variance of the housekeeping 
gene expressions for the different hepatic templates (p = 0.74). Separate 
analyses of the variability between normalising with different reference genes 
and between the expression patterns for different patients, revealed that 
1.21% of the systemic variation (p = 0.56) was due to normalisation with 
different reference genes. However including different patient templates 
accounts for 2.74% of the variation (p <0.05). This observation is likely to be 
the result of larger variation seen in the gene expressions for patient 17 
(Figure 4.2). Excluding patient 17 from the data set makes the observed 
variation between patient templates non-significant  (p = 0.6). 
 
The low variability for normalising with different reference genes means that 
any one of the 8 housekeeping genes could be used as a reference for 
normalising HCV RNA in the 22 explanted livers. Given this result, we decided 
to employ the widely used GAPDH as the reference gene for normalising RNA 
quantities in samples where the total amount of liver RNA cannot be 
determined.   
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Figure 4.2 Evaluation of reference genes in end-stage liver disease. 
The GeNorm panel of 12 different housekeeping genes were used for evaluating the 
most stable reference genes among HCV positive patients with end-stage liver 
disease. Biopsy 1 from two patients with cirrhosis (patients 2 and 17) and three 
patients with HCC (patients 4, 7, 14) were used as template. Between 63 and 270ng 
total liver RNA was used for each evaluation. The expression levels were measured 
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by qRT-PCR with target specific probes. Four of the 12 genes had Ct values either 
above 25 or below 15 and were not included in subsequent analysis. The raw Ct 
values for each of the remaining 8 genes were used in turn to normalise the 
remaining 11 expression levels (Δ Ct) and the fold difference calculated (2^Δ Ct). The 
data is presented as median (horizontal line), upper and lower quartile and the 
maximum and minimum values. One-way ANOVA between gene expressions 
normalised with the same reference gene did not reveal any significant differences 
between the patients (in all cases p >0.05). In addition, the data set did not show any 
systemic variance by two-way ANOVA (p = 0.74).  
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4.3 HCV burden across the liver explant 
To this date, it is not known whether the HCV chronically infected liver is 
homogenously infected or if infected cells exists in pockets of isolated 
populations. In order to investigate hepatic HCV distribution, multiple biopsies 
were taken from 22 HCV infected explanted livers. Twenty-one of the patients 
had 8 biopsies taken and one (patient 10) had 4 biopsies collected because of 
a large hydatid cyst in the left lobe due to an Echinococcus infestation. Patient 
12 samples are not included in the analysis as the time between the removal 
of the explant and sample processing exceeded 24 hours.  
 
As biopsy sampling is highly invasive it would not be ethically possible to take 
8 samples from a functioning liver, justifying the use of samples collected from 
explanted HCV positive livers following liver transplantation. All 22 patients 
gave informed consent for the donation of their explant liver and for blood 
sampling taken at the time of transplantation. The patients included in this 
study were mainly infected with genotype 1 (n=9), followed by 3a (n=6), 2a 
and 4a (n=1 and n=1), which agree with the local geographical distribution of 
these HCV genotypes (Mohd Hanafiah et al., 2013; Sharma and Feld, 2014; 
Simmonds, 2004). The higher number of patients with cirrhosis compared to 
hepatocellular carcinoma is in agreement with the previous observation that 
approximately 20% of chronic infected patients will proceed to develop 
cirrhosis and 2.5% will develop HCC (Hoofnagle, 2002). An overview of the 
patient characteristics can be found in Table 4.1.  
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Samples were taken form the 8 anatomical segments in the liver less than 24 
hours after it was removed from the transplant recipient (see section 3.1.1). 
Total liver RNA was extracted from the hepatic biopsies and the viral load 
measured by HCV specific qRT-PCR. Each of the 8 biopsies from the 22 
included livers was evaluated in duplicate by two experimental repeats (n=2). 
In Figure 4.3A the results are shown for two randomly selected patients 
(patient 1 and 2). The repeated measurements for each biopsy varied by less 
then 0.5 log and are therefore within the expected variation of the assay (0.5-
log). This pattern was also observed for the remaining 22 patients when 
measuring duplicate samples in two experimental repeats.. These data justify 
the use of a mean viral load for each biopsy in subsequent analyses. The 
mean biopsy loads for the remaining patients are shown in Figure 4.3B. Each 
of the 22 livers had comparable levels of HCV RNA between the 8 biopsies, 
with a variance ranging from 0.2-log to 0.75-log, however the HCV RNA levels 
between patients varied up to 2-logs (Figure 4.3B). Comparison of the different 
hepatic anatomical sites showed no correlation between the viral burden and 
the anatomical origin of the sample. (Figure 4.3C; one-way ANOVA; p = 0.44), 
suggesting that no single site within the liver hosts a higher viral burden than 
others.  
 
Patient 14 had a mean viral load of 1.4 HCV copies / ng total liver RNA, which 
is below the estimated assay’s threshold (10 copies / sample, McKeating 
group protocol applied to Primer Design reagents in accordance with 
manufacturer’s instructions). This patient is not considered HCV negative as 
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viral copies were detected in the plasma at the time of transplantation (3.9 x 
104 HCV copies /ml). Likewise, it is unlikely that the low detection is due to 
errors in the RNA extraction, since all 8 hepatic extractions contained high 
levels of total RNA and gave typical signals with the GAPDH endogenous 
control (data not shown). The apparent low level HCV RNA in patient 14 may 




Figure 4.3 HCV RNA expression in the liver explant. 
Biopsies were taken from the 8 anatomic segments in 22 explanted livers and the 
total hepatic RNA extracted. The amount of HCV RNA per biopsy was measured for 
duplicate samples in two experimental repeats (n=2) and the absolute value 
calculated from an internal standard curve. The HCV copy number was normalised to 
Patient 1































































































































the total amount of liver RNA in the particular sample. A. The data are here shown for 
patient 1 and 2. The plotted bars represent the mean measurements with standard 
deviations. B. The mean HCV copies / ng total liver RNA for the 22 patients included 
in the study represented as a scatterplot. Each pink diamond represents one biopsy 
and the mean ± standard deviations are shown for each set of 8 biopsies. C. The 
HCV copies / ng liver RNA for each biopsy was normalised to the mean load for livers. 
The normalised HCV loads for the 22 patients are stratified according to the hepatic 
site the biopsy originated from. The data is presented as median (horizontal line), 
upper and lower quartile and the maximum and minimum spreads. The data set were 
analysed by the one-way ANOVA, which showed no statistical evidence of variation 




Linear regression analyses were done for the hepatic viral load versus the 
patient’s age and the time between transplantation and sample processing. 
Pearson’s correlation coefficient (r2) revealed no association between the viral 
load and patient’s age (r2 = 0.02, p = 0.051) (Figure 4.4A) and between viral 
load and processing time (r2 = 0.0007, p = 0.74) (Figure 4.4B). The hepatic 
viral loads were also compared between the HCV genotypes 1 and 3 
Genotypes 2 and 4 were only represented by one patient each and were 
therefore not included in the analysis. The hepatic viral load in genotype 1 
infected patients were significantly higher than for genotype 3 (Mann-Whitney 
p = 0.006), consistent with previous publications (Rong et al., 2012; Soriano et 
al., 2008).(Figure 4.4C). Furthermore we did not find an association between 
viral load and indication for transplantation (cirrhosis versus HCC, Mann-
Whitney p = 0.87, Figure 4.4D) or between viral load and the patient’s known 
response to PEG-IFN response (One-way ANOVA: p = 0.2) (Figure 4.4E).  
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Figure 4.4 Association between hepatic RNA burden and clinical features. 
A. Linear regression of hepatic viral burden and the age of the patient. B. Linear 
regression of hepatic viral burden and the time between the liver was removal and 
biopsies processed. Each patient is represented by the mean viral load (black circle) 
± standard deviations and the line of best fit between the data points is indicated in 
the graph. Pearson’s correlation coefficient (r2) was calculated for each of the data 
sets (A + B). C. HCV viral loads were compared between patients infected with 
genotype 1 and 3. D. Comparison of viral loads between patients diagnosed with 
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cirrhosis or hepatocellular carcinoma (HCC). Statistical analysis using Mann-Whitney 
were applied to the data in C + D. E. Viral load comparisons between patients with 
known PEG-IFN response. One-way ANOVA revealed comparable viral load between 
patients who did not respond to treatment, those who relapsed, those who did not 
tolerate the treatment and those who did not received treatment (p = 0.20). Each 
black circle represents the mean hepatic load for one patient. The mean and standard 
deviations are shown for each group.    
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4.4 HCV RNA burden in hepatic sections  
During chronic infection, HCV-induced apoptosis of the hepatocytes triggers a 
pro-fibrogenic activation of hepatic stellate cells. These activated cells 
generate fibrotic tissue, which takes over the normal hepatic architecture 
(Wang et al., 2013). In end-stage liver disease the natural hepatic structure is 
usually lost and the hepatocytes are isolated in islets (nodules) surrounded by 
fibrotic tissue. Since hepatocytes are the major reservoir supporting HCV 
replication, differences in viral populations may exist between these healthy 
nodules, leading to hepatic compartmentalisation of the HCV RNA at the 
microscopic level.  
 
Hepatic samples (1cm3) collected from patients 2, 7 and 9 (genotype 1a) were 
sectioned into 12 x 20µm slices. Lysis of the twelve sections for RNA 
extraction meant we could not directly estimate the exact number of 
hepatocytes in each section. We therefore decided to estimate the number of 
hepatocytes in 5µm sections taken directly before and after the twelve 
sections. These sections were stained by Hematoxylin and Eosin (H&E) and 
the fraction of hepatocytes estimated by scanning the slides and manually 
highlighting islets of hepatocyte nodules. The frequency of hepatocytes were 
comparable for the first and last 5µm section for all three patients; patient 2 
showing 57.6% and 60.4%; patient 7, 71.9% and 73.5%; and patient 9 66.8% 
and 69.7% for the first vs. last sections, respectively (Figure 4.5). We infer that 
the number of hepatocytes is comparable across the 12 x 20µm sections.  
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Figure 4.5 Quantification of hepatocytes in vivo. 
Five µm sections were taken directly before and after a series of 12 x 20µm sections. 
The 5µm sections were histologically stained with H&E, scanned at a magnification of 
10.000 x and analysed by ImageJ. The outline of the whole section and the individual 
nodules are highlighted with yellow lines and each unit has a number. The highlighted 
areas were used to calculate the fraction of healthy hepatocytes in each section. The 
estimated percentage of healthy hepatocytes is shown in the bottom left-hand corner 
for each image. 
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The HCV RNA load was quantified in the total hepatic RNA extractions from 
each section. Since the total hepatic RNA extractions were performed with 
exogenous RNA as a “carrier” to precipitate the relatively low levels of RNA, 
the viral loads could not be normalised to the total amount of liver RNA. For 
these samples normalisation to endogenous GAPDH was used, since previous 
studies showed stable GAPDH expression between hepatic samples from 5 
patients included in this study (Figure 4.2). The quantities of HCV RNA varied 
between the sections with patient 2 showing up to 100-fold variation, patient 7 
approximately 10-fold and patient 9 demonstrated 30-fold variation in the HCV 
RNA burden (Figure 4.6). One-way ANOVA demonstrated that each patient 
had significant heterogeneity in viral RNA loads across the 12 sections (p < 
0.001). Interestingly, we found that the HCV RNA levels had continuous 
inclines and declines over several adjacent sections, instead of fluctuating 
levels (Figure 4.6). This suggests that the infected hepatocytes are not in 
20µm sections within the liver. Instead, some of the islets of infected cells may 
spread over two or more adjacent sections resulting in smoothing of the HCV 
detection curve.  
 
The presence of hepatocytes in each section was indirectly confirmed by 
measuring the albumin mRNA present (in vivo, albumin is almost exclusively 
produced by hepatocytes (Hoofnagle, 2002)). All the investigated hepatic 
sections proved positive for albumin mRNA (Figure 4.6B). Patient 7 and 9 
showed significant variation in albumin levels by one-way ANOVA (patient 7: p 
= 0.02 and patient 9: p <0.0001), this either indicates variation in the number 
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of hepatocytes in each section or that the hepatocytes in the individual 
sections show varying levels of albumin expression. Patient 2 did not show 
statistical variation in albumin expression across the twelve sections (one-way 




Figure 4.6 HCV RNA and albumin expression in hepatic sections. 
Total liver RNA was extracted from 12 x 20µm adjacent liver sections obtained from 
patients 2, 7 and 9. The viral load for each section was determined by HCV specific 
qRT-PCR and the absolute quantity calculated from an internal standard. Relative 
amounts of albumin mRNA estimated by target specific qRT-PCR. All HCV and 
albumin estimates were normalised to the endogenous GAPDH expression. The data 
is represented as the mean of triplicate measurements with standard deviation. One-
way ANOVA was performed for the HCV RNA levels and albumin expressions across 
the 12 sections. The probability (p) can be found in the graphs.  
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4.5 Comparison of hepatic and plasma viral burden  
The association between the hepatic and plasma viral burden for the same 
patient is a controversial topic. Some investigators claim to have found a 
strong correlation between these parameters (Descamps et al., 2012; Idrovo et 
al., 1996), whereas others found none (Ballardini et al., 1997; Cabot et al., 
2000). To our knowledge no study have looked at the association between 
plasma and liver viral load in end-stage liver disease and we decided to throw 
some light on the subject by comparing the viral load in the plasma and liver at 
the time of transplantation. The viral load in the last plasma samples obtained 
before anaesthesia (1-2 hours before the explant was removed) was quantified 
at the Heartlands Hospital, Birmingham, UK.  
 
The viral load at the time of transplantation for the 22 patients varied between 
823 and 3.2 x 107 HCV copies/ ml plasma. This large variation was 
independent of the patient’s age (Figure 4.7A; r2 = 0.005, p = 0.77), the 
response to previous PEG-IFN treatment (Figure 4.7B; One-way ANOVA p = 
0.57), the indication of liver transplantation (Figure 4.7C; p = 0.27) and the 




Figure 4.7 Comparative analysis of plasma HCV RNA. 
Plasma viral loads were measured by the Roche Cobas amplicor 2.0 and the 
estimated HCV load (IU) converted to HCV copies /ml. A. Linear regression analysis 
between the plasma viral burden and the age of the patient. A black circle represents 
each patient and the linear regression (line of best fit) is indicated. Spearman’s  
correlation coefficient (r2) can be found at the top of the graph. B. Plasma viral loads 
were compared between patients who did not respond to PEG-IFN treatment, those 
who had relapsed, those who did not tolerate the treatment and those patients who 
had not been treated with PEG-IFN previously. One-way ANOVA revealed no sign of 
significant variation between the HCV RNA levels (p = 0.57) C. Comparison of plasma 
viral loads between patients diagnosed with cirrhosis and hepatocellular carcinoma 
(HCC). The statistical analysis was performed by two-tailed unpaired t-test. D. The 
HCV viral loads in genotype 1 and 3. The statistical analysis was performed by two-
tailed Mann-Withney. The mean plasma loads for the different groups are represented 
with a mean ± standard deviation (B + C + D). 
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Comparison of hepatic HCV copies/ ng total liver RNA with the plasma HCV 
copies/ml revealed significant differences between the loads, with the liver 
showing an average of 184.1 ± 256.4 HCV RNA copies/ng total RNA for each 
patient and the plasma showing 2.9 x 106 ± 6.89 x 106 HCV RNA copies/ml. 
Investigation of the distribution of plasma and liver HCV RNA levels for the 
patient cohort revealed that the two data sets showed non-Gaussian 
distribution of the loads (Kurtosis ≠ 0). Instead, HCV RNA quantified in the 
plasma showed a flat distribution (Kurtosis = -0.07) and in the liver a peaked 
distribution (Kurtosis = 2.24) (Figure 4.8B). Further investigation of the 
symmetry in the data sets showed that both the plasma and liver HCV RNA 
loads were non-symmetrical (skewness ≠ 0), however the distribution of HCV 
RNA quantities were highly similar in the two compartments, with plasma 
revealing a skewness of 1.27 and liver a skewness of 1.77 (Figure 4.8B). 
 
The smallest difference between HCV RNA quantities in the plasma and liver 
were found for patient 5 (0.5-log) and the largest for patient 23 (4-logs) (Figure 
4.8A). Analysis of the viral load ratios for the patients, indicated a limited, albeit 
significant, correlation between hepatic and plasma viral load estimates 
(Figure 4.8C; r2 = 0.49, p < 0.02).  
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Figure 4.8 Comparative analysis between hepatic and plasma viral load. 
A. The plasma and liver viral loads are shown for each of the 22 patients. The plasma 
HCV copies/m is represented with green circles and the mean hepatic HCV copies 
/ng total liver RNA per biopsy by pink diamonds. The mean and standard deviation 
are indicated for the hepatic viral loads. B. Histogram of the liver and plasma HCV 
RNA loads. C. Linear regression analysis of plasma and hepatic viral burden. Each 
black circle represents the mean hepatic and plasma load mean ± standard 
deviations for each patient. The linear regression (best fit) line is indicated. 
Spearman’s coefficient is indicated for the data set.  











Plasma viral load 
(HCV copies/ml)
Biopsy viral load 
















r2 = 0.49 (p < 0.02)






















Plasma (HCV RNA copies / ml) 
Liver (HCV RNA copies / ng liver RNA












4.6 Discussion  
The intrinsic limitation of studying liver biopsies is their potential bias in terms 
of representing the whole liver. In this study, we investigated the spatial 
pattern of HCV RNA expression in the liver by sampling 150mg pieces from 
each of the 8 anatomical hepatic segments in chronically infected explanted 
livers. HCV RNA levels were quantified and compared to vireamic loads, 
infecting HCV genotype, indication for transplantation and previous response 
to PEG-IFN treatment.  
  
The levels of HCV RNA were comparable across all 8 liver biopsies from one 
liver, suggesting that the liver is uniformly infected during end-stage liver 
disease. This observation supports previous publications stating that HCV 
RNA is comparable between multiple hepatic sites (2 – 7 sites) (Fanning et al., 
2001; Idrovo et al., 1996; Sakai et al., 1999; Terrault et al., 1997).  
 
Recent studies have reported that only a limited number of hepatocytes are 
infected and that HCV antigen or RNA expressing cells exists in clusters 
surrounded by naïve cells (Kandathil et al., 2013; Liang et al., 2009; Wieland 
et al., 2013). It is therefore possible that variation in HCV levels exist at a 
microscopic level, instead of a macroscopic. These microscopic differences 
may be overlooked when sampling larger sections of the liver. Characterising 
viral RNA expression across twelve adjacent 20µm liver sections revealed 
significant differences in HCV RNA levels. However, we did not observe any 
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sections that failed to express HCV RNA, contradicting previous reports by 
Liang et al., Kandathil et al. and Wieland et al..The H&E stained sections 
(5µm) immediately before and after the twelve 20µm sections, analysed for 
viral RNA, demonstrated high numbers of hepatocytes (57.2 – 73.5%, Figure 
4.5). Given the low levels of HCV RNA detected in each of the 20µm sections 
from patients 2, 7 and 9, it is unlikely that all hepatocytes are infected. Instead, 
it is more reasonable to model that only a limited number of hepatocytes are 
infected with HCV and that each section contained a fraction of infected cells, 
explaining why all sections contain HCV RNA. Quantifying viral RNA within 
isolated nodules containing healthy hepatocytes or single hepatocytes would 
provide a deeper understanding of the distribution of HCV infected cells and 
the potential formation of compartments supporting HCV infection at a 
microscopic level.  
 
For 5 of the 22 investigated patients HCV RNA levels varied with more than 
0.5-log across the liver, exceeding the variability of the assay. According to a 
previous report, variable HCV RNA levels between hepatic biopsies sampled 
from the same liver may represent the time between sample collection and 
RNA processing (Terrault et al., 1997). In the Terrault et al. study, researchers 
were comparing two sets of samples obtained from the same liver explant with 
a 30-minute interval between collections. The sampling process in our study 
takes approximately 1 hour, which potentially could result in significant load 
differences between first and the last conducted sample. However, when 
comparing the viral RNA levels for individual biopsies, we did not see any 
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significant differences in viral load for the hepatic specimen, suggesting that 
the variability seen for these 5 patients is true. The lack of association between 
HCV RNA levels and the specimen collection time for one liver, furthermore 
suggests that RNA in the explanted liver is stable for at least 1 hour and that 
the HCV RNA degradation occurs simultaneously across the liver within the 
first 24-hours post-transplantation.  
 
The mean intra-hepatic load measured for our cohort differed up to 2-logs 
between patients. These differences were independent of patient age, 
indication for transplantation, infecting HCV genotype or previous response to 
treatment. It is unlikely that the variation in viral load would result from varying 
numbers of hepatocytes between patients, since the estimated percentage of 
hepatocytes for patients 2, 7 and 9 microscopic sections did not reflect the 
hepatic viral load for these patients. However, it is likely that patients with high 
hepatic viral loads have a higher fraction of HCV infected cells, an observation 
previously made by Wieland et al. (Wieland et al., 2013) or that these patients 
have higher viral load per infected hepatocyte. Histological staining for HCV 
antigens in the collected biopsies would have provided further information on 
the frequency of infected cells, however staining for HCV antigens ex vivo has 
proven difficult and requires highly sensitive antibodies (Liang et al., 2009) or 
patient-specific mRNA probes (Wieland et al., 2013) that currently are not 
available in our laboratory. The reasons for variable hepatic viral loads 
between patients are not known, however it likely that differences in hepatic 
immune pressure may play a role. Investigation of the potential association 
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between host innate immune response in the liver and hepatic HCV RNA 
levels can be found in Chapter 5.  
 
Measurements of plasma HCV RNA at the time of transplantation were 
provided by the clinic. Comparing the mean intra-hepatic and plasma load-
ratio between patients showed a minimal correlation (r2 = 0.13, p < 0.001), 
demonstrating that the plasma viral RNA level is a poor predictor of the hepatic 
burden in end-stage liver disease. Our study contrasts with previously reports 
of high correlation between liver and plasma viral burdens (Cabot et al., 2000; 
Descamps et al., 2012; Idrovo et al., 1996; Sakai et al., 1999; Vona et al., 
2004), however most of these did not consider the stage of hepatic 
inflammation or fibrosis of subjects under study. The detection of correlation 
between plasma and liver viral burden for patients with mild fibrosis and the 
lack of correlation for patients with cirrhosis (Cabot et al., 2000) highlights the 
importance of matching patient disease stage when performing cross-patient 
comparisons. Other studies have failed to observe a correlation between 
hepatic and plasma load (Ballardini et al., 1997; Fanning et al., 2001; Sugano 
et al., 1995). All of these studies were retrospective and utilised frozen 
samples, which may have made it more difficult to obtain complete medical 
records. However, it is possible that patients in Ballardini et al., Fanning et al. 
and Sugano et al.’s studies also had late chronic infection or end-stage liver 
disease, which would explain our comparable results.  
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The variable HCV RNA levels between plasma and liver observed in this study 
may be the result of extra-hepatic viral replication followed by the release into 
circulation. Previous studies have detected negative strand HCV RNA in 
tissues such as PBMCs and CNS (Natarajan et al., 2010; Ramirez et al., 2009; 
Willems et al., 1994), suggesting viral replication at other anatomical 
compartments. However, HCV negative strand qRT-PCR probes are 
considered to have low strand-specificity and these results should be 
interpreted with care (Blackard et al., 2006). Another reason for the poor 
correlation could be explained by the presence of viral variants with differing 
modes of virus transmission. Some variants may have a higher rate of cell-cell 
transmission than others and may be retained in the liver. High numbers of 
liver resident viruses could lead to a high intra-hepatic load and low plasma 
HCV RNA levels. Different modes of dissemination have previously been 
reported for laboratory prototypes of all the HCV genotypes (Brimacombe et al., 
2011).  
 
During the optimisation of the qRT-PCR protocol to quantify HCV RNA, we 
observed up to 2.6-fold increase in detectable HCV RNA when adding 5% 
DMSO to the RNA template and pre-incubating the mixture at 95°C prior to the 
quantification assay. Surprisingly this was significantly less than the 2-log 
change presented at the Annual HCV meeting in 2011). The discrepancy 
between our studies may be the result of different types of starting material 
(the presented study was conducted on hepatic needle biopsies collected from 
patients with earlier stages of liver fibrosis) or an inhibitory presence of DMSO 
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during the PCR. DMSO is widely used for its ability to lower the Tm of RNA 
and DNA double-stranded structures, but it may also increase the renaturation 
rate (Markarian et al., 2006). We did not test potential RNA re-annealing in the 
presence of denaturation enhancers, but did observe limited re-annealing of 
the dsRNA ladder in the absence of the chemical compounds and consider it 
unlikely that 5% DMSO would have a significant effect on this process. A 
future experiment could investigate whether DMSO accelerates the 
renaturation of double-stranded structures during the 50°C cDNA synthesis 
stage and 60°C annealing step of the qRT-PCR. As far known the RNA 
denaturation data presented at the Annual HCV meeting 2011 has not been 
published and it is possible that the result were not reproducible.  
 
During our investigation of optimal dsRNA denaturation we observed a 
decrease in detected SYBR green for the dsRNA ladder in the presence of 
DMSO. It is possible that DMSO may affect the dsRNA structure at room 
temperature (25°C), however it should be mention that the effect could have 
resulted from DMSO interfering with the SYBR green. As the experiments 
stands today, we did not test the effect of DMSO on SYBR green fluorescence. 
Decreasing the temperature for the RNA ladder showed decreased re-
annealing, which are likely to be the result of the ladder containing different 
length of the same nucleotide sequence. Mismatched re-annealing of 
sequences with different length may explain the lower detection of SYBR 
during decreasing temperatures.  
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The HCV genome has a high guanine-cytosine (GC) content of 58% (Tan et 
al., 2012) and will have a higher Tm50 than other sequences of the same 
length with lower GC content. The GC-level in the dsRNA ladder (NEB N0363) 
is 51.1% and heat-treating the ladder will show a lower Tm than the HCV 
genome. It is therefore possible that we would have obtained a larger increase 
in HCV detection if RNA extracts were incubated at 106°C, as suggested by 
Branch, instead of the 95°C.  
 
Heat-treating liver RNA samples led to a small increase in the detection of 
HCV RNA, but not synthetic HCV strain H77 genomic RNA. The HCV H77 
RNA was included as a control for potential secondary structures in the 
genome that could affect the 5’UTR availability for the probe. Failure to detect 
any change in the quantification of HCV H77 RNA following DMSO and heat 
treatment suggests that either the H77 genome does not form secondary 
structures in the 5’UTR probing site or that potential secondary structures doe 
not interfere with the reverse transcription of amplification. Considering the 
close relationship between HCV sequences, it is unlikely that the detection of 
patient-derived HCV genomes are affected by secondary structures in the 
5’UTR either. If this is the case, the increase in detectable HCV genomes for 
the patient-derived total RNA extractions from patient 1 and 5 may be the 
result from denaturation of the negative / positive stranded duplex RNA, 
formed during viral replication. A recent study has reported that patients with 
end-stage liver disease express negative to positive RNA at a ratio of 1:3 to 
1:340 (Lin et al., 2009). The authors reported that the amount of positive and 
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negative HCV RNA strands correlated between different sites in the liver, but 
not with the detection of serum positive strand HCV RNA. (Lin et al., 2009; 
Yuki et al., 2006). Patients being infected for different lengths of time may 
explain the large range in ratios reported by Lin et al.. Assuming that the 
increase in HCV RNA detection following heat and DMSO treatment is due to 
RNA duplex denaturation, the increased value would represent the number of 
negative strands in the sample. The negative : positive ratio for the two patient 
biopsies would be inferred to 1:1.5  and 1:5.4 for patient 1 and 1 : 1.3 and 
1:1.7 for patient 5. The comparable ratio of negative and positive strands 
between samples collected from the hepatic lobes suggests that HCV does not 
form replication hot-spots during end-stage liver disease. Still, more samples 
needs to be evaluated to confirm the observation. In addition, qRT-PCR of the 
HCV negative strand in the hepatic samples is required to confirm the potential 
detection of HCV negative strands following heat and DMSO treatment.  
 
To our knowledge, this is the first time that intra-hepatic HCV RNA levels 
across multiple sites have been studied in a cohort of patients with comparable 
liver disease staging. Investigating 8 different anatomical sites in the liver 
demonstrates that HCV RNA levels are comparable across macroscopic sites 
in the liver, suggesting that HCV does not form compartments with variable 
levels of HCV RNA. However small, but significant, differences in HCV RNA 
exist at the microscopic level. Comparison of plasma and liver HCV RNA 
levels between patients clearly indicates that a plasma sample does not 
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always represent the hepatic viral burden. Ideally, monitoring HCV burden in 
infected patients should include plasma and hepatic measurements.  
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5 EXPRESSION OF HEPATIC HOST FACTORS IN 
CHRONICALLY HCV INFECTED ADULTS AND CHILDREN 
 
The infecting HCV genotype and viral load prior to PEG-IFN treatment are 
widely used as predictors of treatment response (Berg et al., 2003). However 
recent studies have suggested that the expression pattern of hepatic ISGs 
prior to treatment also can predict treatment response in patients infected with 
HCV genotype 1, 2, 3 and 4 (Chen et al., 2005; Dill et al., 2011; McGilvray et 
al., 2012; Sarasin-Filipowicz et al., 2008).  
 
Dill and colleagues recently reported a predictive set of host genes including 3 
ISGs (ISG15, IFI27, RSAD2), and a ubiquitously expressed tumour suppressor 
gene (HTATIP2) (Dill et al., 2011). Detection of high levels of intra-hepatic ISG 
expression suggests endogenous interferon signalling, which is thought to 
dampening the cellular response to therapeutic IFNs and the patient is 
therefore less likely to achieve SVR (Dill et al., 2011; Heim, 2013b; Honda et 
al., 2010; Qashqari et al., 2013). However, minimum information is available 
on whether the hepatic ISG expression varies across the liver. Information 
about the hepatic distribution of ISG expression may increase their accuracy 
as predictors for PEG-IFN response. In addition, evidence of a potential 
association between intra-hepatic ISG expression and viral burden are limited. 
This chapter will focus on studying the spatial ISG distribution across the 
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infected liver to gain a better understanding of the relationship between HCV 
replication and the ISG expression.  
 
For this study, the expression patterns of intra-hepatic ISG15, IFI27, RSAD2 
and HTATIP2 were evaluated for the 8 hepatic specimens collected from 22 
chronically HCV infected adult patients with end-stage liver disease. For 
comparison, expression levels were evaluated in adult patients with end-stage 
liver disease due to NonAlcoholic SteatoHepatitis (NASH), Alcoholic Liver 
Disease (ALD), Auto-Immune Hepatitis (AIH) and non-A, non-B, non-C viral 
hepatitis (nA/nB/nC). Donor livers from deceased individuals were included as 
normal controls. Pre-treatment needle biopsies from 11 chronically infected 
paediatric patients were also included to evaluate any age-dependent 
expression of the 4 classifiers.  
 
5.1 ISG expression in HCV related end-stage liver disease 
The previously described RNA extractions from the 8 segments in 22 HCV 
infected livers were subjected to gene expression profiling by qRT-PCR using 
primers specific for ISG15, IFI27, RSAD2 and HTATIP2. The relative 
quantities for each target gene in the biopsies were evaluated in duplicate 
samples in two experimental repeats (n=2). (Figure 5.1; here represented by 
patients 1 and 2). The low variation observed for these repeated 
measurements (< 0.5log) for each biopsy justify the use of mean expression 
levels for the individual ISGs in the following analysis. Linear regression 
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analysis between the gene expressions and the collection time of the hepatic 
specimen revealed no correlation (Pearson’s correlation coefficient: ISG15: r2 
= 0.007, p = 0.78, IFI27: r2 = 0.003, p = 0.79, RSAD2: r2 = 0.015, p = 0.30 and 




Figure 5.1 Intra-hepatic expression of the 4-gene classifiers for two 
representative patients. 
The amount ISG15, IFI27, RSAD2 and HTATIP2 mRNA were quantified by target 
specific qRT-PCR. The internal GAPDH level was used for normalisation. The data is 
presented as means ± standard deviations for quadruplicate values. Patients 1 (A) 
and patient 2 (B) are representative of the high consistency between duplicate 
samples measured in two experimental repeats (n=2).  
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The mean expression levels for each of the 4 classifiers across the 22 HCV 
positive livers are shown in Figure 5.2. The expression levels for most 
individual gene were comparable across all 8 biopsies, with less then ± 15% 
deviation from the mean. However, a few patients showed a greater level of 
diversity with up to ± 58% deviation from the mean (patients 5, 9, 15 and 17) 
(Figure 5.2A). These atypical observations are independent of HCV genotype, 
indication of transplantation, previous respond to PEG-IFN treatment and 
plasma and hepatic viral loads (data not shown).  
 
Comparative analysis of the gene expression pattern within one liver showed 
that the level of relative expression significantly differed for the 4 genes with 
IFI27 usually showing the highest expression level (mean expression level = 
0.11 ± 0.12), followed by HTATIP2 (mean expression level = 0.04 ± 0.01), 
ISG15 (mean expression level = 0.04 ± 0.05) and RSAD2 (mean expression 
level = 0.03 ± 0.05) (Figure 5.2B). Calculation of the Pearson’s correlation 
coefficient between the individual gene expressions showed that ISG15, IFI27 
and RSAD2 are highly correlated with one another (mean r2 = 0.89, p < 0.001), 
whereas the correlation with HTATIP2 is somewhat lower (mean r2 = 0.63, p < 
0.01) (Table 5.1).  
 
Cross-sectional analysis of the mean gene expressions revealed significant 
differences in hepatic ISG expression between the patients. The relative 
expression differed up to 34-fold for ISG15, 62-fold for IFI27 and 
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approximately 43-fold for RSAD2. In comparison HTATIP2 only differed by 






Figure 5.2 Intra-hepatic expression levels of the 4-gene classifiers for 22 
chronically infected patients. 
A. The expression levels for the 4 classifiers were quantified for the 8 hepatic 
specimens collected from 22 HCV positive liver explants and normalised to GAPDH. 
Each point in the graph represent the mean of duplicate samples measured in two 
independent qRT-PCR runs. The horizontal lines indicate the mean of all biopsies in 
one liver ± standard deviation. Hepatic samples with a deviation above 30% from the 
mean are indicated with asterisks.  B. The combined expression patterns for the 4 








Most HCV infected patients with end-stage liver disease has received PEG-
IFN based treatment for the viral infection at some stage, but the treatment 
has either failed to eliminate the virus or had to be terminated early due to 
adverse effects in the patient. In this study the PEG-Interferon treatment status 
is known for 18 of the 22 patients (Table 3.1) and it was decided to investigate 
whether patients with end-stage liver disease who had either never received 
PEG-IFN treatment (n = 3), not responded to the administrated PEG-IFN 
treatment (n = 8), relapsed following initial successful treatment (n = 5) or had 
the treatment terminated prematurely (n = 2) would show different patterns of 
expression for the 4 gene classifiers (Figure 5.3A). Stratifying the gene 
expressions for the four treatment response groups revealed that those 
patients that were treatment naïve and those that had relapsed from previous 
treatment had lower expression of ISG15, IFI27 and RSAD2, but the 
observation was not statistically significant when comparing to the non-
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responders (unpaired two-tailed t-test: p > 0.26). The high variation observed 
for ISG15 and IFI27 expressions for patients who did not tolerate the treatment 
is likely to be the consequence of the small sample number (Figure 5.3A).  
 
Previous studies have reported that patients infected with genotype 1 and 4 
show significantly higher hepatic expression of ISG15 and IFI27 compared to 
patients infected with genotype 2 and 3 (Broering et al., 2010; Sarasin-
Filipowicz et al., 2008). Analysing the expression patterns of the 4-gene 
classifiers for patients infected with genotype 1 (n = 9) and 3 (n = 6) showed 
that patients with genotype 1 tended to have a higher expression of the three 
ISGs, however the observation were not statistical significant (unpaired two-
tailed t-test: ISG15: p = 0.14, IFI27: p = 0.33, RSAD2: p = 0.06) (Figure 5.3C).  
 
The expression patterns for the 4 gene classifiers were furthermore stratified 
for patients who had been diagnosed with HCC (n = 5) and cirrhosis (n = 17) 
prior to the transplantation. The results showed that patients diagnosed with 
HCC tended to have a higher expression of all the investigated genes, 
however in none of the cases were the observation statistical significant 
(unpaired two-tailed t-test: ISG15: p = 0.34, IFI27: p = 0.06, RSAD2: p = 0.58 
and HTATIP2: p = 0.16) (Figure 5.3B). 
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Figure 5.3 Influence of host and viral factors on the expression patterns for the 
4-gene classifiers. 
The hepatic expression patterns of the 4-gene classifiers were divided into groups 
according to; A. previous response to PEG-IFN treatment, B. the diagnosis prior to 
liver transplantation (HCC: Hepatocellular carcinoma) and C. the viral genotypes 1 
and 3 (Genotype 2 and 4 were not included since these consisted of only 1 patient 
each).  All data are presented as means with standard deviations for each patient 
group and are based on duplicate measurements in two independent qRT-PCRs. 
Statistical analyses for each data set was performed by unpaired two-tailed t-test. 
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5.2 ISG expressions in non-HCV related end-stage liver diseases and 
in donor livers 
Most current research studying hepatic ISG expression has been performed 
with samples from HCV or HBV infected subjects. It is therefore not known 
whether patients with comparable end-stage liver disease would have similar 
levels of hepatic ISG expressions. To address this question we measured the 
relative levels of ISG15, IFI27, RSAD2 and HTATIP2 in patients with end-
stage ALD, NASH, AIH and nA/nB/nC viral hepatitis, together with hepatic 
tissues donated from diseased healthy individuals.  
 
The hepatic specimens from the above mentioned non-HCV associated liver 
diseases were all diagnosed with end-stage liver disease staging by 
Pathologist Dr. Gary Reynolds (data not shown), nevertheless different liver 
diseases may have variable expression of housekeeping genes. It was 
therefore decided to identify the housekeeping gene with the least variable 
expression between the ALD, NASH, AIH, nA/nB/nC viral hepatitis liver 
specimens and the healthy donor liver by the GeNorm panel of housekeeping 
genes (see section 4.2), before comparing the normalised relative expressions 
between patient groups.  
 
Normalising the gene expressions for each disease group with the same 
reference gene (2^∆Ct) revealed no significant variation in the relative 
expression levels between the different groups (One-way ANOVA; p > 0.1). 
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However, comparing the normalised values by two-way ANOVA showed that 
there is a systemic difference in the expression of housekeeping genes for the 
different diseases (p < 0.01). This variation mainly reflects the different 
reference genes applied to the template (9.9% of the variation, p < 0.05) and 
not variation in gene expression between disease groups (0.47% of the 
variation, p = 0.055) (Figure 5.4). The expression levels of the housekeeping 
genes are therefore considered independent of the type of end-stage liver 
disease tissue, justifying our use of GAPDH for normalising the expression of 




Figure 5.4 Evaluation of reference genes for different end-stage liver diseases 
and donor livers. 
The GeNorm panel of 11 different housekeeping genes were used for evaluating the 
stability of the reference gene between single samples from livers with alcoholic liver 
disease (ALD), non-alcoholic steatohepatitis (NASH), auto-immune hepatitis (AIH), 
non-A, non-B, non-C viral hepatitis (nA/nB/nC). Livers from healthy donors were 
included as normal controls. The expression levels were measured by qRT-PCR. The 
raw Ct values for each housekeeping gene were used to normalise each of the other 
10 expressions and the result expressed as 2^Δ Ct. The data is presented as median 
(horizontal line), upper and lower quartile and the maximum and minimum spreads. 
One-way ANOVA between gene expressions normalised with the same reference 
gene did not reveal any significant differences between the disease groups (in all 
cases p > 0.1). However, two-way ANOVA revealed systemic variance between 
different RNA templates and the different reference genes (p < 0.01). 
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Total hepatic RNA was extracted from single specimens collected from 6 
patients in each disease group and from 6 donated livers. The relative 
expression levels of the classifiers were quantified in duplicate samples by two 
independent qRT-PCRs. Minimal variation was observed between the 
repeated measurement for each sample (< 0.5log, data not shown) and it was 
therefore decided to use the mean expression for each hepatic specimen in 
the following analyses.  
 
The individual gene expressions for ISG15, IFI27 and RSAD2 varied between 
2.5- and 5.2-fold for the samples in the same disease group, whereas the 
gene expression of HTATIP2 showed lower variability (2.1- to 3.2-fold, 
dependent on the disease group) (Figure 5.5). Comparing the mean and the 
range of the individual gene expression between the groups revealed 
comparable levels of variation in the expressions (Table 5.2). Interestingly, the 
hepatic specimens from the healthy donor livers showed a significantly greater 
range of the three measured ISG expressions compared to hepatic samples 
from non-HCV associated end-stage liver disease, with ISG15 showing 110% 
variation from the mean expression, IFI27 showing 102% and RSAD2 100% 
variation from the mean expression. Statistical analyses of the gene 
expression levels between the disease groups and the donor liver revealed 
that the level of RSAD2 significantly differ between the groups (One-way 
ANOVA: p = 0.046), however the observation is likely to be the result of the 
large range in expression levels for the donor liver. None of the remaining 
 162 
classifiers differed significantly between the groups (One-way ANOVA: p > 
0.1).  
 





The expression of the 4-gene classifiers was compared between the hepatic 
samples collected from patients with HCV-related liver disease, non-HCV 
associated liver disease and from donor livers (Figure 5.5). The HCV infected 
livers show higher median expression for all ISGs compared to the other 
disease groups. However the difference were only statistical significant for the 
ISG15 expression in samples collected from NASH (Mann-Whitney test: p = 
0.03) and for the IFI27 expression in samples from ALD, NASH, AIH, 
nA/nB/nC viral hepatitis and the donor liver (Mann-Whitney test: 0.0006 > p < 
0.04) (Figure 5.5). 
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Figure 5.5 Intra-hepatic expression patterns for the 4-gene classifiers for end-
stage liver diseases and donor livers. 
Total RNA was extracted from 6 specimens representing the disease group; ALD, 
NASH, AIH and nA/nB/nC viral hepatitis. RNA extractions from 6 donor livers were 
also included. Here the expression levels are shown as means from duplicate 
measurement in two independent qRT-PCRs. All 4 classifiers are normalised to the 
internal GAPDH mRNA expression. The data is presented as median (horizontal bar), 
upper and lower quartile and the maximum and minimum spreads. Statistical analysis 
was performed by Mann-Whitney and the statistical values (p) below 0.05 are noted in 




5.3  Association between ISG expression levels and the hepatic and 
plasma HCV RNA loads at end-stage liver disease 
In section 4.3 we found that chronically infected patients express comparable 
levels of HCV RNA across the liver, but that these levels vary by up to 100-fold 
between patients. These observations are independent of infecting viral 
genotype, plasma load, patient age and indication for transplantation. Similar 
variation was seen for the expression patterns of the 4-gene classifiers on the 
same sample set (Figure 5.6A). To investigate whether the expression 
patterns of these 4-classifiers correlate with the hepatic viral loads we 
compared the two data sets.  
 
Multiple linear regression modelling was performed to evaluate the correlations 
between the hepatic viral loads and the measured gene expression (Figure 
5.6B). As shown in in Table 5.1 the expression of the 4-gene classifiers are 
strongly inter-correlated with one other, however single-variant analysis of the 
viral load against the individual gene expression show limited correlation (-
0.095 to 0.087, p > 0.67). Calculation of the multiple correlation coefficient (r2) 
revealed that the combination of the 4-gene expression patterns do not predict 
the hepatic viral load (r2 = 0.1473, p = 0.58). The F statistic is calculated as the 
ratio of expression variance within each gene groups and between the groups 
of gene expressions. The null hypothesis, that all correlation coefficients are 0, 
can only be rejected if the F ratio is significantly greater than 1. For this 
dataset the F ratio was 0.73, indicating that the correlation coefficients 
between the viral load and the combined gene expressions are not different 
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from 0. As previously mentioned, the HTATIP2 expression remained constant 
for all patients, which is likely to be a reflection of the fact that HTATIP2 is not 
an ISG. The multiple linear regression modelling was therefore repeated 
without HTATIP2 and the result demonstrated no association between the 
hepatic HCV RNA load and the expression of ISG15, IFI27 and RSAD2 (r2 = 
0.0394, p = 0.86, F-ratio = 0.25). 
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Figure 5.6 Association between the expression of the 4-gene classifier and 
hepatic HCV RNA. 
A. The expression patterns for the 4 classifiers in the liver specimens collected from 
HCV infected patients. Left Y-axis; gene expressions normalised to GAPDH, Right Y 
axis HCV copies/ng total liver RNA. Each point in the graph represents the mean of 
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duplicate samples for two independent qRT-PCRs. The horizontal lines indicate the 
mean of all biopsies in one liver ± standard deviation. B. Scatter plot matrix of all 
components. The density plot for each gene expressions and viral load are seen in 
the diagonal boxes. On each side of the diagonal are the scatter plot (black circles) 
and the linear correlation line (green) for each pairwise comparison. The x- and y-
axes are labelled relative gene expression (2^delta Ct). The matrix is exported from 
the software program R-commander.  
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In the analysis above we showed that the hepatic HCV RNA load and the 4-
gene classifiers expression pattern do not correlate, however the hepatic ISG 
expressions could instead have an effect on the level of released virus from 
the infected hepatocytes. A potential association between ISG15, IFI27, 
RSAD2 and HTATIP2 would explain the relative poor correlation between 
plasma and hepatic viral load observed for our patient cohort in section 4.5.  
 
 Linear regression modelling revealed a negative correlation between the 
plasma viral load and the individual gene expressions, but in none of the cases 
did the correlation significantly differ from 0 (Pearson’s correlation coefficients 
(r2): ISG15 =  -0.11, IFI27 = -0.10, RSAD2 = -0.07 and HTATIP2 = -0.26. p > 
0.05) (data not shown). The multiple correlation coefficient between the 
plasma viral burden and the 4-gene classifiers were 0.077, however the 
correlation was not statistical significant (p = 0.84, F-ratio = 0.35) (data not 
shown). Repeating the multiple linear regression modelling after excluding the 
expression of HTATIP2 resulted in a lower non-significant multiple correlation 
(r2 = 0.0411, p = 0.85, F-factor = 0.26) (data not shown). 
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We have previously showed that although the patients do not have any 
significant variation in viral loads across 8 anatomical segments in the liver, 
they do show differences in viral burden in defined tissue sections. This 
observation led us to investigate the expression patterns for the 4 classifiers in 
adjacent liver sections (12 x 20µm thick) from patients 2, 7 and 9.  
 
The relative gene expression profiles for ISG15, IFI27, RSAD2 and HTATIP2 
were highly comparable between the 12 sections obtained from the three 
patients (one-way ANOVA: p > 0.1), however the viral load differed 
significantly among the same sections (one-way ANOVA: p < 0.001) (Figure 
5.7). This discrepancy between the HCV RNA levels and the ISG expression 
patterns supported our earlier conclusion that the expression levels of the 4 









Figure 5.7 Expression pattern of the 4-gene classifiers within hepatic sections. 
The HCV copies /µl and the expression levels of the 4 classifiers (normalised to GAPDH) were quantified in 12 adjacent 20µm sections from 
patients 2, 7 and 9. The samples were measured in duplicates in one qRT-PCR run. Significant differences were found for the viral loads in all 
patients (left Y-axis, p <0.001), but not for the classifiers’ expression levels (right Y-axis, p > 0.1) when applying the one-way ANOVA to the 
data sets.  
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5.4 Anti-viral gene expression profile in HCV-related end-stage liver 
disease 
In previous sections we found that ISG15, IFI27, RSAD2 and HTATIP2 do not 
correlate with the viral RNA loads in the plasma or in the liver. To identify new 
potential candidate genes that may predict host pathways regulating HCV 
replication, we screened the expression of 84 different anti-viral genes using a 
SABiosciences anti-viral PCR array. Biopsy 1 from four patients was selected 
for these arrays, representing HCV genotype 3a (patients 4 and 5) and 1a 
(patients 6 and 13), which had low (patient 4 and 13) or high (patient 5 and 6) 
intra-hepatic viral loads compared to the mean hepatic HCV RNA level in the 
patient cohort. The samples were evaluated twice and on each occasion the 
templates passed the human genomic DNA contamination (HGDC) test, the 
reverse transcription control (RTC) test and the positive PCR control (PPC) 
test. Heat-maps were generated from the fold-difference in expression levels 
between the tissue containing low and high HCV RNA loads. Comparing 
hepatic expression levels for patients infected with the same HCV genotype 
demonstrated that genotype 1a patient 6 had significantly higher expression 
level for most genes compared to patient 13 (Figure 5.8A). The genotype 3a 
patients showed more comparable expression patterns across the array, with 
only a few exceptions of above 2-fold differences, one being ISG15 (Figure 
5.8B, well D10). The expression levels of the 84 anti-viral genes were 
normalised to the combined expressions of housekeeping genes ACTB, B2M, 
GAPDH, HPRT1 and RPLPO and used for cluster analysis (Figure 5.9). The 
cluster analysis of the gene expressions in the individual specimens verified 
that the genotype 3a patients 4 and 5 are closely related in regards to hepatic 
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anti-viral gene expression and are closely followed by patient 13 (genotype 1a). 
Approximately 60 to 75% of the detected gene expressions for patients 4, 5 
and 13 were below the level of the housekeeping genes (Figure 5.9, green), 
whereas patient 6 showed significantly higher expression of most genes, 
thereby forming an outlier in the cluster analysis (Figure 5.9). The close 
association of the genotype 3a patients with low and high intra-hepatic viral 
loads (patient 4 and 5), leads us to conclude that the expression of the 
evaluated genes are independent of hepatic HCV RNA load. The high 
difference in expressions between patient 6 and 13 may be specific to 




Figure 5.8 Heat-maps of anti-viral gene expressions between patients with high and low HCV RNA burdens. 
Total hepatic RNA extractions from samples collected from patients with high (patient 5 and 6) and low (patient 4 and 13) HCV RNA 
loads were used as template for the 2-step RT2 profiler SABiosciences human antiviral micro-array (384 wells). The gene profiles were 
measured twice for each template. Representative results are here shown for one array. A. Comparison of expression levels for the 
genotype 1a patients 13 (low viral load) versus patient 6 (high viral load). The colours represent the magnitude of log2 (fold changes). 
Green represent decreased expressions, red increased. B. Comparison of expression levels for genotype 3a patients 4 (low viral load) 
versus patient 5 (high viral load). C. Overview of the investigated genes on the 96 well-plate. Well A1 to G12 are anti-viral genes; well H1 
to H5 are housekeeping genes; well H6 is human genomic DNA control (HGDC), H7 to H9 are reverse transcription controls (PPC) and 
well H10 – H12 are positive PCR controls (PPC). 
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Figure 5.9 Dendrogram of anti-viral expressions for patients with high and low 
HCV RNA burdens. 
Cluster analyses were performed for the anti-viral expression profiles for patients 
infected with HCV genotype 1a (patients 6 and 13) and genotype 3a (patients 4 and 
5). All antiviral gene expressions were normalised to the internal reference genes 
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ACTB, B2M, GAPDH, HPRT1 and RPLPO. Association between the patients’ hepatic 
gene expressions is shown as the X-axis and between individual gene expressions as 
the Y-axis. Two independent anti-viral arrays were evaluated. Representative results 




Comparing the micro-array data between tissues collected from patients with 
low and high hepatic HCV RNA levels revealed that the regulated genes were 
involved in the RIG-I, TLR and nucleotide-binding oligomerization domain 
(NOD-like) receptor pathways. Unexpectedly, the raw Ct-values for IFN-α1, 
IFN-α2, IFN-β1, IL12α or IL12β were all above 30, suggesting low expression 




Table 5.3: Anti-viral gene-array 
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Interestingly the DDX3 gene was found to be 5-fold down-regulated in patient 
13 (low viral load) compared to patient 6 (high viral load). This Dead-Box 
helicase has previously been demonstrated to facilitate HCV replication in vitro 
(Angus et al., 2010; Ariumi et al., 2007) such that low expression may limit 
viral replication. To investigate this hypothesis, DDX3-specific qRT-PCRs were 
performed on all liver biopsies from the 22 HCV infected patients and on the 6 
biopsies from donor, ALD, NASH, AIH and nA/nB/nC viral hepatitis livers. All 8 
biopsies showed comparable levels of DDX3 for the same patient (Figure 
5.10A +B) and the expression was highly comparable between 21 of the 22 
HCV positive livers (mean relative expression of 0.28 over GAPDH) (Figure 
5.10C). Comparing these values to the hepatic viral loads measured in the 
same patient cohort revealed a weak correlation (r2 = 0.017, p = 0.94). 
Furthermore, comparing the plasma viral load with the expression levels for all 
22 patients showed no correlation (r2 = 0.22, p = 0.4).  
 
Comparative analyses of DDX3 expression between samples collected from 
subjects with different liver diseases and from the donor livers demonstrate 
comparable levels of mean DDX3 expression between subject groups, 
however high variations were observed within most of the data sets (Figure 
5.10C). Hepatic samples from NASH, AIH and donor livers revealed an outlier 
for each group with up to 2.2-fold higher expression levels than the mean 
expression (Figure 5.10C). These observations suggest that variation in DDX3 
expressions occurs naturally in the population and is not associated with a 




Figure 5.10 Association between hepatic DDX3 expression and HCV RNA loads. 
DDX3-specific qRT-PCR was performed for HCV positive liver samples and the 
additional non-HCV hepatic specimens.  The expression levels were normalised to 
GAPDH. Linear regression analyses were performed for the DDX3 expressions 
versus A. mean hepatic viral loads (Spearman’s correlation coefficient: r2 = 0.0.02, p 
= 0.94) or B. the plasma viral loads (Spearman’s correlation coefficient: r2 = 0.22, p > 
0.40). C. DDX3 expressions for all studied disease groups. Each point represent the 
mean DDX3 expression for one patient/donor and the horizontal lines the overall 




5.5 Hepatic ISG expression in HCV-infected paediatric patients 
Between 0.05 and 5% of children are believed to be infected with HCV 
worldwide (Le Campion et al., 2012). These children are likely to respond 
better to PEG-Interferon-α + ribavirin treatment than adults and have a higher 
chance of achieving SVR independent of their IL28-β genotype (Domagalski et 
al., 2013; Komatsu et al., 2013). The reasons for these different treatment 
outcomes for adults and children are unknown, but could potentially be related 
to age-dependent hepatic response to interferon. Knowledge of the paediatric 
hepatic immune response to HCV is limited and it is not known if the ISG 
expression profiles can predict treatment response.  
 
To assess this, the expressions of the 4-gene classifiers were evaluated in 
single needle biopsies obtained from 11 chronically infected children with 
genotype 1a/1b (n = 7) or 3a (n = 4). The biopsies were taken prior to the 
treatment with PEG-Interferon-α and ribavirin, which led to SVR for 9 of the 11 
children. Information about the pediatric patient cohort can be viewed in Table 
5.4.  
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Table 5.4: Paediatric patient overview 
 
 
Total liver RNA was extracted from the biopsies for quantifying viral load and 
gene expressions by qRT-PCR. The quantity of GAPDH-adjusted HCV RNA 
copies demonstrated up to 4-log variation between the children samples 
(mean: 98 HCV copies/µl total RNA extract ± 166.8) (Figure 5.11A) The 
estimated quantity of HCV RNA in the sample from child 2 (conc. 0.056 HCV 
RNA copies/µl RNA extract) is well below the estimated assay threshold of 10 
copies / µl sample (McKeating group protocol). However we know that this 
child is HCV positive since his/her plasma burden was 1.7 x 104 copies / ml at 
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the time of biopsy sampling and the low hepatic load could be due to technical 
errors in the RNA extraction.  
 
Comparison analysis between the hepatic HCV RNA burden in the needle 
biopsy and the plasma load measured at the same time the biopsy was taken 
(excluding child 2), revealed inverted correlation between the loads in the two 
compartments, however the association were non-significant (r2 = -0.58, p = 
0.08) (Figure 5.13B). It is unknown why infected children would have an 
inverted association between HCV RNA loads, but low release of virus from 






Figure 5.11 Paediatric intra-hepatic HCV RNA loads and the correlation with 
plasma load. 
A. Total liver RNA was extracted from needle biopsies collected from 11 HCV positive 
children and the HCV RNA levels quantified by target-specific qRT-PCR. The viral 
loads are normalised to the internal GAPDH expression level. The data is presented 
as means plus standard deviations for duplicate samples in two independent 
measurements. B. Linear regression curve between paediatric plasma and mean 
hepatic viral load (Pearson’s correlation coefficient: r2 = -0.58, p = 08).  
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The expression levels of the 4-gene classifiers were quantified using the same 
protocol as for the adult samples. Like the adults, the IFI27 expression levels 
in the children samples were significantly higher than the other 3 gene 
classifiers. The data set also revealed that the expression levels were variable 
between subjects with the ISG15 expression differing by 28.6-fold, IFI27 by 
37.5-fold and RSAD2 up to 19.5-fold. Unexpectedly, variations were also 
observed for HTATIP2 (up to 6.5-fold) (Figure 5.12A). Plotting the ISG15, 
IFI27, RSAD2 and HTATIP2 expression levels together with the plasma and 
hepatic viral loads for each child provides a clearer overview of the patient-
specific RNA levels (Figure 5.12B). The ISG15 expression level in the sample 







Figure 5.12 Hepatic expression profile for the 4-gene classifiers in paediatric 
patients. 
Total liver RNA was extracted from needle biopsies of 11 HCV positive children and 
HCV viral load quantified by target-specific qRT-PCR. All mRNA values are 
normalised to GAPDH. A. Expression pattern for the individual classifiers for 11 
children. Each point represents the expression in one biopsy. B. Re-plotting the 
individual gene expressions (right Y-axis) in one graph together with hepatic and 
plasma HCV RNA loads (left Y-axis) for each child. Green hollow circle: plasma load 
(HCV copies/ ml plasma), pink diamond: biopsy load (GAPDH adjusted HCV copies / 
µl), blue circle: ISG15, red square: IFI27, orange triangle: RSAD2, black inverted 
triangle: HTATIP2. 
 190 
Linear regression analysis was performed for the plasma and hepatic viral 
RNA loads measured for the paediatric patients and the expression levels of 
the 4-gene classifiers (Figure 5.15A + B). Amongst the classifiers, correlations 
were noted between ISG15 and IFI27 (r2 = 0.78, p < 0.01) and between 
RSAD2 and HTATIP2 (r2 = 0.99, p < 0.001). Unlike our earlier biopsy data 
collected from adults, we noted an association between the liver viral load and 
IFI27 (0.64, p < 0.05), but not for any of the other classifiers. However, this 
value alone was not sufficient to make the combined expression pattern for the 
classifiers predictive of the hepatic viral load (multiple correlation coefficient: r2 
= 0.49, p = 0.41, F-factor = 0.41). Excluding the non-ISG gene, HTATIP2, from 
the analysis did not change the result significantly (r2 = 0.45, p = 0.28, F-factor 
= 1.6).  
 
The plasma viral loads in the children showed a strong correlation with both 
the RSAD2 (0.90, p < 0.001) and HTATIP2 (0.88, p < 0.001) expressions 
(Figure 5.13A + B). As a result the overall multiple correlation coefficient 
indicates an association between the plasma load and the combined gene 
expression of the classifier (r2 = 0.84, p = 0.03, F-factor = 6.95). Excluding 





Figure 5.13 Association between the 4-gene classifiers and HCV RNA loads for 
paediatric patients. 
A. Scatter plot matrix of all components. The density plot for each gene expressions 
and viral loads are seen in the diagonal boxes. On each side of the diagonal are the 
pairwise comparisons represented as scatter plots (black circles) together with the 
linear correlation line (green). The graph is exported from the analyses using the R 
commander software. B. Pearson’s correlation coefficient calculated in a pairwise 
manner for the viral loads and the 4 classifiers’ gene expressions. Statistical 
significance was evaluated by the two-way unpaired t-test (*: p < 0.05,  **: p <0.01, 
***: p <0.001, NS: Not significant.  
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Dill and colleagues previously reported that adult patients with high 
expressions of ISG15, IFI27 and RSAD2 prior to PEG-IFN treatment are less 
likely to achieve SVR compared to those with lower expression (Dill et al., 
2011). It is not know if the expression of these ISG predicts treatment outcome 
in paediatric patients. In this study 9 out of 11 children had responded to the 
treatment. Association analysis between gene expression and treatment 
outcome indicated higher ISG15 and IFI27 expression and lower levels of 
RSAD2 for the 9 children that responded compared to the 2 non-responders. 
However, the limited number of non-responders, prevented any statistical 
interpretation of this data (Figure 5.14A). 
 
Comparative analysis of the gene expression levels between children and 
adults revealed that the two age groups vary in their relative hepatic 
expression patterns quantities. The children generally had lower expression of 
ISG15 and higher expression of IFI27, RSAD2 and HTATIP2, with IFI27, 
RSAD2 and HTATIP2 being statistical significant (unpaired two-tailed t-test p < 
0.5) (Figure 5.14B). The observation that the treatment responsive children 
have greater gene expressions for 2 out of 3 ISGs contradicts the prediction by 
Dill and his colleagues that in adults high ISG expression decreases the 
likelihood of responding to treatment.  
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Figure 5.14 Association between the 4-gene classifiers and treatment response 
for paediatric patients.  
A. The expression profiles for the 4-gene classifiers were divided into groups 
according to the treatment outcome for the particular paediatric patient. The data is 
represented by the means plus standard deviation for each patient group. B. 
Comparative analysis of the 4 classifiers’ gene expressions between HCV chronically 
infected adults and children. The horizontal lines represent the means and standard 




In 2011, Dill et al. reported that the level of hepatic ISG15, IFI27, RSAD2 and 
HTATIP2 expression in liver biopsies from chronically HCV infected patients 
collected prior to PEG-IFN treatment could predict treatment outcome. The 
predictive value of these 4-gene classifiers was independent of the infecting 
HCV genotype or IL28-β status (Dill et al., 2011). High expression of these 
transcripts in the liver is consistent with endogenous activation of IFN 
signalling that dampens the cellular response to IFN-based therapies and as a 
result patients with high expression of the 4-gene classifiers have a lower 
chance of responding to treatment.  
 
Previous studies characterising hepatic ISG expression have utilised single 
biopsies from the chronically infected liver and it is unknown if the ISG 
expression varies across the liver. In this study we investigated the expression 
pattern of ISG15, IFI27, RSAD2 and HTATIP2 across multiple sites in the 
explant liver from subjects with HCV-associated end-stage liver disease and 
compared expression patterns to disease matched samples of non-viral 
aetiology including ALD, NASH, AIH and nA/nB/nC viral hepatitis. In addition, 
we had the opportunity to study hepatic ISG expression in biopsies from HCV 
infected children with early stage liver disease.  
 
We investigated the potential association between hepatic ISG expression and 
HCV replication to gain a better understanding on how these parameters may 
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influence each other. The potential models include: (i) high levels of HCV 
replication would stimulate RIG-I and TLR pathways and consequently high 
ISG expression; (ii) high levels of HCV replication lead to an increased 
cleavage of MAVS and deactivation of the RIG-I pathway leading to low ISG 
expression; or (iii) high local production of IFN would lead to high ISG 
expression that controls viral replication and limits HCV RNA levels.  
 
The expression level of ISG15, IFI27, RSAD2 and HTATIP2 were measured in 
8 hepatic specimens collected from the explant liver of 22 subjects with end-
stage liver disease. Liver biopsies showed similar expression levels of 
HTATIP2 across the liver and 18 of 22 (82%) patients also showed 
comparable levels of ISG15, IFI27 and RSAD2. This observation suggests a 
uniform stimulation of the hepatic innate and adaptive immune response by 
the production of type I, II and III IFNs from infected hepatocytes and from liver 
resident and infiltrating immune-cells. Dill et al. used single needle biopsies 
from early stage chronically infected patients without previously showing that a 
single specimen would represent the expression pattern in the whole liver (Dill 
et al., 2011). The observation from our patient cohort indicates that a single 
liver biopsy is representative for the hepatic expression level of the 4-gene 
classifiers, during end-stage liver disease in most cases.  
 
Four of the 22 patients showed variable expression of the three ISGs across 
the liver (patients 5, 9, 15 and 17). This variability is not linked to a specific 
genotype or to differences in sample processing time. HTATIP2 hepatic mRNA 
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levels for these patients did not vary significantly, leading us to believe that the 
variability in ISG expressions across the liver for these patients is real. One 
possible explanation for the differences in ISG mRNA levels is that the three 
investigated ISGs respond to different stimuli; IFI27 and ISG15 expressions 
are stimulated by Type I IFNs (Dill et al., 2012) and RSAD2 by Type I, II and III 
(Fitzgerald, 2011). Although patients with chronic HCV infection show high 
levels of infiltrating T cells in the liver, it is possible that only a minority of these 
are HCV-specific (Bowen and Walker, 2005a). This would suggest that some 
livers might have compartments of high Type II IFN concentrations in 
association with the HCV specific lymphocytes, leading to a variable 
expression of Type II ISG such as RSAD2. Furthermore, the liver may in some 
instances have an uneven distribution of infected hepatocytes, leading to 
areas of high Type I and III IFN production and expression of ISG15 and IFI27.  
 
Recently Wieland et al. reported that variable levels of IFI27 expression in vivo 
associated with the non-random distribution of infected hepatocytes (Wieland 
et al., 2013). However other studies failed to report a correlation between the 
frequency of infected hepatocytes and expression of the ISGs MxA, IFI1, IFI27 
(Stiffler et al., 2009) and IFITM3 (Kandathil et al., 2013). The contradicting 
observations in the Wieland et al. and Kandathil et al. studies are likely to 
result from either different technical approaches being used, the study cohorts 
having different levels of fibrosis or that IFITM3 and IFI27 are stimulated by 
different types of interferon, i.e. IFITM3 expression is stimulated by Type I and 
II IFNs (Kandathil et al., 2013) and IFI27 by Type I IFN (Dill et al., 2012). We 
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were unable to determine the frequency of infected hepatocytes in biopsies 
from any patients in our study, due to technical difficulties in staining liver 
biopsies for HCV antigens and it is therefore not possible to reject or support 
the hypothesis of variable numbers of infected hepatocytes leading to 
differences in ISG expression for patient 5, 9, 15 and 17.  
 
Comparative analysis of the expression level for the 4-gene classifiers 
demonstrated up to 65-fold variation in hepatic ISG15, IFI27 and RSAD2 
expression between the explanted livers. We noted that the expression levels 
of the ISGs correlated, suggesting comparable expression within one liver, but 
that the level of stimulation may vary between patients.  
 
In chapter 4 we found comparable levels of HCV RNA between different sites 
in the liver, however, the viral burden varied significantly between study 
subjects. These observations led us to investigate a potential association 
between the ISG expression and hepatic viral burden. To our surprise, we 
failed to detect any relationship between hepatic ISG expression levels and 
HCV RNA levels at macroscopic and microscopic levels. Furthermore, 
comparing the ISG expression levels with the plasma viral burden revealed no 
correlation, indicating that the hepatic ISG expression does not affect the level 
of HCV particles release to the periphery.  
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Our observations agree with previous reports stating that hepatic (Bellecave et 
al., 2010; Kandathil et al., 2013; Stiffler et al., 2009) and plasma HCV RNA 
levels (Bellecave et al., 2010; Urban et al., 2010) do not correlate with hepatic 
ISG expression during chronic infection. However, they stand in contrast to a 
previous study, which reported a negative correlation between serum HCV 
RNA and the transcript level of 15 different ISGs, when performing multivariate 
analysis for patients who responded to treatment and those who had relapsed 
(Honda et al., 2010). In that study, biopsies were taken prior to PEG-IFN and 
ribavirin treatment, but it is not known when the serum HCV RNA was 
measured. Comparing hepatic ISG levels and serum viral burden at different 
time points during IFN-based treatment may lead to misleading conclusions.  
 
The expression pattern of the 4-gene classifiers was further stratified for 
clinical and viral parameters, such as HCV-associated liver disease (cirrhosis 
or HCC), prior response to IFN treatment and infecting HCV genotype. We did 
not find any association between these clinical parameters and ISG 
expression that could explain why these patients had failed to respond to IFN 
treatment. Neither did we find an association between ISG expression pattern 
and the infecting HCV genotype. Previous reports have shown that patients 
infected with HCV genotype 1 have higher hepatic ISG15 and RSAD2 
expression compared to those infected with genotype 3 viruses (Bellecave et 
al., 2010; Broering et al., 2010). This is supposedly due to HCV genotype 1 
exposing poor NS3/NS4 cleavage of MAVS compared to other HCV 
genotypes (Bellecave et al., 2010), leading to higher IFN-α/β expression. 
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Investigating the level of cleaved MAVS in our patient cohort would provide 
new insight into the HCV regulation of endogenous IFN and ISG expressions 
during end-stage liver disease.  
 
In this study we investigated the expression of the 4-gene classifiers in hepatic 
tissue from patients diagnosed with NASH, ALD, AIH and nA/nB/nC viral 
hepatitis end-stage liver disease and from healthy liver donors. Comparing 
ISG15, IFI27 and RSAD2 expression levels within each disease group 
revealed up to 5.2-fold variations between samples. In contrast, the HCV 
infected patients showed variations up to 65-fold. The difference in spread 
between the HCV and the ALD, NASH, NIH and nA/nB/nC viral hepatitis 
cohorts are likely to reflect the variable number of samples in each disease 
group. Unexpectedly, hepatic samples donated from healthy individuals varied 
up to 24-fold in the ISG levels, leading us to question whether the donor livers 
are as healthy as first assumed. The term “donor livers” in this study, covers 
livers donated for transplantation by healthy donors. These livers were not 
used for transplantations because of their high fat content and instead send to 
the pathology department. A fatty liver will in 20-30% of the cases lead to liver 
inflammation (Tilg and Moschen, 2010) and it is therefore likely that some of  
these donated livers already had an activated immune response. The ideal 
control for all in vivo liver studies would be specimens from disease-free livers 
with no sign of hepatic inflammation, however there is no clinical justification to 
conduct needle-biopsies from healthy individuals or to take samples from livers 
suitable for transplantation.  
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Comparing ISG expression in hepatic tissue from HCV infected end-stage liver 
disease patients with tissue from donor liver and end-stage NASH, ALD, AIH 
and nA/nB/nC viral hepatitis livers revealed significant differences in IFI27 
expression level, suggesting, that HCV infected patients have a unique 
expression pattern of IFI27 compared to other advanced liver disease and 
donor livers. In addition, significant differences were found for ISG15 in hepatic 
tissue collected from NASH patients, however the difference was minimal and 
may result of low sample numbers. 
 
The mean expression of the 4-gene classifiers was comparable between 
tissues collected from the non-viral associated end-stage liver diseases, 
independent of aetiology. This observation suggests that these end-stage liver 
diseases have activated IFN signalling pathways. Searching the literature we 
found that all three non-viral associated liver diseases can be linked to active 
IFN production. The inflammatory condition in NASH is believed to be partly 
caused by free fatty acids acting on TLRs in the liver (Tilg and Moschen, 2010) 
and for ALD the heavy alcohol consumption may lead to increased gut 
epithelial permeability, which in turn result in elevated endotoxemia and an 
increased activation of hepatic TLRs (Wang et al., 2012). Although we did not 
observe high RSAD2 expression compared to ISG15 and IFI27 in the samples 
collected from AIH livers, this condition is believed to be driven by self-
antigenic peptides being presented by the major histocompatibility molecule to 
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cellular members of the adaptive immune response, leading to high production 
of type II IFN (Liberal et al., 2013).  
 
Although children tend to have a higher response rate than adults to PEG-IFN-
α (Abdel-Hady et al., 2011; Wirth, 2012), it is not known whether this 
correlates with a lower hepatic ISG expression pre-treatment. To address this 
issue we studied the expression of the 4-gene classifiers in hepatic needle 
biopsies collected from children and adolescents chronically infected with HCV. 
Comparing hepatic and plasma viral burden with the expression of the 4-gene 
classifiers for the children samples revealed that IFI27 significantly correlated 
with hepatic HCV RNA load, whereas RSAD2 and HTATIP2 correlated with 
the plasma load. The current knowledge about the RSAD2 and HTATIP2 
expression pattern and protein function does not reveal a reason why these 
genes are found to correlate with the plasma instead of hepatic load. Since 
HTATIP2 is a ubiquitously expressed tumour suppressor gene, we did not 
expect the expression level to be correlated with the plasma viral load and 
therefore suspect that the detected association between high plasma HCV 
RNA levels and HTATIP2 is unrelated and the same may apply to RSAD2.  
 
Multiple component analysis revealed that the combined expression pattern for 
the 4 classifiers correlated with plasma, but not hepatic HCV RNA levels for 
the children samples. However looking at the expression of individual genes 
we found that the positive correlation was mainly driven by the high RSAD2 
and HTATIP2 partial correlation coefficients, such that ISG15 and IFI27 did not 
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show any correlation. These observations highlight the importance of 
evaluating the individual expression patterns for the genes as well as the 
combined. Additional biopsies from other HCV infected children are currently 
being evaluated for the expressions of the 4-gene classifiers and will form a 
more robust data set for the multiple component analysis.  
 
Nine of the eleven children in this study responded to IFN treatment. 
Stratifying ISG expression data for the treatment response revealed limited 
association between the 4-gene classifiers and treatment outcome. However, 
the low number of samples from non-responders (n = 2) makes it difficult to 
assign any statistical significance to this observation. High response rates in 
adults have previously been associated with young age, short infection period, 
low fibrosis levels, low alcohol consumption and low body weight (Komatsu et 
al., 2013). Since children have all these characterisations it may be that they 
automatically are more likely to clear the virus following treatment than adults, 
independent of their ISG expression status. The medical records of the 11 
evaluated children have not yet been reviewed, but visiting these may help 
identifying any potential host factors, such as liver fibrosis stage and body-
weight, which may explain the high response rate for this cohort.  
 
Comparing the hepatic expression pattern of the 4-gene classifiers between 
adults and children reveal that children biopsies show higher mean expression 
levels of IFI27, RSAD2 and HTATIP2 and a lower expression of ISG15. The 
particular expression pattern of high anti-viral IFI27 and RSAD2, together with 
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low pro-viral ISG15 may pose an alternative explanation for the higher 
clearance rate in children. This rationalisation is in contrast with current 
knowledge about treatment response in adults. The detection of high IFI27 and 
RSAD2 suggests that children, do not experience endogenous IFN 
refractoriness – a condition where high endogenous IFN expression 
desensitises IFN signalling cascades. Instead the PEG-IFN treatment may 
boost anti-viral ISG expression even higher for children, leading to an 
increased clearance rate. Although this explanation seems attractive, it should 
be noted that the samples from adults and children are not matched for liver 
disease in this study and that adults with end-stage-liver disease may have a 
very different expression pattern compared to early-stage infections. An 
indication of unmatched adult and children samples is seen for the linear 
regression data for the HCV RNA loads between plasma and liver, where an 
inverted correlation is seen for the children samples (Figure 5.11) compared to 
a positive correlation for the adults (Figure 4.8). 
 
Observations from this study suggest a potential age-dependent 
responsiveness to IFN treatment. Previous studies have shown that age has a 
negative effect on the IFN-γ production in individuals infected with influenza-A, 
leading to a higher clearance rate for younger individuals than adults (Powers, 
1993). This observation is believed to result from lower CD4+ and CD8+ T-
cells counts in elderly individuals (Linton and Dorshkind, 2004). To date it is 
not known whether aging effect hepatic ISG expression during HCV infection. 
To investigate this longitudinal needle biopsies would be required over the 
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period of childhood, adolescent and adulthood. Considering that most children 
clear the virus it is not clinical practise to take later hepatic samples. Instead 
we are currently assessing the ISG expressions in chronically infected adults 
without end-stage liver disease, which are better matched the children 
samples. In addition, we are planning to study hepatic ISG expression in 
biopsies from uninfected children.  
 
In the search for alternative genes that may associate with the viral replication, 
we found that DDX3 was up-regulated in the hepatic tissue collected from 
adult patient 6 (the patient with the highest mean hepatic viral burden in our 
adult cohort). The human DDX3 belongs to the family of DEAD-box RNA 
helicases, which are involved in a large variety of cellular RNA processing. 
Knockdown of this helicase results in reduced HCV replication in vitro through 
an as yet unidentified mechanism (Angus et al., 2010; Ariumi et al., 2007). The 
observation has lead to a model where high DDX3 expression may associate 
with HCV RNA levels. Investigating the DDX3 levels in the 8 hepatic sites 
collected from the remaining 21 HCV positive patients revealed no correlation 
with hepatic or plasma HCV RNA loads. Furthermore, DDX3 levels were 
comparable between the 21 HCV positive livers and the specimens collected 
from livers with non-HCV associated advanced liver diseases and donor livers, 
suggesting that this RNA helicase is constitutively expressed in the liver 
regardless of the hepatic condition. A previous study reported that the vaccinia 
virus encoded K7 protein can bind DDX3 helicase, leading to a reduction in 
Type I IFN expression (Schroder et al., 2008). HCV core has also been 
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reported to bind DDX3 (Angus et al., 2010; Ariumi et al., 2007), but it is 
unknown if this interaction would blunt Type I IFN expression. A potential 
down-regulation of innate immune response by a DDX3-core complex could 
explain the high viral burden in patient 6, however the hepatic ISG expression 
for patient 6 was not significantly lower compared to the other patients in the 
cohort. The anti-viral array revealed that TNF and IL-8 were up-regulated in 
samples from patients 6 and 5 (patients with high viral loads). HCV NS5A has 
previously reported to induce IL-8 expression, which may desensitise cells to 
IFN mediated signalling (Polyak et al., 2001). This gene would be a relevant 
candidate for future investigations.  
 
In conclusion we found comparable expression of the previously published 4-
gene classifiers across the liver of subjects with HCV-related end-stage liver 
disease. Although the expression pattern within a liver was constant the 
pattern of ISG expression varied significantly between subjects. The variable 
hepatic ISG expression levels between patients did not correlate with plasma 
and hepatic viral load, infecting HCV genotype, indication for liver 
transplantation and prior response to IFN treatment. Comparing the 
expression of the 4-gene classifiers with samples collected from subjects with 
non-HCV associated advanced liver disease revealed that the high level of 
IFI27 was unique to patients infected with HCV. In this study we also found 
that biopsies from HCV infected children express higher levels of anti-viral 
ISGs and a lower expression of the pro-viral ISG15 compared to liver 
specimens collected from adults with end-stage liver disease. This observation 
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suggests age-dependent responsiveness to IFN and may explain the higher 






6 PHYLOGENETIC ANALYSIS OF PATIENT-DERIVED HCV 
VARIANTS 
 
HCV is capable of forming heterogeneous populations in vivo, which has led to 
intensive studies of its quasispecies genetic complexity within infected 
individuals and experimentally infected chimpanzees (Brown et al., 2005; Farci, 
2011; Farci et al., 2000; Farci et al., 1996; Gomez et al., 1999; Logvinoff et al., 
2004; Ray et al., 2005; Simmonds, 2004). Most of these studies have focused 
on the longitudinal evolution of the hyper-variable region 1 (HVR1), located at 
the 5’-end of the viral encoded E2 gene. Several samples are required for 
these types of studies and the preferred specimens have therefore been 
plasma and/or serum, which are obtained by far less invasive methods than 
liver biopsies.  
 
In other studies a single liver biopsy has been included in the investigation of 
HCV genetic distribution between the plasma and the liver, but without any 
empirical evidence that one needle biopsy is predictive for the whole liver. To 
date only 2 studies have looked at the HCV quasispecies at different 
anatomical sites in the liver, however the results from these have been 
contradicting. In 1999 Sakai and colleagues reported evidence for hepatic 
compartmentalisation between non-cancerous hepatic tissue and HCC 
nodules (Sakai et al., 1999), whereas Cabot et al. reported limited support for 
compartmentalisation between three hepatic sites (Cabot et al., 1997).  
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In contrast to most other HCV quasispecies studies, our study focuses on the 
full-length region of the most variable domains of the HCV genome; E1 and E2  
(1.7kb). In addition, the downstream p7 gene was included for HCV genotype 
3a. As mentioned in the previous chapters samples were taken from different 
sites in the explanted liver, which enabled the direct investigation of intra-
hepatic distributions of the genetic HCV population (phylo-anatomy). In the 
same study we compared hepatic viral sequences to those in the plasma at 
the time of liver transplantation.  
 
This study provides a snapshot into the distribution of HCV quasispecies 
variants within 8 different sites of the liver and in the plasma for 6 individual 





6.1 Evaluating HCV cDNA synthesis in the presence of total hepatic 
RNA  
The amount of HCV RNA make up a tiny fraction compared to the vast amount 
of total liver RNA in the RNA extractions. To assess whether the amount of 
total RNA would interfere with the synthesis of HCV cDNA, a spiking assay 
was performed. Increasing amounts of total RNA from a HCV negative liver 
explant diagnosed with ALD, were mixed with a constant amount of full-length 
H77 HCV RNA (genotype 1). The RNA mixture was used for cDNA synthesis 
and the quantity of HCV cDNA assessed by qPCR (Figure 6.1). This spiking 
assay revealed that the synthesis of HCV cDNA remained constant even in the 
presence of large amounts of total liver RNA. This indicates that total liver 





Figure 6.1 Detection of HCV RNA in the presence of total liver RNA. 
Increasing amounts of total hepatic RNA from a HCV negative (-ve) ALD liver were 
spiked into a constant level of HCV RNA (8.3 x 105 copies). The concentration of the 
HCV –ve RNA can be seen in the x-axis. HCV specific and random cDNA was 
afterwards synthesised from the RNA mixtures and the HCV cDNA levels (black 
circles) detected by target specific qPCR. All relative quantifications were done in 
duplicate samples. The lines between the measurements represent the mean for the 
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6.2 Phylogenetic analysis of HCV consensus sequences 
Total hepatic RNA from patients 1, 4 and 5 (genotype 3a) and from patients 2, 
7 and 9 (genotype 1a) were used for reverse transcription and amplification of 
5’UTR, core, E1, E2, p7 and NS2 (3.4kb) or E1, E2 (1.7kb), respectively. The 
initial aim was to amplify the core to NS2 fragment from both genotypes, which 
could be used to generate chimeric HCVcc clones (Lindenbach et al., 2005). 
However, after several unsuccessful attempts to amplify this fragment from 
genotype 1a, it was decided to assess the ease with which the shorter 1.7kb 
E1 E2 fragment could be amplified. The amplification of this shorter fragment 
was found to be reliable and we adopted this approach to recover HCV 
sequences from genotype 1 infected material.  
 
In the first instance bulk amplification was performed for each total liver cDNA 
synthesis and the PCR products gel extracted on separate gels for later 
consensus sequencing of the desired fragments. The bulk amplifications of 
patient 1 and 2 can be seen in Figure 6.2A and are representative for the 
remaining four patients, except for the patient 4, biopsy 6 specimen which, for 
unknown reasons, did not contain RNA.  
 
To ensure good detection of potential HCV variants in the bulk PCR products, 
a sequencing sensitivity assay was performed. Previous sequenced bulk 
amplification from P1-B8 and P4-B4 had showed no nucleotide ambiguities in 
their consensus sequence and these were therefore used for evaluating the 
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sequencing sensitivity. The PCR products from the P1-B8 and P4-B4 samples 
were mixed at different ratios and subjected to consensus sequencing of the 
5’-end of E2. Evaluating the consensus sequences for each mixture revealed 
that the Sanger sequencing had detected patient-specific sequences down to 
a ratio of 1:9, indicating that the sequencing sensitivity of our assay is ≥ 90% 






Figure 6.2 Bulk amplification of hepatic HCV sequences and evaluation of 
sequencing sensitivity. 
A. Bulk amplification of the viral encoded genes 5’UTR, core, E1, E2, p7 and NS2 
(3.4kb) from patient 1 hepatic tissue and E1 and E2 (1.7kb) from patient 2. The 
positive control (+ve) contained a genotype 1a template (H77) and the negative 
contained dH2O instead of a cDNA template. B. Bulk PCR products from patient 1, 
biopsy 8 (P1-B8) and patient 4, biopsy 4 (P4-B4) were mixed at different ratios and 
the HVR1 sequenced by Sanger sequencing. The arrows indicate nucleotide 




The liver derived HCV bulk amplifications should in theory contain all the HCV 
variants found at the particular site and the HCV amplifications from each 
biopsy were therefore directly sequenced to get an estimate of the viral 
polymorphisms. The resulting consensus sequences contained relatively low 
numbers of ambiguities across the genotype 1; E1, E2 amplified region 
(average 112 difference ±39.59 in 1.7kb) and the genotype 3a; E1, E2, p7 
region (average 64 difference ±17.34 in 1.8kb). Most of the changes were 
located in the E2 gene. An alignment of the consensus sequences for 
genotype 1 HVR1 can be seen in Figure 6.3A. Alignments of HVR1 and the 
genotype 3a specific HVR495 and HVR575 consensus sequences are shown 
in Figure 6.4A, B and C, respectively.  
 
Nearest Neighbour sequence analyses of the genotype-specific full length 
consensus sequences demonstrate that HCV sequences isolated from one 
liver are highly comparable, with mean genetic distances between 0 and 8.0 x 
10-4 (Figure 6.3B and Figure 6.4D). However, the genetic distances between 
patient-specific HCV sequences with the same genotype were significantly 
larger; mean branch length between genotype 1a sequences was 0.046 
±0.022 and between genotype 3a sequences the length was 0.057 ±0.028. 
These large distances between patient-derived HCV consensus sequences 
are supported by a bootstrap value of 1000.   
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Figure 6.3 Analysis of genotype 1a hepatic E1, E2 consensus sequences. 
A. Alignment of the liver-derived HVR1 consensus nucleotide sequences generated 
from each of the 8 segments (B1-8) from patients 2, 7 and 9 (P2, 7 or 9). The HCV 
H77 clone (genotype 1a) is used as a reference sequence. B Un-rooted Neighbour 
Joining phylogenetic tree generated with 1000 bootstraps. The branch lengths are a 
direct measure of the genetic distances. Mean HCV genetic distance within one liver 
is indicated next to the patient lineage. Only bootstrap-values above 750 are indicated.  
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Figure 6.4 Analysis of genotype 3a hepatic E1, E2, p7 consensus sequences. 
A. Alignment of the liver-derived HVR1 consensus nucleotide sequences detected in 
the 8 specimens from patients 1, 4 and 5 (P1, P4 and P5). B. + C.  Nucleotide 
alignment of the hepatic HVR495 and HVR575 for the same patients. The HCV S52 
clone (genotype 3a) is included as a reference. D. Un-rooted Neighbour Joining 
phylogenetic tree generated with 1000 bootstraps. The branch lengths are a direct 
measure of the genetic distances. Mean genetic distances are indicated next the 
patient lineage. Bootstrap-values above 750 are indicated in the phylogenetic tree.  
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6.3 Phylogenetic analysis of SGA-derived HCV sequences isolated 
from the liver  
The low genetic variability in the HCV consensus sequences could potentially 
be the result of sequencing major HCV variants at the expense of the minor 
sequences (<10% abundance, see Figure 6.2A). To evaluate the efficiency of 
minor sequence amplifications, a spiking experiment was performed using 
RNA from the genotype 3a infected patient 1 (P1-B6.H3-1.6) and patient 5 
(P5-B3.F3-B9) HCV clones (see Table 3.5). Decreasing amounts of P5-B3.F3-
B9 RNA were spiked into a constant volume of P1-B6.H3-1.6 RNA together 
with a constant concentration of total hepatic RNA from an ALD liver.  
  
Mixtures of the three RNA templates were subject to genotype 3a specific 
cDNA synthesis, PCR amplification for the 3.4kb fragment (Figure 6.5A) and 
finally Sanger sequencing of the consensus HVR1 region (Figure 6.5B). 
Detection of the P5-B3.F3-B9 sequences in the chromatogram was only 
possible at a HCV RNA mixing ratio of 1:1. Lower dilutions of P5-B3.F3-B9 
RNA resulted in loss of the minor sequence (Figure 6.5B). These data indicate 
that HCV variants present at a concentration below 1 : 1 will either not be 
reversed transcribed into cDNA or not amplified during PCR. 
 
Failure to detect HCV sequences present at low concentrations justifies the 
approach of single genome amplifications (SGAs) for the investigation of HCV 
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genetic compartmentalisation. In total 120 HCV clones were generated from 
liver and plasma specimens collected from patients 1, 2, 4, 5, 7 and 9 (Table 
3.5). In average 20 clones were generated per patient. The E1 and E2 
sequences isolated from patients infected with genotype 1 and the E1, E2 and 





Figure 6.5 Amplification of major and minor sequences in vitro. 
A. Synthetic RNA was transcribed from patient 5, biopsy 3 (P5-B3.F3-B9) and patient 
1, biopsy 6 (P1-B6.H3-1.6) clones. A 0.5-log dilution series of P5-B3.F3-B9 RNA was 
spiked into a constant level of P1-B6.H3-1.6 RNA (5000ng/reaction) and total hepatic 
RNA from an alcoholic liver disease (ALD) patient (1500ng/reaction). HCV cDNA was 
generated with reverse primers against the NS2-NS3A junction, followed by a nested 
PCR with genotype 3a specific primers for the 3.4kb fragment. The PCR product 
where separated by gel electrophoresis. PCR products, which failed sequencing, are 
indicated with a question mark. B. Chromatograms from consensus Sanger 
sequencing of the PCR products in A. The consensus sequencing failed to detect the 
minor sequence at 1500ng (dilution 1:3.3 with P1-B6.H3-1.6) and 136ng (dilution 1 : 
36.8 with P1-B6.H3-1.6) template RNA. 
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Comparative sequence analyses were performed for HVR1 in the hepatic SGA 
sequences. The Nearest Neighbour sequence analysis revealed that the 
HVR1 sequences formed patient-specific lineages and that sequences isolated 
from the same patient had shorter genetic distance than sequences isolated 
from different patients (Figure 6.6A). Interestingly, patient 5 showed up to 2-
fold larger internal genetic distance than the other patients, which is due to a 
sub-clustering of P5-B1.D9-A12 and P5-B3.F3-B9.  
 
Several identical HVR1 sequences were detected in the same liver, with the 
highest number found for P2-B1 (60%). In general, patients infected with 
genotype 3a, showed significantly higher HVR1 variation, with multiple unique 




Figure 6.6 HVR1 sequence analysis. 
A. The 81 nucleotide long HVR1 was isolated from the patient SGAs and used in 
Nearest Neighbour sequence analyses. The phylogenies are here shown as un-
rooted Neighbour Joining trees for each of the genotypes (1000 bootstraps). The 
mean genetic distances can be seen for each patient lineage and a scale for the 
distances can be seen underneath the trees. The bootstrap value is indicated for the 
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central node. B. The HVR1 sequences (Seq) isolated from the same patient were 
aligned and the number of unique HVR1 noted. The fraction of SGAs with identical 
HVR1 sequences are presented as a percentage of the total number of sequences 




Neighbour joining sequencing analysis was also performed for the HCV 
genotype 3a specific HVRs (HVR495 and HVR575) (Humphreys et al., 2009). 
As for HVR1, the HVR495 and HVR575 were highly comparable within the 
same liver, indicated by low mean genetic distances (Figure 6.7A).  
 
The frequency of identical HVR495 and HVR575 sequences within one liver 
was considerable higher than for the HVR1 sequences and in some instances 
the isolated sequences were all identical (Figure 6.7B). These observations 
led to the decision not to perform further phylogenetic analysis on the SGA-




Figure 6.7 Genotype 3a HVR495 and HVR575 sequence analysis. 
A. Nearest Neighbour analyses were applied to the SGA-derived HVR495 and 
HVR575 sequences from the genotype 3a patients. The phylogenies are here shown 
as un-rooted Neighbour Joining trees generated with 1000 bootstraps. The patient-
specific HVRs are indicated in colour; P1: black, P4: blue and P5 green. The 
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boostrap-value is indicated for the central node. B. The intra-hepatic HVR495 and 
HVR575 sequences were aligned and the number of unique sequences found for 
each patient. The fraction of identical HVR495 and HVR575 sequences are indicated 
as a percentage of the total number of sequences from the particular site.  
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As mentioned above, all 6 patients showed low genetic variability in the 
detected HVR sequences. To date, there is no evidence that polymorphisms in 
HVR1 directly predict the number of variations outside this region and it was 
decided to analyse the genetic variability of the E1, E2 structural genes for 
genotype 1a infected patients and the E1, E2 together with p7 for genotype 3a. 
Initial alignment analysis revealed that the patient-specific SGAs had a mean 
of 113 ±39.5 polymorphic sites for genotype 1a sequences (1.7kb) and 120 
±67.6 sites for genotype 3a (in 1.8kb). Interestingly, the number of changes 
per nucleotide in each viral gene varied between patients. Sequences isolated 
from patients 2, 4 and 5 contained a higher number of differences in E2, 
whereas patients 7 and 9 contain more in E1. Patient 1 showed the highest 




Figure 6.8 Distribution of polymorphisms for SGA-derived hepatic HCV 
sequences. 
The number of changes per nucleotide was quantified for the patient-specific E1, E2 
and p7 SGA sequences. The number of changes per nucleotide is normalised to the 
size of the particular gene (E1 = 576nt, E2 = 1089nt and p7 = 189nt). 
 
  



























Comparing the SGA-derived sequences with the consensus found for the 
same cDNA template revealed that most of the ambiguities detected in the 
consensus sequence chromatograms were represented among the SGA-
derived clones. However, in some instances the polymorphisms among the 
consensus sequences were not represented in the clones, indicating that not 
all HCV variants had been isolated. In addition, several polymorphisms 
detected among the SGAs, were not represented by the consensus 
sequences (Appendix 1).  
 
Phylogenetic analysis of the SGA-derived HCV sequences were performed by 
Nearest Neighbour with a bootstrapping of 1000. The data are presented as 
rooted Neighbour Joining trees instead of un-rooted, in order to better 
distinguish between highly similar sequences. The inferred biopsy consensus 
sequence of the aligned intra-hepatic consensus “bulk” sequences (BCC: 
Biopsy Consensus Consensus) was included in the analysis as a 
representative for the bulk sequences. The molecular clone H77 (genotype 1a) 
and S52 (genotype 3a) was included as reference sequences (Figure 6.9A + 
B). The phylogenetic tree places the BCC sequence in the middle of the trees 
with approximately equal genetic distance to the patient-specific SGAs. The 
analysis further revealed that patient 5, P5-B1-C2.B1 and P5-B6.B7-G9 and 
patient 9 P9-B6.C12-E4 and P9-B6.G6-C11 were identical. 
 
Although the remaining 116 HCV SGAs differed from each other, they did not 
form site-specific lineages. For Patient 1, 2, 4 and 9 clusters were formed of 
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two to four SGA sequences originating from the same hepatic site, however in 
most cases these clusters had shorter branch length to SGAs from a different 
hepatic site, than to sequences derived from the same biopsy (Figure 6.9A +B). 
Evaluating the mean genetic distance between sequences identified at 
difference hepatic compartments revealed that these were either smaller or 
equal to the mean genetic distances between SGAs originating from the same 
site (Appendix 2). HCV sequences from patient 7 showed more defined 
formation of site related lineages, demonstrated by the formation of four 
distinct clusters of sequences isolated from biopsy 1 and 6. However, the 
positioning of the clusters revealed interruption of site-specific lineages (Figure 
6.9A). The observation is supported by the equal genetic distance between 
HCV sequences detected within biopsy 1 and 6 and between the two sites 
(Appendix 2). In comparison, the 20 SGAs generated from patient 5 did not 
form any clusters. Instead the site-specific SGAs were scattered across the 
phylogenetic tree (Figure 6.9B) and the mean genetic distance were larger 
between sequences originating from the same biopsy than from different ones 
(Appendix 2).  
 
Additional phylogenetic analysis of the hepatic HCV sequences was performed 
with the tree-based Hasegawa-Kishino-Yano (HKY) substitution model. The 
generated Maximum Likelihood phylogenetic tree was highly comparable with 
the Neighbour Joining model and it was therefore decided not to use the more 






Figure 6.9 Phylogenetic analysis of hepatic HCV nucleotide sequences.  
Nearest Neighbour analyses were applied to the SGA sequences isolated from each patient and represented as rooted Neighbour 
Joining trees with 1000 bootstraps. Branches supported with more than 750 bootstraps are indicated in the trees. The branch lengths 
are a direct measure of the genetic distances between the SGAs and a scale for the length can be seen underneath each tree. The 
branches from biopsy 1 (B1) are turquoise, biopsy 3 (B3) SGAs are orange and biopsy 6 (B6) and 7 (B7) blue. The branch for the 
consensus sequence (BCC: biopsy consensus consensus) generated from the 8 hepatic consensus sequences are coloured black and 
are indicated with an arrow. A. Genotype 1a patients 2, 7 an 9. The E1E2 nucleotide sequence for the genotype 1 H77 variant is used as 
a reference. B. Genotype 3a patients 1, 4 and 5. The E1E2, P7 nucleotide sequence for the genotype 3a S52 variant is used as a 
reference.  
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6.4 Phylogenetic analysis of SGA-derived HCV sequences isolated 
from plasma 
In addition to the intra-hepatic SGA-derived HCV sequences, phylogenetic 
analyses were carried out on HCV SGAs detected in the plasma from patients 
1, 2, 4, 7 and 9 (list of SGA clones can be seen in Table 3.5). For unknown 
reasons HCV sequences could not be amplified from the plasma of patient 5. 
 
Alignments of the plasma-derived HCV sequences revealed that each patient 
had variables level of nucleotide changes for the investigated genes. 
Sequences from patient 2, 9 and 4 showed higher level of changes per 
nucleotide for the viral encoded E2, whereas patient 7 had higher levels in E1 
and patient 1 in p7 (Figure 6.10). Notably, all patients except for patient 1 
showed a lower number of polymorphic sites between the plasma-derived 
HCV sequences compared to the liver-derived. However the difference is 
believed to be the result of more liver- than plasma-derived sequences being 
included in the analyses. The analysis of patient 1 included more sequences 
from the plasma than the liver, which explains why this patient show more 




Figure 6.10 Distribution of polymorphisms for SGA-derived plasma HCV 
sequences. 
Number of gene-specific differences between SGA sequences isolated from the same 
patient. The value is expressed as changes per nucleotide for the genes and are 
normalised to the size of the individual genes (E1 = 576nt, E2 = 1089nt, p7 = 189nt). 
The number of differences in the patient’s hepatic SGA sequences is indicated with a 
red line.  
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Neighbour Joining phylogenetic trees were generated for the plasma- and 
liver-derived sequences isolated from patient 1, 2, 4, 7 and 9 (Figure 6.11A+B). 
The analysis revealed that none of the plasma-derived SGA clones were 
identical within one patient. Furthermore none of them were identical to the 
liver-derived sequences.  
 
Although the plasma- and the liver-derived HCV sequences represent different 
anatomical compartment, we did not observe distinct site-specific lineage. 
Instead most plasma-derived sequences revealed closer genetic relation with 
sequences from hepatic sites (Figure 6.11A+B). This pattern was especially 
seen for the sequences isolated from patients 2, 4 and 9, who also showed 
lower mean genetic distances between plasma- and liver specific sequences 
than between the individual plasma sequences (Appendix 2). Small clusters of 
two - four plasma sequences were seen for patient 1 and 7, however the 
clusters was scattered in between hepatic sequences and the mean genetic 
distance between the site-specific sequences and within the plasma-derived 
sequence alignments were highly comparable (Appendix 2).  
 
Since the hepatocytes are the main site for HCV replication we decided to 
investigate any potential links between plasma- and site-specific liver-derived 
HCV sequences. Interestingly, plasma sequences isolated from patient 2 
showed significantly closer relation to HCV sequences from biopsy 1 than 6 
and for patient 9 the plasma-derived HCV sequences demonstrated shorter 
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genetic distance to sequences isolated from biopsy 6 than for biopsy 1 
(Appendix 1). The remaining patients had comparable distances between the 





Figure 6.11 Phylogenetic analysis of hepatic- and plasma-derived HCV nucleotide sequences.  
Nearest Neighbour analyses were applied to the SGA sequences isolated from each patient and the data is here presented as rooted 
Neighbour Joining trees with 1000 bootstraps. Branches supported with more than 750 bootstraps are indicated at the branchings. The 
branch lengths are a direct measure of the genetic distances between the SGAs and a scale for the length can be seen underneath each 
tree. The branches representing plasma (Plas) are red, biopsy 1 (B1) turquoise, biopsy 3 (B3) SGAs are orange and biopsy 6 (B6) and 7 
(B7) blue. The branch for the consensus sequence (BCC: biopsy consensus consensus) generated from the 8 hepatic consensus 
sequences are black and are indicated with an arrow. A. Genotype 1a patients 2, 7 and 9. The E1E2 nucleotide sequence for the 
genotype 1a H77 variant is used as a reference. B. Genotype 3a patients 1 and 4 The E1E2, P7 nucleotide sequence for the genotype 
3a S52 variant is used as a reference.  
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6.5 Analysis of HCV entropy and migration events 
Shannon entropy analysis was performed for the SGA-derived sequences 
originating from the same hepatic site or from the plasma (One-way Shannon 
entropy). The analysis revealed that the HCV sequences shared a high 
number of identical nucleotides (entropy = 0) and that the positive entropies 
were comparable between site-specific sequence alignments. The highest 
density of entropies was found in the 5’-end of E2, consistent with the location 
of HVR1 (here position 573-654nt) (Figure 6.12A).  
 
The hepatic sequences generated from patient 2, 5, 7 and 9 had overall more 
sites with polymorphisms (more number of sites with entropies above 0) and 
higher complexity at the polymorphic sites (high level of entropy at variable 
sites) (Figure 6.12A right, represented by patient 2) than seen for patient 1 and 
4 (Figure 6.12A left, represented by patient 1), leading to higher mean 
entropies for the patient 2, 5, 7 and 9 (Appendix 3). These results are 
supported by the observation that hepatic SGA alignments for patient 2, 5, 7 
and 9 show higher levels of changes per nucleotide than patient 1 and 4 
(Figure 6.8). Plasma sequences isolated from patient 1, 2, , 7 and 9 had higher 
numbers of polymorphic sites than the patient 4 plasma sequences. However 
patient 4 had a higher level of complexity, with entropies up to 0.995, than 
seen for any of the other patients (data not shown). The mean entropy for the 
patient 4 plasma SGA alignment is therefore significantly higher than for the 
other patient-derived plasma sequences (Appendix 3).     
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Performing Shannon entropy between the biopsy- and plasma-derived HCV 
sequence alignments (two-way Shannon entropy) demonstrated significantly 
more variable sites than for the one-way Shannon entropy analyses (Figure 
6.12B). Furthermore, patient 2 and 7 showed higher levels of complexity at the 
variable position between site-specific sequence alignments, indicating that 
the site-specific sequences do not share the same sequence diversity. In 
contrast, patient 9 showed decreased levels of two-way entropies compared to 
the one-way, suggesting that the HCV sequences isolated from the different 
compartments shares the same polymorphisms (data not shown). Patient 1, 4 
and 5 showed similar complexity between the one- and two-way Shannon 






Figure 6.12 Shannon entropies. 
Shannon entropies were calculated for each nucleotide position in the SGA sequence alignments. Entropies above zero indicate 
polymorphisms at the particular site in the alignment. Here patient 1 and 2 are shown as representatives for the two different entropy patterns 
seen for all patients. Patients 5, 7, 9 showed similar patterns as patient 2, whereas patient 4 is comparable with patient 1. A. One-way Shannon 
entropies for SGA sequences isolated from the same anatomical site B. Two-way Shannon entropies between sequences alignments 
generated from different sites.  
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Estimation of the minimum number of HCV migration required for the observed 
spatial distribution of sequences between sites was done by Slatkin-Maddison 
modelling. In this model a probability (p) below 0.05 is considered significant 
evidence for genetic compartmentalisation (Rodrigo et al., 2001). Performing 
Slatkin-Maddison modelling for the SGA-derived HCV sequences revealed 
that migration may have occurred between the hepatic sites within one liver. 
However for patients 2, 4, 5, 7 and 9, the migration from biopsy 1 only 
occurred in one direction (Table 6.1). Statistical significance for the number of 
migration events was only seen for the HCV sequences isolated from patient 7 
(p = 0.02). Fourteen hepatic HCV sequences were analysis for patient 7 and of 
these only two were required to predict the distribution of sequences between 
the hepatic compartments. This observation confirms the formation of four site-
specific clusters in the Nearest Neighbour phylogenetic tree (Figure 6.9) and it 
is concluded that the liver collected from patient 7 may demonstrate genetic 
compartmentalisation of the viral-encoded E1 and E2 genes. 
 
Slatkin-Maddison modelling for the plasma-derived HCV sequences indicated 
that HCV migration events occurred both from plasma to the individual 
biopsies and in reverse to the plasma, but in none of the case was the number 
of migration events significant (p > 0.05). Comparing the plasma-derived 
sequences with the combined intra-hepatic sequences showed that migration 
is more likely to occur from the liver to the plasma (patient 2, 7, 9 and 4). 
However the data was not statistical significant (Table 6.1).  
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6.6 Analysis of selective pressure on SGA-derived HCV sequences 
The identification of polymorphisms among the HCV SGA nucleotide 
sequences suggests potential differences between the inferred SGA-derived 
HCV amino acid sequences. The presence of amino acid polymorphism 
depends on whether the detected nucleotide changes are synonymous (ds) or 
non-synonymous (dn). Prior to measuring ds and dn changes, clones with 
deletions (P2-B1.A9-G1*, P2-B1.F6-H8* and P7-B6.C3-C11*) were edited by 
inserting nucleotides identical to the consensus of the other SGAs in the 
alignment. At the same time the guanine insertion in P7-Plas.E2-A10* was 
deleted to avoid out of frame codons.  
 
Evaluation of the mean ds and dn changes per codon for SGA-derived HCV 
sequences isolated from different compartments revealed low levels of 
changes (ds: 0.007 – 0.084 changes per nucleotide and dn: 0.003 - 0.013 
changes per nucleotide) with most of the codons having no changes. Those 
codons that did differ between sequences were more likely to contain ds than 
dn changes (two-tailed paired t-test: p < 0.0001), suggesting higher levels of 
random mutation than non-random at the investigating sites (Table 6.2 and 
6.3). Similar observations were made when comparing SGA-derived 
sequences originating from the same compartment (Figure 6.13A), leading to 
a mean ds/dn-ratio per codon of above 1 for the site-specific sequence 
alignments (Table 6.2 and 6.3).  
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The position of the ds and dn changes were further evaluated for the SGA-
derived HCV sequences. (Figure 6.13A and B). As mentioned above, SGA-
derived sequences from the same and from different anatomical sites show 
higher numbers of ds than dn changes across the investigated sequences. 
Interestingly, high numbers of dn changes were mainly observed between 
positions 155 and 210 in the 5’UTR-end of E2, consistent with the HVR1 
(Figure 16.13A + B, here represented by patient 1. Sequences isolated from 
the remaining patients showed similar distribution of ds and dn changes). 
Furthermore, patient 1, 4 and 5 showed ratios below 1 at positions 390 to 435, 
which potentially coincide with the HVR575, which is located between codon 
positions 384 and 392 (Figure 16.13A + B).  
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Table 6.2: ds/dn ratio for HCV genotype 1a 
 sequences
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Figure 6.13 ds and dn distribution across E1 E2 and p7.  
The ds and dn values were calculated for each codon by SNAP v1.1.1. The position 
of the codons can be seen underneath the graph. Patient 1 is here shown as 
representative for the typical distribution of ds and dn changes observed for all 
patients. A. ds and dn changes found for the site-specific SGA sequences. B. ds and 
dn changes found between SGA site-specific alignments.  
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6.7 Analysis of inferred HCV amino acid sequences isolated from 
plasma and liver 
To investigate potential compartmentalisation of the inferred HCV amino acid 
and their theoretic phenotype the SGA-derived HCV sequences were 
translated to amino acid using the CLC main workbench. Initial analysis of the 
amino acid sequences revealed that P9-Plas.E8-D4, P4-B7.G7-F3, P4-B7.B6-
C8 and P5-B3.F3-B9 contained in-frame stop codons in the E1 E2 region. Due 
to genotype variability in the length of the E1 and E2 sequences the stop 
codon in P9-Plas.A5-G2 (W425*) is the same as seen in P4-B7.B6-C8 
(W433*). Same stop codons were also detected in P5.B3-F3-B9 (Y603*) and 
in P4-B7.G7-F3 (Y605*) (Table 6.4). Whether these terminations reflect in vivo 
defective particles or artefacts in cDNA synthesis cannot be established using 
current methods.  
 
During post-translation modifications oligosaccharyltransferase may add 
oligosaccharides to the asparagine in the tri-peptide motif, Asn – x – Ser/Thr 
(NxS/T). This glycosylation process does not occur at all NxS/T motifs, but is 
essential for specific sites in the E1 and E2 proteins in order to maintaining 
stability and for correct folding (Goffard et al., 2005; Helle et al., 2010; Meunier 
et al., 1999). The SGA-derived amino acid sequences were manually 
screened for polymorphisms in the potential N-linked glycosylation (PNG) sites. 
None of the HCV sequences from patients 1, 5 and 9 had NxS/T 
polymorphisms, however polymorphic sites were identified in P2-B6.H10-F12 
(N385) and P7-B1.F2.D11 (T387I). Surprisingly, 12 out of 20 SGA-derived 
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sequences from patient 4 showed polymorphisms in PNG sites independently 
of the anatomical origin of the sequences. All except for 1 clone had more than 
one effected PNG and the most frequently altered sites were N287T and 
N342K (Table 6.4).    
 
Table 6.4: Sequence analysis of HCV amino acid sequences   
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The identification of relatively few polymorphic sites, suggested that the 
inferred SGA-derived amino acid sequences would be similar. To evaluate this 
Nearest Neighbour analyses were performed on the translated HCV 
sequences. The phylogenetic analysis revealed an increase in the number of 
identical sequences isolated from patient 1, 2, 4, 5 and 7. However, the 
identical sequences had derived from different anatomical sites (Figure 
6.14A+B). As a result the mean distance between amino acid sequences were 
comparable with the distances between the original nucleotide sequences 
(Figure 6.15) (unpaired two-tailed t test: p > 0.85). In addition, we did not 
observe any significant differences for the mean distance between amino acid 
sequences deriving from the same anatomical site and between sites (Figure 
6.15). Interestingly, the analysis for patient 9 revealed no increase in the 
number for identical amino acid sequences compared to the analysis of the 
nucleotide sequences (data not shown). This observation indicates that the 
SGA-derived sequences detected in patient 9 mainly contain ds changes or 
that dn changes potentially were located at the same positions. As a 
consequence the distance between the translated SGA sequences remained 
unchanged from the genetic distance between nucleotide sequences isolated 
from patient 9.  
 
Nearest Neighbour analysis assumes equal frequency of nucleotide and amino 
acid changes and will weigh all substitutions the same. In nature amino acid 
substitutions do not occur randomly, some are more likely to happen than 
others. Identifying rare amino acid substitutions between sequences would 
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therefore suggest that they are related. We decided to evaluate the similarity 
between sequences by evaluating the weighted substitutions by BLOcks 
SUbstitution Matrix (BLOSUM) modelling. Unsurprisingly, the SGA derived 
sequences scored up to 99.4% similarity between SGA-derived HCV 
sequences originating from the same site and 99.3% similarity for sequences 
from different sites (Appendix 4). The minimum level of identity between sites 
were 97.4%, suggesting that the SGA-derived HCV sequences are highly 
comparable and that they contain similar levels of weighted substitutions.  
 
Slatkin-Maddison modelling of the patient-derived nucleotide sequences 
previously showed significant evidence of genetic intra-hepatic 
compartmentalisation for patient 7. The analysis was repeated to see if the 
differences were still apparent for the amino acid sequences. This time the 
Slatkin-Maddison model estimated 4 migration events; two from biopsy 1 to 6 
and two in the opposite direction, however the result was no longer significant 





Figure 6.14 Phylogenetic analysis of hepatic and plasma HCV amino acid sequences.  
Nearest Neighbour analyses with 1000 bootstraps were applied to the SGA-derived sequences from patient 1, 2, 4, 5, 7 and 9 and 
represented as rooted Neighbour Joining trees. Branches supported with more than 750 bootstraps are indicated in the trees. The 
branch lengths are a direct measure of the genetic distances between the SGAs and a scale for the length can be seen underneath each 
tree. The branches from plasma (Plas) are red, biopsy 1 (B1) turquoise, biopsy 3 (B3) SGAs are orange and biopsy 6 (B6) and 7 (B7) 
blue. The branch for the consensus sequence (BCC: biopsy consensus consensus) generated from the 8 hepatic consensus sequences 
are coloured black and are indicated with an arrow. Sequences corrected for nucleotide deletions and insertions are indicated with *. A. 
Genotype 1a patients 2, 7 and 9. The E1E2 amino acid sequence for the genotype 3a S52 variant is used as a reference.  B. Genotype 




Figure 6.15 Distances between SGA-derived nucleotide and amino acid 
sequences. 
The distances between SGAs were found for the nucleotide and amino acid 
sequences and the mean distance calculated between SGAs isolated from the same 
site and between sites. The data is here represented for patient 1 and 2 as a mean 
with standard deviation. Two-way unpaired t-test applied to the data set revealed no 
statistical differences in the mean distance between nucleotide and amino acid 






































































































6.8 HCV sequences identified by next generation 454 pyro-sequencing 
Analysing quansispecies distribution by the SGA sequencing approach 
requires extensive cloning of the PCR products to ensure coverage of major 
and minor sequences in the population. One of the concerns with the SGA 
sequencing approach is whether enough HCV variants are investigated to 
reach valid conclusions. 
 
Within recent years next-generation sequencing platforms have been 
developed to investigate viral quasispecies in much greater detail. Its high 
throughput approach allows the generation of thousands of sequence reads in 
a single sample and facilitate in-depth sequencing of even low frequency 
variants (Beerenwinkel et al., 2012; Henn et al., 2012; Yang et al., 2012). To 
generate a more detailed investigation of the HCV quasispecies population at 
end-stage liver disease, total liver RNA and plasma from patients 1 and 2 were 
subjected to next generation 454 pyrosequencing (NGS). Our collaborators Dr. 
Damien Tully, Dr. Karen Power and Prof. Todd Allen at Harvard University, 
USA, performed the NGS and the following data processing. 
 
Total liver RNA from all 8 biopsies and the plasma from patients 1 (genotype 
3a) and 2 (genotype 1a) were sequenced across core, E1, E2, p7 and NS2 
region (3.1kb). The efficiency of the emulsion PCR and the pyro-sequencing 
can be found in Table 3.6. The sequence reads were organised into 32 bins 
according to their size and the codon diversity were determined at 32 
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nucleotide long fragments (Figure 6.16A + B). The heat-maps of the hepatic 
sequence diversity revealed heterogeneity at each of the investigated sites. 
Not surprisingly, the highest level of diversity was found at the HVR1 site in the 
5’UTR-end of E2  (Figure 6.16A + B). In addition, the fraction of polymorphic 
codons between sequences isolated from different hepatic sites only differed 
with approximately 1.4-folds (Figure 6.16C).  
 
Comparing the sequence diversity between liver and plasma NGS data sets 
showed that the plasma-derived sequences from patient 1 shared similar 
levels of heterogeneity across the core-NS2 region as the liver (Figure 6.16A). 
However, for patient 2 the plasma sequences had lower numbers of 
polymorphic bins and an overall lower diversity across the investigated region 
(Figure 6.16B). This difference in sequence diversity for patient 2 plasma and 
liver became more appearent when comparing the number of changes per 
codon between the site-specific sequences. For patient 2 the number of 
polymorphism differs with approximately 1.5-fold between liver- and plasma-
derived sequences, whereas patient 1 had a similar level of changes per 












Figure 6.16 Heat-maps for HCV codon diversity detected by NGS. 
Our collaborators Dr. Damien Tully, Dr. Karen Power and Prof. Todd Allen at Harvard 
University, USA, performed the NGS and data processing. A + B. The heat-maps 
show the codon diversities across the HCV core – NS2 region (Y-axes: bins of ~32 
codons) for different sizes of read length (X-axes: bins of 6 bp).  The diversity is 
indicated as a percentage (A. Patient 1, B. Patent 2). C. Quantifications of the total 
number of polymorphism per codon between the core-NS2 sequences identified in 
the plasma and liver specimens collected from patients 1 and 2. 
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The polymorphisms observed for the HCV sequences isolated from patient 1 
and 2 were further divided into ds and dn changes. HCV diversity heat-maps 
for each of the collected samples revealed that the sequences contained both 
types of changes, however there was up to 4-fold more ds than dn changes 
(Figure 6.17A and B). As seen for the SGA-derived sequences (section 6.6), 






Figure 6.17 Heat-maps for HCV ds and dn diversity detected by NGS. 
Our collaborators Dr. Damien Tully, Dr. Karen Power and Prof. Todd Allen at Harvard 
University, USA, performed the NGS and data processing. A. Heat-maps of ds and dn 
changes observed for each codon (Y-axes: bins of ~32 codons) in the different sized 
sequence reads (X-axes: bins of 6 bp). The diversity is indicated as a percentage. B. 
Quantifications of the ds and dn changes per codon were calculated for patient 1 and 
patient 2 specimens.  
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Statistical analyses of the viral population distribution require alignments of the 
isolated sequences. One of the disadvantages with NGS is that sequencing is 
performed on relatively short fragments  (~350 base) and we can therefore not 
assume true linkage of the 3.1kb region. Instead of risking erroneous 
alignments of the full-length core-NS2 fragment, our collaborators decided to 
use HVR1 for the compartmentalisation analysis. Alignments of the HVR1 
amino acid sequences showed that patient 1 and patient 2 had identical major 
sequence in the specimens collected from one liver, but whereas patient 1 had 
four dominating strains with prevalence above 10%, patient two had one 
(Figure 6.18). Instead, patient 2 had far more unique minor variants at the 




Figure 6.18 HVR1 amino acid diversity across liver and plasma specimens. 
The frequencies of the different HVR1 sequences (Seq) were calculated as a 
percentage of the total number of sequences detected. All HVR1 sequences were 
specific to each patient. Sequences with frequencies below 5% are presented 
together in a white bar. The data has been provided by Dr. Damien Tully, Dr. Karen 
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Performing four independent statistical analyses (Slatkin-Maddison, correlation 
coefficient of branch number, Wright’s measure of population subdivision and 
Nearest neighbour statistics) reveal no significant evidence for HVR1 genetic 
compartmentalisation between biopsy and plasma for patient 1 and 2 (Table 
6.5). Statistical compartmentalisation analysis between the intra-hepatic 
sequences has not yet been received, but recent conversations with our 
collaborators reveals that the HVR1 sequences do not form 
compartmentalisation between different sites in the liver.  
 







6.9 Comparing data from next generation sequencing to the single 
molecule amplification 
For this study two sequence amplification methods and sequencing strategies 
were used for analyzing the HCV sequence diversity in samples collected from 
different anatomical sites in patients with end-stage liver disease. This allows 
us to evaluate and compare the efficiency between the two techniques.   
 
The NGS- and SGA-derived HCV sequences collected from patient 1 and 2 
were compared for the E1, E2 and p7 region or the E1 and E2, respectively. 
Polymorphisms detected by one of the techniques and not the other were 
noted and the number of unique codons displayed across the investigated 
region (Figure 6.19A). As expected, NGS identified more unique codons 
across the fragment than the SGA and Sanger sequencing had. Quantifying 
the fraction of unique codons detected by the two approaches, demonstrated 
that up to 89% of all polymorphisms detected by NGS were also found by SGA. 
In comparison, up to 97% of the SGA detected codons were also found by 
NGS (Table 6.6). We also detected multiple amino acid polymorphisms unique 
to each sequencing approaches, but their frequencies and the level of variety 
was far less than for the codons (Figure 6.19B). As a consequence NGS had 
coverage 99% of the SGA amino acid sequences and SGA had covered 98% 
of the amino acids detected by NGS (Table 6.6). The difference in NGS and 
SGA coverage for nucleotide and amino acid coverage is likely to be the result 
of minor HCV variants, which are more efficiently detected by NGS. However, 
it is important to note that NGS did not have 100% coverage of all SGA 
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sequences, indicating that although NGS is resourceful in detecting many 
different variants it might not detect extremely rare variants, which are below 








Figure 6.19 Detection of unique codons and amino acids by SGA and NGS. 
Diversities were compared between the sequences detected by SGA and NGS and 
the number of unique sites, not detected by the competitive approach, was noted. The 
value zero indicates that the same codon(s) were detected by both techniques. The 
position of the sites can be seen underneath the graphs. A. Quantification of unique 
codons for plasma, biopsy 1 and biopsy 6 from patient 1 and 2. B. Quantification of 
the unique amino acids detected by SGA and NGS are found for the same samples 
as in A.     
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Table 6.6: Identification of unique codons and amino acids by SGA and NGS 
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6.10 Discussion  
Limited information is available on the distribution of HCV quasispecies within 
the liver and between liver and plasma for patients with end-stage liver 
disease. Increasing our understanding of the spatial distribution of HCV 
genetic variants within infected tissue will help elucidate the factors controlling 
viral replication and dissemination routes. The goal of this study was to 
investigate the genetic compartmentalisation of HCV variants in the chronically 
infected liver and to compare these with the virus circulating in the periphery. 
Detection of the HCV quasispecies was performed with three different 
approaches: (i) bulk amplification followed by consensus Sanger sequencing; 
(ii) Single molecule amplification (SGA) followed by Sanger sequencing, and 
(iii) 454 next-generation pyro-sequencing (NGS).  
 
HCV bulk amplifications were made from each of the 8 hepatic sites from 6 
patients and the PCR products sequenced by consensus sequencing. The 
HCV consensus sequences contained relatively few polymorphisms across the 
E1, E2 (and p7) region and were comparable between sites of the same liver. 
This high level of similarity is considered a result of low sensitivity of the assay, 
since a spiking experiment with different concentrations of HCV RNA revealed 
that sequences present at low concentrations (below a ratio of 1:1) were not 
efficiently detected (Figure 6.5). This hypothesis would predict that consensus 
sequencing underestimates the HCV genetic variability for a sample and 
favours the detection of the dominating sequences. As a result any 
comparison of consensus sequences could create false inferences. Our 
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phylogenetic analyses of the SGA-derived HVR1 sequence also 
underestimated the HCV complexity of the samples, indicating that analyses of 
small regions should only be performed on large data sets, such as the data 
generated by NGS, which will have a greater level of sequence coverage. 
 
The SGA-derived HCV sequences from selected hepatic sites revealed that 
only 2 pairs of patient-specific sequences were 100% identical and that the 
remaining sequences in each patient differed with up to 105 substitutions. The 
high number of non-identical sequences from the same patient is consistent 
with previous sequencing studies on serum-derived HCV ORFs isolated from 
acutely infected HCV patients and chimpanzees (Yanagi et al., 1997; Yanagi 
et al., 1998). As predicted, the SGA-derived sequences from different sites 
had significantly more substitutions than the HCV consensus sequences 
generated from the 8 hepatic sections, strengthening our earlier conclusion 
that consensus sequencing underestimated the HCV complexity in the hepatic 
samples.  
 
The phylogenetic and Shannon entropy analyses revealed a high level of 
similarity between SGA-derived sequences independent of the hepatic site 
they had been isolated from and in most cases it was impossible to 
differentiate between the site-specific sequences in the patient-specific 
phylogenetic trees. Statistical analysis of the minimum migration events 
required to explain the distribution of HCV sequence within one liver (Slatkin-
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Maddison modelling) revealed no evidence of statistical compartmentalisation 
for five of six patients. Furthermore, the NGS data sets for patient 1 and 2 
showed limited evidence of compartmentalisation across all 8 investigated 
sites in the explanted liver. From these observations we conclude that intra-
hepatic HCV genetic compartmentalisation is limited during end-stage liver 
disease.  
 
The SGA-derived sequences isolated from the liver of patient 7, showed 
statistical evidence of compartmentalisation between biopsies 1 and 6. The 
non-random distribution of HCV variants between individual sites in the liver 
may be the result of high RIG-I and TLR activation (see Chapter 5), leading to 
higher turnover of infected hepatocytes than seen for the other patients. This 
would result in new naïve hepatocytes being generated, which in principle 
could be infected by genetically distinct HCV founder viruses and eventually 
the formation of genetic compartmentalisation (Heim, 2013b). An alternative 
explanations may be that the HCV variants isolated from the patient 7 liver 
have a higher fraction of cell-cell transmission compared to cell-free, leading to 
the formation of genetically distinct foci in the infected patient. This hypothesis 
is supported by previous reports of HCV antigen and RNA positive foci in the 
chronically infected liver (Kandathil et al., 2013; Liang et al., 2009; Wieland et 
al., 2013).  
 
 277 
In this study, all SGA-derived HCV sequences were subjected to Sanger 
sequencing, however it is possible that we only sampled HCV sequences that 
were significantly different between the sites in patient 7 liver or that only 
highly similar sequences were sampled from the livers of patient 1, 2, 4, 5 and 
9. This phenomenon is known as “re-sampling bias” and may result in false 
interpretation of the results. One of the major concerns when sequencing 
individual HCV clones is to ensure that enough variants are included in the 
analyses to support valid conclusions. Previous studies suggested that 99 
HVR1 clones were needed to identify 95% of all variants present at a 
frequency of at least 3% (McCaughan et al., 2003) and for HIV 
compartmentalisation studies at least 20 HIV envelope clones should be 
studied from each site (Zarate et al., 2007). These high numbers are not 
achieved for the SGA analyses of any of the studied patients and one may 
argue that more SGAs are required in our analyses. The NGS data for the 8 
hepatic samples collected from patient 1 and 2 confirms the limited detection 
of HCV compartmentalisation between hepatic sites and suggests that 
analysing at least 4 SGA-derived HCV envelope sequences from each hepatic 
specimen are enough to avoid “re-sampling bias” of samples collected during 
end-stage liver disease. The observation is further confirmed by SGA-derived 
sequences covering up to 89% of the polymorphisms detected by NGS. It 
should be noted that more sequences might be acquired from earlier HCV-
associated disease stages. Performing NGS for the samples collected from 
patient 7 would be required to confirm valid sequence representation among 
the SGA-derived sequences in this patient. 
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It should be mentioned that the statistical evidence for HCV genetic 
compartmentalisation found for hepatic SGA sequences isolated from patient 7 
may be a result of overestimation of the degree of segregation between 
branches by the statistical model. The Slatkin-Maddison model estimates the 
tree topology without bootstrapping and the compartmentalisation score may 
lead to an overestimation because short interior branches may have a higher 
(false) weight, which is achieved through a low (not accounted for) 
bootstrapping value (Zarate et al., 2007). Performing additional 
compartmentalisation analysis for the SGA-derived sequences, such as 
Mantel’s or Wright’s test would potentially lead to non-statistically significant 
results for the hepatic sequences isolated from patient 7. 
 
Investigating the internal genetic between SGA-derived plasma sequences, 
collected at the time of transplantation, revealed that the mean genetic 
distance did not statistically differ from the mean distance found between the 
liver- and plasma-derived sequences detected in the same patient. In addition, 
we did not find any statistical evidence of HCV genetic compartmentalisation 
between the two compartments by Slatkin-Maddison analysis. The observation 
was confirmed by NGS of the HVR1 amino acid sequences isolated from 
patient 1 and 2 and it is concluded that HCV genetic compartmentalisation 
between plasma and liver is limited during end-stage liver disease.  
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NGS provided in depth information about the HCV diversity and complexity 
within the samples collected from patient 1 and 2. Not surprisingly, the liver-
derived HVR1 sequences had higher diversity than the sequences isolated 
from the plasma and contained several unique minor sequences, which were 
not detected in the plasma specimens. Similar observation has previously 
been reported for patients with early chronic infection (Fan et al., 1999). This 
finding suggests that not all HCV sequences are released into the periphery. It 
is likely that these minor sequences either were not packed into virus particles 
or that the viral progeny were not released. Interestingly, the NGS data 
revealed that 2% of the HVR1 sequences detected in the plasma of patient 1 
were not found in the hepatic samples. Their low frequency implies that the 
sequences do not form a distinct viral population within the plasma, which is 
also confirmed by the lack of statistical evidence for HVR1 
compartmentalisation between plasma and liver. The observation of unique 
plasma-derived HVR1 sequences suggests that the 8 hepatic specimens do 
not cover all the HCV variants found in the periphery. It is possible that these 
plasma-derived minor sequences would be identified in the liver if NGS was 
applied to additional hepatic specimens, however the sequences would 
probably remain rare since the 8 investigated sections already showed 
identical dominant sequences. Alternatively, the unique plasma-derived HVR1 
sequences may have originated from HCV replication in extra-hepatic sites, 
such as the CNS (Maggi et al., 1999), PBMCs (Natarajan et al., 2010; Willems 
et al., 1994) or lymph nodes (Pal et al., 2006). All of these studies have used 
negative-strand qPCR to determine HCV replication; a technique that is 
considered to have low specificity and the prediction of active replication at 
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these sites is debateable. At the time of writing, there is no reliable evidence 
for or against extra-hepatic HCV replication in vivo and it is not possible to 
reject the theory that these NGS detected minor sequences in the plasma may 
have derived from HCV replication outside the liver. To determine whether the 
identified plasma-derived sequences were present in the liver, additional 
hepatic samples would be required and the NGS continued until all HVR1 
sequences in the plasma had been accounted for in the liver.  
 
In this study we found limited statistical evidence of genetic 
compartmentalisation between HCV sequences deriving from different sites in 
the liver and between liver and plasma, when using the SGA and NGS 
approaches. These observations contrast with Li et al. who previously reported 
that 78% of patients with chronic HCV infection had statistical evidence for 
HVR1 genetic compartmentalisation between liver and plasma (Li et al., 2010) 
and with Sobesky et al. who reported that the HCV core sequences formed 
distinct compartments between micro-dissected hepatic sections (Sobesky et 
al., 2007). The statistical analysis were in both studies performed by the 
Mantel’s test, which compares matrixes of genetic and phenotypic distances to 
determine whether sequences in one compartment are more similar with each 
other or with sequences in another compartments (Beerli et al., 2001). 
Difference in the statistical approach may explain our contradicting results. It is 
however considered more likely that either the different technical approach 
taken by Li et al. and the dissimilar disease stage of the collected samples in 
the Sobesky et al. study are the source of the discrepancy between our 
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observations. In the Li et al. study HVR1 bulk amplifications from each 
compartment were cloned and the HVR1 positive colonies were afterwards 
screened by heteroduplex gel mobility to identify unique HVR1 sequences. 
Only unique HVR1 sequences were included in the statistical analysis and the 
complexity of HVR1 minor and major sequences are not taken into 
consideration (Li et al., 2010). It should be mentioned that the same 
researchers found close to identical HVR1 sequence complexity, when 
performing the heteroduplex gel mobility assay for 10 hepatic specimens 
sampled from two explanted livers (Li et al., 2010). Although a conclusion on 
intra-hepatic HCV compartmentalisation cannot be made from that analysis, it 
is notable that Li et al. reported high HVR1 variability between hepatic and 
plasma sequences and low HVR1 variability between hepatic specimens from 
patient’s with end-stage liver disease. In contrast, our cohort showed 
comparable HCV diversity and complexity between all investigated 
compartments. The differences observed between ours and the Sobesky et al. 
intra-hepatic compartmentalisation study may be the result of our samples 
being collected from patients with end-stage liver disease whereas the 
patient’s in the Sobesky’s study had earlier stages of liver disease, which 
required hepatoctomy and not liver transplantation (Sobesky et al., 2007). To 
the best of our knowledge no other studies have reported statistical evidence 
for or against HCV genetic compartmentalisation. Instead several studies have 
reported that identical dominant and sub-dominant HCV variants were found 
between plasma- and liver-derived HCV clones (Cabot et al., 2000; Ramirez et 
al., 2009; Sakai et al., 1999) and between multiple hepatic sites (Cabot et al., 
1997). In the Cabot et al. study researchers reported that HCV does not form 
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large-scale intra-hepatic compartmentalisation based on the detection of 
identical dominant and sub-dominant 5’UTR and E2-NS2 junction sequences, 
despite each sample containing multiple unique minor sequences (Cabot et al., 
1997). Since these researchers did not account for the minor sequences their 
conclusion disputes the fundamental concept behind quasispecies modelling; 
“A quasispecies population acts as a whole unit rather than an individual 
sequence acting in isolation” (Holmes, 2010a). According to this concept, 
conclusions on population distribution should be based on the whole unit of 
HCV sequences and not on individual clones. 
 
The SGA and NGS data sets revealed that most substitutions were found in 
the E2 region, followed by E1. The identification of a high substitution rate in 
E2 is not surprising, since this region is believed to contain multiple nAb 
epitopes, leading to a positive selection (Fournillier et al., 2001; Helle et al., 
2011; Law et al., 2008; Logvinoff et al., 2004; Tarr et al., 2011). However, 
when investigating the translated sequences we found higher fractions of 
synonymous (ds) than non-synonymous changes (dn) for most of the 
investigated regions, except within the HVR1 region (ds/dn < 1). The high 
number of ds changes outside the HVR1 supports a model of high turnover of 
viral variants with deleterious dn changes, leading to an excess of ds 
mutations that do not have an effect on the phenotype (Wang et al., 2007b). It 
is concluded that the overall selective pressure across the envelope genes are 
limited to the HVR1 during end-stage stage liver disease. The identification of 
ds/dn ratios below 1 in HVR1 may be driven by selective pressure from nAbs 
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targeting this region (Booth et al., 1998; Kato et al., 1994; von Hahn et al., 
2007) and/or from variability in the SR-BI affinity (Bankwitz et al., 2010). The 
exact source of the selective pressure on the HVR1 evolutionary path in this 
cohort is unknown.  
 
The main focus of this study was to investigate the HCV genetic distribution 
during end-stage liver disease. A potential next step would be to biologically 
characterise the clones generated by SGA. Although analysis of the clone’s 
phenotypes has not yet been done, the examination of essential N-linked 
glycosylation sites can reveal important information about the potential 
phenotype (Bungyoku et al., 2009; Helle et al., 2007; Helle et al., 2010; Wei et 
al., 2003). Investigation of the SGA sequences revealed that HCV variants 
isolated from patient 4 had polymorphic changes in E2N6 and E2N8, resulting 
in loss of the N-linked glycosylation. These variants are likely to have less 
stable E1E2 heterodimerization, leading to defective viral assembly (Helle et 
al., 2010) and a higher sensitivity to neutralisation by antibodies targeting the 
CD81 binding site, but potentially also a stronger interaction with CD81 since 
glycans is no longer shielding the binding site (Bungyoku et al., 2009). The 
SGA-derived HCV sequences isolated from patient 4 also contained 
polymorphisms in E2N5 and the P7-B1.F2-D11 had a substitution in E2N9, 
however, these sites do not appear essential for a specific phenotype (Helle et 
al., 2007; Helle et al., 2010). These postulated biological characterisations are 
at this point only speculations, empirical testing is required to confirm the 
phenotypes. All SGA sequences are cloned into the pcDNA3.1D expression 
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vector for producing infectious virus particles in the HCVpp system, but due to 
limited time these experiments are still to be performed. In the future we also 
hope to have SGAs isolated from the same patients following transplantation 
in order to characterise potential bottleneck effects during the liver-graft re-
infection, as previously reported by Fafi-Kramer et al. (Fafi-Kremer et al., 
2010) and identification of potential patient-derived ITX5061 escape variants 
(Zhu et al., 2012). 
 
In conclusion, we found that HCV sequences isolated from different sites in the 
liver and plasma are highly comparable and found limited evidence for genetic 
compartmentalisation between different sampling sites collected from patients 
with end-stage liver disease. Identification of nearly identical HCV variants 
across the liver and between plasma and liver may have an impact on the 
choice of DAA treatment for patient with end-stage liver disease. 
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7 GENERAL DISCUSSION 
 
The main site of HCV replication is hepatocytes in the liver. From here 
thousands of virus particles are produced and released. During the replication 
process the error-prone viral encoded RNA-dependent polymerase (NS5B) 
make mistakes, especially in the E1 and E2 envelope encoding genes, and 
the end-result is a 2nd generation of virus variants with these mutational 
changes expressed in the envelope proteins. Several studies have shown that 
patient-derived HCV ORFs encoding variable E1 and E2 amino acid 
sequences escapes the immune response (Keck et al., 2009; von Hahn et al., 
2007) and anti-viral treatments (Catanese et al., 2013; Wu et al., 2013). They 
may also show different dependencies on the four viral entry factors (Grove et 
al., 2008; Prentoe et al., 2013), explaining why some HCV variants are more 
successful in infect new hosts (Brown et al., 2012; Bull et al., 2011; Wang et 
al., 2010) and re-infect the new liver graft (Fafi-Kremer et al., 2010). The 
observations of variable phenotypes among the patient-derived HCV particles 
could hypothetically be expanded to virus variants having diverse abilities to 
spread via a cell-free or cell-cell route, resulting in some variants being 
restricted to neighbouring cells and others released to the periphery. Recent in 
vivo data have found HCV antigen and/or RNA positive foci, surrounded by 
naïve hepatocytes in needle biopsies from HCV chronically infected patients 
(Kandathil et al., 2013; Liang et al., 2009; Stiffler et al., 2009; Wieland et al., 
2013), supporting a model of cell-cell spread. These observations suggest that 
the HCV genetic pool at these foci may vary due to independent evolution at 
particular sites.  
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In this study we investigate the HCV quasispecies distribution within different 
sites of the liver and between plasma and liver for patients with end-stage liver 
disease and at the same time investigated host factors that may determine the 
HCV population dynamics. Comparing the viral load and the HCV 
quasispeceis sequences between different sites in the liver indicated an equal 
distribution of HCV RNA copies and a low genetic distance between the HCV 
sequences for all patients. This observation may be the result of having 
sampled 8 sites with comparable viral burdens and genetic complexities (re-
sampling bias) and so sampling other sites potentially would have shown 
higher variability. This hypothesis is considered unlikely due to the high 
number of study subjects and the high number of hepatic sites sampled for 
each liver. In addition, the heat-denaturation of two biopsies from patients 1 
and 5 implied no differences in the negative : positive HCV RNA strand ratios, 
which makes it unlikely that the virus would have replication hotspots with high 
content of detectable positive strands and independent viral evolution. The 
observation of highly comparable viral burden and HCV complexity between 
patient-specific specimens could, furthermore, be the result of having detected 
plasma- and not hepatocyte-derived sequences from the liver specimens. 
However, the finding of limited correlation between liver and plasma HCV RNA 
and the identification of unique plasma- and liver-derived sequences by NGS 
makes it unlikely that this would be the case. Instead, the result obtained in 
this study suggests that the observed HCV distribution is real and that 




Similar viral burden and HCV sequence complexity across the liver suggests 
that the liver is exposed to comparable degrees of immune stimulation, leading 
to a uniform selective pressure on viral replication and HCV sequence 
evolution. Measuring the expression level of the 4-gene classifiers across the 
livers of 23 patients demonstrated that most patients had comparable ISG 
expressions. This even distribution of ISG may associate with the observed 
hepatic viral burden and sequence dynamics. In this model the uniform 
distribution of HCV RNA would lead to a concurrent stimulation of the innate 
and adaptive immune response, resulting in comparable ISG expression levels 
across the liver. The uniform immune activation may form comparable 
selective pressure on the HCV variants leading to genetically similar HCV 
sequences across the liver. Although we did not observe any correlation 
between hepatic viral load and ISG expression, the even expression of ISG 
may be stimulated by the mere presence of the virus and not its quantity. This 
posed model offers an attractive explanation to some of the ex vivo results 
obtain in this PhD study, however due to the complexity of the scenario it 
would be impossible to test the hypothesis in vitro. An alternative option would 
be to investigate the association between HCV viral burden, innate immune 
response and HCV sequence complexity in the humanized urokinase-type 
plasminogen activator severe combined immunedeficienct (uPA-SCID) mouse 
with transplanted human hepatocytes, however this model would only provide 
information about the type I and III ISGs since the mouse model does not have 
an adaptive immune system (Billerbeck et al., 2013; Bukh, 2012).  
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It is important to note that the data presented in this thesis were generated 
from livers with end-stage liver disease and many of these subjects may have 
been infected for up to 40 years. The HCV quasispecies dynamics in the liver 
and plasma may differ considerably during earlier stages of infection as a 
result of a more vigorous immune response or a higher hepatocyte turnover. 
This may explain the different observations made in our study and the studies 
reported by others (Kandathil et al., 2013; Li et al., 2010; Liang et al., 2009; 
Sobesky et al., 2007; Wieland et al., 2013). 
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8 CONCLUDING REMARKS 
 
This study is the first to investigate the distribution of HCV at multiple sites 
during end-stage liver disease. The genetic and viral load data indicate that 
infectious HCV variants do not target specific sites in the liver, but that the liver 
is uniformly infected during end stage-liver disease.  
 
The viral load between the plasma and liver show limited correlation, 
suggesting that the plasma is a poor predictor of the hepatic viral burden. 
Detection of higher HCV sequence complexity in the liver compared to the 
plasma, suggests that not all liver residential HCV sequences are released to 
the periphery. This observation may be clinically important when monitoring 
viral infections or assessing viral respond to treatments.  
 
Furthermore, we conclude that the expression pattern of the 4-gene classifiers 
is comparable across the liver, however independent of the viral load in both 
the liver and the plasma. It is likely that the expression levels of ISG are not 
initiated in a dose-responsive manner to viral replication or the frequency of 
infected cells. In addition we found that the expression level of IFI27, but not 
ISG15, RSAD2 or HTATIP2 are unique to adults with HCV-related end-stage 
liver disease. 
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Investigating the dynamics of the HCV quasispecies are important in order to 
understand how the virus can persist despite the presence of a vigorous anti-
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10.1 Appendix 1 
SGA-derived sequence alignments for patient 1, 2, 4, 5, 7 and 9. The position of E1, E2 and p7 differs between patients and is 
stated above each sequence alignment.  
 
10.1.1 Patient 1 
Gene position: E1: 1 - 576nt, E2: 577 - 1683nt, p7: 1683-1872nt , HVR1: 577 – 657nt, HVR494: 913 - 933nt, HVR595: 1153 - 
1179nt. 
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P1-B6.D6-G10       ....................................................................................................  
P1-B6.D7-D12       ....................................................................................................  
P1-B6.H3-1.6       ........................................................................A...........................  
P1-Plas.A5-G2      .....................................................................A..............................  
P1-Plas.F6-E3      ...T.........................A......................................................................  
P1-Plas.B10-F2     ....................................................................................................  
P1-Plas.D11-A11    ....................................................................................................  
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P1-Plas.1/4-1-B1   ...........................A........................................................................  
P1-Plas.1/4-3-F3   ...T.........................A......................................................................  
P1-Plas.1/4-4-A5   ....................................................................................................  
P1-Plas.1/4-6-E8   ...T.........................A......................................................................  
P1-Plas.1/8-1-12B  ....................................................................................................  
 
                           1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P1-BCC        TCGACAGGTCTAATACACCTCCACCAAAACATCGTGGATGTCCAATACCTTTATGGTGTTGGATCYGGCATGGTGGGATGGGTGTTGAAATGGGAGTTTG  
P1-B1.B2-F7        ....................................................................................................  
P1-B1.C2.1-B7      ....................................................................................................  
P1-B1.C2.2-D1      ....................................................................................................  
P1-B1.B4-H2        ....................................................................................................  
P1-B6.B6-F4        ....................................................................................................  
P1-B6.D6-G10       ....................................................................................................  
P1-B6.D7-D12       ....................................................................................................  
P1-B6.H3-1.6       ....................................................................................................  
P1-Plas.A5-G2      ....................................................................................................  
P1-Plas.F6-E3      .....................................................C.....C........................................  
P1-Plas.B10-F2     ....................................................................................................  
P1-Plas.D11-A11    ....................................................................................................  
P1-Plas.1/4-1-B1   ..................................................................................................C.  
P1-Plas.1/4-3-F3   ..................................................................................C.................  
P1-Plas.1/4-4-A5   ..........................................................................A.........................  
P1-Plas.1/4-6-E8   ....................A................................................G..............................  
P1-Plas.1/8-1-12B  ................................A...................................................................  
 
 
                           1610      1620      1630      1640      1650      1660      1670      1680      1690      1700         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P1-BCC        TTATCCTCGTTTTTCTCCTCCTAGCAGACGCACGCGTGTGCGTTGCCCTTTGGCTAATGCTGATGATATCACAAGCAGAAGCAGCCTTGGAGAACCTTGT  
P1-B1.B2-F7        .............C......................................................................................  
P1-B1.C2.1-B7      ...............................G....................................................................  
P1-B1.C2.2-D1      .............C......................................................................................  
P1-B1.B4-H2        ....................................................................................................  
P1-B6.B6-F4        ....................................................................................................  
P1-B6.D6-G10       ....................................................................................................  
P1-B6.D7-D12       ..................................................................................G.................  
P1-B6.H3-1.6       ....................................................................................................  
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P1-Plas.A5-G2      ....................................................................................................  
P1-Plas.F6-E3      ....................................................................................................  
P1-Plas.B10-F2     ....................................................................................................  
P1-Plas.D11-A11    ....................................................................................................  
P1-Plas.1/4-1-B1   .............C.............................C........................................................  
P1-Plas.1/4-3-F3   ....................................................................................................  
P1-Plas.1/4-4-A5   .C............................................T.....................................................  
P1-Plas.1/4-6-E8   ....................................................................................................  
P1-Plas.1/8-1-12B  ....................................................................................................  
 
                           1710      1720      1730      1740      1750      1760      1770      1780      1790      1800         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P1-BCC        CACGCTGAAYGCCRTCGCTGCTGCCGGGACACATGGTATCGGCTGGTACCTGGTAGCCTTTTGCGCGGCGTGGCACGTGCGGGGTAAACTTATCCCGCTG  
P1-B1.B2-F7        ....................................................................................................  
P1-B1.C2.1-B7      ....................................................................................................  
P1-B1.C2.2-D1      ...................A................................................................................  
P1-B1.B4-H2        ....................................................................................................  
P1-B6.B6-F4        .......................................T............................................................  
P1-B6.D6-G10       .........................................................T........A.................................  
P1-B6.D7-D12       ....................................................................................C...............  
P1-B6.H3-1.6       ....................................................................................................  
P1-Plas.A5-G2      ....................................................................................................  
P1-Plas.F6-E3      ..............................G.....................................................................  
P1-Plas.B10-F2     ..T....................................................................................G............  
P1-Plas.D11-A11    ....................................................................................................  
P1-Plas.1/4-1-B1   .....................................................................A..............................  
P1-Plas.1/4-3-F3   ....................................................................................................  
P1-Plas.1/4-4-A5   ............T...............................................C.......................................  
P1-Plas.1/4-6-E8   ...............................T....................................................................  
P1-Plas.1/8-1-12B  ..T.................................................................................................  
 
                           1810      1820      1830      1840      1850      1860      1870      
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
P1-BCC        GTGACCTACAGCCTGACAGGYCTTTGGTCCCTAGCATTGCTCGTCCTCTTGCTCCCCCAACGGGCGTATGCT  
P1-B1.B2-F7        ........................................................................  
P1-B1.C2.1-B7      ..............A.........................................................  
P1-B1.C2.2-D1      ........................................................................  
P1-B1.B4-H2        ..............................T.........................................  
P1-B6.B6-F4        ........................................................................  
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P1-B6.D6-G10       ........................................................................  
P1-B6.D7-D12       ........................................................................  
P1-B6.H3-1.6       .....................................................A..................  
P1-Plas.A5-G2      ............T...........................................................  
P1-Plas.F6-E3      ........................................................................  
P1-Plas.B10-F2     ........................................................................  
P1-Plas.D11-A11    ........................................................................  
P1-Plas.1/4-1-B1   ........................................................................  
P1-Plas.1/4-3-F3   ........................................................................  
P1-Plas.1/4-4-A5   .................G................T.....................................  
P1-Plas.1/4-6-E8   .................................................................A......  
P1-Plas.1/8-1-12B  ........................................................................  
 
 
10.1.2 Patient 2 
Gene position: E1: 1 - 576nt, E2: 577 - 1665nt, HVR1: 577 – 657nt. 
                10        20        30        40        50        60        70        80        90        100                   
 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC           TACCAAGTGCGCAAYTCCACGGGGCTTTACCATGTCACCAAYGATTGCCCTAACTCGAGTATTGTGTACGAGACAGCTGATGCCATCCTACACRCTCCGG  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ........A...........................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ..................................................C.................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ....................................................................................................  
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P2-B6.H10-F12   ......................................T.....C.......................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ................................C...................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ........A...........................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
       110       120       130       140       150      160       170       180        190       200           
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          GGTGTGTCCCYTGCGTTCGCGAGGGTAACGTCTCGAGGTGTTGGGTGGCGATGACCCCCACGGTGGCCACTAGGGAYGGCARACTCCCYGCRACGGAGCT  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    .........................C............................................C.............................  
P2-B1.G5-F11    ..................................................C.................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ........................................C...........................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ................G...................................................................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ........................................................................................G..........C  
P2-B6.C10-C7    ...............................................................................T....................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ..........................................................T.........................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  .....................................A..............................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  




       210      220        230      240        250      260       270       280       290        300   
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          TCGACGTCACATCGATCTGCTTGTCGGGAGYGCCACCCTYTGCTCGGCCCTCTACGTGGGGGACTTGTGCGGGTCTGTCTTYCTTGTCGGTCAGCTGTTT  
P2-B1.G4-B2     ...................................................................................................C  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     .........T..........................................................................................  
P2-B1.E2-C8     ...................................................................................................C  
P2-B1.F6-H8     .....................................................................................A..............  
P2-B1.A9-G1     ...................................................................................................C  
P2-B1.H7-C12    ..........................................T.........................................C.........T....C  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   .............................................A......................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ...................................................................................................C  
P2-Plas.B5-B11  ...................................................................................................C  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ...................................................................................................C  
P2-Plas.G11-D6  ...................................................................................................C  
                              
            310       320       330      340       350        360       370       380      390        400          
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC         ACCTTCTCTCCCAGGCGCCACTGGACGACGCAAGACTGCAACTGTTCYATCTATCCCGGCCACATAACKGGTCATCGCATGGCATGGGATATGATGATGA  
P2-B1.G4-B2     .......................................................................C............................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     .........................................T..........................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
 339 
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ...........................G........................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
                       410       420       430       440       450       460       470       480      490  500  
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          ACTGGTCCCCTACGACGGCATTGGTAGTAGCTCAGCTGCTCCGGRTCCCACAAGCCATCTTGGATATGATCGCTGGTGCTCACTGGGGSGTCCTAGCGGG  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ..........C.............................................................................A...........  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ................A...................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ..........................................................T.............................A...........  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ................T...................................................................................  
P2-B1.F8-F5     .........................G..........................................................................  
P2-B1.F7-F5     .........................G..........................................................................  
P2-B6.H10-F12   ...................G...............T....................................................T...........  
P2-B6.C10-C7    ...........................................................................................T........  
P2-B6.E6-G11    ............................G.......................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ...................G................................................................................  
P2-Plas.D12-E3  ..........C.........................................................G...............................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ...........................................................C..................................G.....  
P2-Plas.G11-D6  ....................................................................................................  
 
 340 
                        510       520       530       540       550       560      570       580       590        600          
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BBC          CATAGCGTATTTCTCCATGGTGGGAAACTGGGCGAAGGTCCTRGTRGTGCTGCTGCTATTTGCCGGCGTTGACGCGMASACCCACGTCACCGGGGGATCT  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     .............................................................T......................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    .......................................A............................................................  
P2-B1.H3-F11    ...................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ......................................................A.............................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ...........................T................C.......................................................  
P2-Plas.C2-C11  ............................................................C.......................................  
P2-Plas.G11-D6  ......A.............................................................................................  
 
                        610       620       630       640      650        660      670       680       690        700          
 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC     GCCGCTCRCRMCGYGTGGGGAYTCACSARYYTCYTTRCACYGGGCSCCARGCAGAAYATCCAGCTGRTCAACTCYAAYGGCAGTTGGCACATCAATAGGA  
P2-B1.G4-B2     ................T.......CG................A.........................................................  
P2-B1.A12-A5    .....G..........TT.......G....A.........G...........................................................  
P2-B1.G5-F11    ................T.......CG.................................A........................................  
P2-B1.D8-B4     ................T.......CG..........................................................................  
P2-B1.E2-C8     ................T.......CG..........................................................................  
P2-B1.F6-H8     ................T.......CG..........................................................................  
P2-B1.A9-G1     ................T.......CG..........................................................................  
P2-B1.H7-C12    ................T.......CG..........................................................................  
P2-B1.H3-F11    ................T.......CG..........................................................................  
P2-B1.F8-F5     ................T.......CG...............A..........................................................  
 341 
P2-B1.F7-F5     ................T.......CG.................................T........................................  
P2-B6.H10-F12   ............................................................................................T.......  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ................T.......CG..........................................................................  
P2-B6.H4-D11    ................T.......CG..........................................................................  
P2-Plas.B5-B11  ................T.......CG..........................................................................  
P2-Plas.G6-C8   ................T.......CG..........................................................................  
P2-Plas.A11-D2  ................C.......G....G.......T..G.........C................................C...........C....  
P2-Plas.D12-E3  ................T.......CG..........................................................................  
P2-Plas.G10-D3  ................T.......CG..........................................................................  
P2-Plas.C2-C11  ................T.......CG..........................................T...............................  
P2-Plas.G11-D6  ..........G.....T.......CG..........................................................................  
 
                         710       720       730       740       750      760       770       780       790        800          
                 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC           CGGCCCTGAACTGYAACGACAGCCTSAACACCGGCTGGATAGCAGGGCTTCTCTACTACARCAAATTCAACTCTTCAGGCTGTCCCGAGAGAATGGCCAG  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ..................................................A............G....................................  
P2-B6.H10-F12   ..........T.........................................................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ...............................T....................................................................  
P2-Plas.B5-B11  .......................................................T..............T.............................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....T................................................................................T..............  
P2-Plas.D12-E3  .................................................C.............G....................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ................T...................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
 342 
                        810      820        830      840       850       860       870       880       890        900          
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          CTGTCGACCYCTTACCGATTTTGCTCAGGGCTCGGGCCCYATCAGGTACACCAACGGAAGCGGCCCCGACCATCGCCCCTACTGCTGGCACTACCCCCCA  
P2-B1.G4-B2     .............G......................................................................................  
P2-B1.A12-A5    .............G........................................T.....T......A................................  
P2-B1.G5-F11    .............G..................................................................................A...  
P2-B1.D8-B4     .............G...............................................................................T......  
P2-B1.E2-C8     .............G......................................................................................  
P2-B1.F6-H8     .............G......................................................................................  
P2-B1.A9-G1     ...C.........G......................................................................................  
P2-B1.H7-C12    .............G................................................................A.....................  
P2-B1.H3-F11    .............G......................................................................................  
P2-B1.F8-F5     .............G......................................................................................  
P2-B1.F7-F5     .............G......................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    .............G......................................................................................  
P2-B6.H4-D11    .............G......................................................................................  
P2-Plas.B5-B11  .............G......................................................................................  
P2-Plas.G6-C8   .............G......................................................................................  
P2-Plas.A11-D2  .............G..........C...........................................................................  
P2-Plas.D12-E3  .............G......................................................................................  
P2-Plas.G10-D3  ............CG....................................................A.................................  
P2-Plas.C2-C11  .............G......................................................................................  
P2-Plas.G11-D6  .............G....................................................T.................................  
 
                        910      920       930        940      950        960      970       980       990       1000         
   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC     AAACCTTGTGGTATTGTGCCCGCACAGAGCGTYTGTGGCCCGGTATATTGTTTCACTCCCAGTCCTGTAGCGGTGGGAACGACCGACAGGTCGGGCGTSC  
P2-B1.G4-B2     ........................................................C...........................................  
P2-B1.A12-A5    ..G.........................................G.......................................................  
P2-B1.G5-F11    ...............................................C........C...........................................  
P2-B1.D8-B4     ..................................................C.....C........C..................................  
P2-B1.E2-C8     ........................................................C...........................................  
P2-B1.F6-H8     ........................................................C...........G...............................  
P2-B1.A9-G1     ........................................................C...........................................  
P2-B1.H7-C12    ........................................................C...........................................  
P2-B1.H3-F11    ........................................................C.............................T...........T.  
P2-B1.F8-F5     ........................................................C...........................................  
 343 
P2-B1.F7-F5     ..................T...................T.................C...........................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    .................................................................................................C..  
P2-B6.E6-G11    ........................................................C...........................................  
P2-B6.H4-D11    ........................................................C...........................................  
P2-Plas.B5-B11  ........................................................C...........................................  
P2-Plas.G6-C8   ........................................................C...........................................  
P2-Plas.A11-D2  ............................................G.......................................................  
P2-Plas.D12-E3  ........................................................C...........................................  
P2-Plas.G10-D3  ........................................................C...........................................  
P2-Plas.C2-C11  ...................................C....................C...........................................  
P2-Plas.G11-D6  ........................................................C.........................................T.  
 
1010      1020     1030       1040      1050      1060      1070      1080     1090       1100                                 
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          CTACCTACAACTGGGGYGCGAAYGATACGGACGTYTTYGTCCTTAACAACACCAGGCCACCGCTYGGCAATTGGTTCGGCTGCACCTGGATGAACTCRAC  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ..............................................................................................T.....  
P2-B1.F6-H8     .....................................................................................T..............  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    ....................................................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ..............................................T.....................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  .................................................T..................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
 344 
                       1110      1120      1130      1140     1150      1160      1170      1180      1190       1200         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          TGGATATACCAAAGTGTGCGGAGCGCCCCCTTGTARCATCGGAGGGGTGGGCAACAACACYYTGCAYTGCCCCACTGATTGCTTCCGCAAGCATCCGGAA  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ...................................................................................................G  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ...................................................T................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     .........................................................T..........................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................G...............................................  
P2-B6.C10-C7    .......................................................................................T............  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
                       1210      1220      1230      1240      1250      1260      1270      1280     1290       1300         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          GCCACATACTCTCGGTGCGGCTCCGGTCCCTGGATTACACCCAGGTGCCTGGTYRACTACCCCTATAGACTTTGGCATTATCCTTGTACYGTCAACTACW  
P2-B1.G4-B2     ...........C........................................................................................  
P2-B1.A12-A5    .................T..................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ...................................C................................................................  
P2-B1.H3-F11    ........................................................T...........................................  
P2-B1.F8-F5     ............A.......................................................................................  
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P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    .............................T......................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ..................................................................................................T.  
P2-Plas.B5-B11  ..................................................T.................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ..........................C.........................................................................  
P2-Plas.D12-E3  .................................................................C..................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
                       1310      1320     1330      1340      1350      1360      1370      1380      1390       1400         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC         CCATATTCAAGGTCAGGATGTAYGTGGGRGGGGTCGAGCACAGGCTGGAAGCTGCCTGCAACTGGACRCGAGGCGAGCGCTGCGATYTGGAAGACAGGGA  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ..................................G.................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ..................................................................................T..C..............  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    .......T.........................................C............................................T.....  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  ....................................................................................................  
P2-Plas.D12-E3  ....................................................................................................  
P2-Plas.G10-D3  ...............................................................................T....................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
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                       1410      1420     1430       1440     1450      1460      1470      1480      1490       1500         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          CAGGTCCGAGCTCAGCCCGCTGCTGCTGTCCACCACRCAGTGGCAGGTCCTTCCGTGTTCATTCACGACCCTTCCGGCCTTRTCCACCGGCCTCATCCAC  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ...................T................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ....................................................................................................  
P2-B1.E2-C8     ....................................................................................................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ....................................................................................................  
P2-B1.F7-F5     ....................................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    .................................T..................................................................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ....................................................................................................  
P2-Plas.G6-C8   ....................................................................................T...............  
P2-Plas.A11-D2  ......T.............................................................................................  
P2-Plas.D12-E3  ...............................................................T....................................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
                       1510      1520     1530      1540      1550      1560      1570      1580      1590       1600         
                ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          CTCCAYCAGAACATTGTGGACGTGCAGTACTTGTACGGAGTGGGGTCAAGCATTGCGTCCTGGGCCATCAAGTGGGAATACGTYGTTCTCCTGTTCCTTC  
P2-B1.G4-B2     ....................................................................................................  
P2-B1.A12-A5    ....................................................................................................  
P2-B1.G5-F11    ....................................................................................................  
P2-B1.D8-B4     ......................................G.............................................................  
P2-B1.E2-C8     ................................................................................T...................  
P2-B1.F6-H8     ....................................................................................................  
P2-B1.A9-G1     ....................................................................................................  
P2-B1.H7-C12    ....................................................................................................  
P2-B1.H3-F11    ....................................................................................................  
P2-B1.F8-F5     ...................................................................................................  
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P2-B1.F7-F5     ..............C.....................................................................................  
P2-B6.H10-F12   ....................................................................................................  
P2-B6.C10-C7    ......................................................................G.............................  
P2-B6.E6-G11    ....................................................................................................  
P2-B6.H4-D11    ....................................................................................................  
P2-Plas.B5-B11  ...........................................................A........................................  
P2-Plas.G6-C8   ....................................................................................................  
P2-Plas.A11-D2  .............................................................................G......................  
P2-Plas.D12-E3  ....................................................................T...............................  
P2-Plas.G10-D3  ....................................................................................................  
P2-Plas.C2-C11  ....................................................................................................  
P2-Plas.G11-D6  ....................................................................................................  
 
                          1610        1620       1630       1640       1650        1660           
                ...|....|....|....|....|....|....|....|....|....|....|....|....| 
P2-BCC          TGCTTGCGGACGCGCGCGTCTGCTCYTGCTTGTGGATGATGTTACTCATATCCCAAGCGGAGGCG  
P2-B1.G4-B2     .................................................................  
P2-B1.A12-A5    .................................................................  
P2-B1.G5-F11    .................................................................  
P2-B1.D8-B4     .................................................................  
P2-B1.E2-C8     .................................................................  
P2-B1.F6-H8     ....C..................................................-.........  
P2-B1.A9-G1     ..............................................-..................  
P2-B1.H7-C12    .................................................................  
P2-B1.H3-F11    .................................................................  
P2-B1.F8-F5     .................................................................  
P2-B1.F7-F5     .......A.........................................................  
P2-B6.H10-F12   ..........................C......................................  
P2-B6.C10-C7    .............................C...................................  
P2-B6.E6-G11    .................................................................  
P2-B6.H4-D11    .................................................................  
P2-Plas.B5-B11  .................................................................  
P2-Plas.G6-C8   .................................................................  
P2-Plas.A11-D2  .................................................................  
P2-Plas.D12-E3  ....C............................................................  
P2-Plas.G10-D3  .................................................................  
P2-Plas.C2-C11  .................................................................  
P2-Plas.G11-D6  .................................................................  
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10.1.3 Patient 4 
Gene position: E1: 1 - 576nt, E2: 577 - 1692nt, p7: 1689-1878nt, HVR1: 577 – 657nt, HVR494: 913 - 933nt, HVR595: 1156 - 
1182nt. 
 
                            10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CTAGAGTGGCGGAATGTGTCTGGTCTTTATGTCCTTACTAACGACTGTTCCAATAGCAGTATTGTGTATGAGGCCGATGACGTYATTCTGCACTCACCTG  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        .....................................................C..............................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ..................................................................................................C.  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    .............................................................................C......................  
 
                           110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        GTTGTGTACCTTGTGTTCAGGACGGCAATACATCCACGTGCTGGACCTCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCACYGCTTCGAT  
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P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       .........................................................................A..........................  
P4-B1.C2-B7        ....C...............................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       .....................................................................................G..............  
P4-B7.F3-E3        ................C...................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ................C...................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ..............................................................................................C.....  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ................C...................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        ACGTAGTCATGTGGACCTATTAGTGGGCGCGGCCACGCTGTGTTCGGCGCTCTACGTGGGTGATATGTGTGGGGCCGTCTTCCTTGTAGGACAAGCCTTC  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ..................G.................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
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P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ................T...................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        ACGTTCAGACCCCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCACTGTACCCAGGCCACCTCACAGGACATCGAATGGCTTGGGACATGATGATGA  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        .............................................................................G......................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      .......................G............................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC          ATTGGTCCCCCGCTGTYGGCATGGTAGTGGCGCATGTCCTGCGTCTACCCCAGACCTTGTTCGACATAATAGCTGGAGCTCATTGGGGCGTCCTGGCGGG  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
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P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CCTAGCCTATTATTCCATGCAGGGTAACTGGGCCAAGGTTGCTATTGTCATGGTCATGTTTTCAGGAGTCGATGCCRMTACACRCGTCAYCGGTGSCACC  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        .................................................T..................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ..................................................................T.................................  
P4-B1.F5-D2        ..............................................................................C.....................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ..................................................................T.................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
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                           610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC       GCAGCTYATARTGTCAWGACCWTMGCTGGGYTTTTCACTTTAGGCCCCMAGCAGAAATTACAGCTAATCAACACCAATGGCTCGTGGCACATCAATAGGA  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        .................................C......................T...........................................  
P4-B1.C4-G11       .............C......................................................................................  
P4-B1.C2-B7        .....................C..............................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ................G................C......................C...........................................  
P4-B3.E9-B2        .............C......................................................................................  
P4-B3.E11-C3       .........G..........................................................................................  
P4-B7.F3-E3        .......T.................................................A..........................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        .........G..........................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................T...............................................................................  
P4-Plas.G12-A9     .......T......T..........................................A..........................................  
P4-Plas.C3-F3      .....................C..................................T...........................................  
P4-Plas.G7-C8      .................................C......................T...........................................  
P4-Plas.D7-E2      ..G.................................................................................................  
P4-Plas.E6-G5      ..................T..C..............................................................................  
P4-Plas.H8-H10     .......T.................................................A..........................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CTGCCCTGAACTGCAATGATTCCTTAAACACCGGGTTTATAGCAGGGTTGWTKYAYTTCCACAGGTTCAACTCTACTGGGTGTCCTCAAAGGCTCAGTAG  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ..................................................C.................................................  
P4-B1.C4-G11       ...............................................................A....................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ..................................................C.................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ...............................................................A....................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ...........................................G........................................................  
P4-B7.G7-E3        ...............................................................A....................................  
P4-B7.H3-C12       ....................................................................................................  
 353 
P4-B7.B6-C8        ...........................................G........................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ................................................................A...................................  
P4-Plas.G7-C8      ..................................................C.................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    .......A............................................................................................  
 
                           810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CTGCAAGCCCATCACTTCCTTTGATCAGGGGTGGGGTCACTTGACAGATGCTAACGTCAMTRACACCTCTGACGACAGACCGTACTGCTGGCACTACGCA  
P4-B1.B11-A4       ...T................................................................................................  
P4-B1.C2-A6        ........................................................................T...........................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ...................................A................................................................  
P4-B1.E8-G2        ........................................................................T...........................  
P4-B3.E9-B2        ..................................................T.................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        .............................................G......................................................  
P4-B7.F9-H6        ...............C....................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     .............................................G......................................................  
P4-Plas.C3-F3      ........................................................................T...........................  
P4-Plas.G7-C8      ........................................................................T...........................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     .............................................G......................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           910       920       930       940       950       960       970       980       990       1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC           CCCAAACCCTGTCRCACTGTCCCGGCGTCGAGTGTCTGCGGCCCCGTGTACTGTTTCACACCATCACCAGTGGTCGTAGGCACCACCGATGCTAAGGGTG  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
 354 
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       .........................................................................................C..........  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     .............T......................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CTCCAACCTACWCTTGGGGTGMGAATGAGTCGGACGTGTTCCTGYTGGAGTCCKTGCGACCTCCTAGCGGCCGGTGGTTCGGATGCGCGTGGATGAACTC  
P4-B1.B11-A4       ...............................................................................................G....  
P4-B1.C2-A6        .........................A..........................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        .........................A..........................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ...............................................................................................G....  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ...............................................................................................G....  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      .......................G.A..........................................................................  
P4-Plas.G7-C8      .........................A..........................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
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P4-Plas.H8-H10     ..................................................................................G.................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CAYGGGGTTTCTCAAGACGTGCGGAGCTCCCCCTTGCAATATCTATGGGGGTGAGRACCGGCRGAGGAGCAATAATAGCTCGCCCCTCYTCTGCCCCACC  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        .................................C..............................................T...................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     .................................C..................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     .................................C..................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        GACTGCTTCAGGAAACACCCTGGGGCTACATATAGCCGGTGTGGTGCGGGGCCCTGGTTGACACCTCGATGTATGGTCGACTACCCATACCGGCTTTGGC  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
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P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................G.............................A.  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ........T...........................................................................................  
 
                           1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        ATTTCCCATGCACTGTCAATTTTWCCCTGTTCAAGGTGAGGATGTTCGTGGGCGGGTTTGAACACCGGTTTAACGCCGCTTGCAATTGGACCAGGGGGGA  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ..........................................................C.........................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ........................................................................G...........................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        GCGCTGCGATATCGAAGATCGTGACCGCAGCGAGCTGCATCCGCTGTTGCATTCAACAACTGAGCTTGCTATACTGCCTTGCTCTTTTACGCCCATGCCC  
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P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        .........C..........................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ..................C.................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        GCATTGTCAACAGGTCTAATACACCTCCACCAAAACATCGTGGATGTCCAGTACCTTTATGGTGTTGGAGCTGGCATGGTGGGGTGGGCGCTTAAGTGGG  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ............................................................................................C.......  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
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P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1610      1620      1630      1640      1650      1660      1670      1680      1690      1700         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        AGATTGTCATCCTCGTCTTCCTCCTCCTAGCAGACGCACGCGTGTGCGTTGCCCTTTGGATGATGCTGATGATATCACAAGCAGAAGCAGCCCTGGAGAA  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        .......................................................................G............................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ............................................................................G.......................  
P4-B1.E8-G2        ....................................................................................................  
P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....C...................................T...........................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       ....................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....C...................................T...........................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      ....................................................................................................  
P4-Plas.D7-E2      ..............................................................................G.....................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....C...................................T...........................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1710      1720      1730      1740      1750      1760      1770      1780      1790      1800         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P4-BCC        CCTCGTCACGCTGAACGCTGTTGCCGCTGCCGGGACACATGGTATCGGTTGGTACCTGGTAGYTTTTTGCGCGGCGTGGTACGTGCGGGGTAAACTTGTT  
P4-B1.B11-A4       ....................................................................................................  
P4-B1.C2-A6        ....................................................................................................  
P4-B1.C4-G11       ....................................................................................................  
P4-B1.C2-B7        ....................................................................................................  
P4-B1.F5-D2        ....................................................................................................  
P4-B1.E8-G2        ....................................................................................................  
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P4-B3.E9-B2        ....................................................................................................  
P4-B3.E11-C3       ....................................................................................................  
P4-B7.F3-E3        ....................................................................................................  
P4-B7.F9-H6        ....................................................................................................  
P4-B7.G7-E3        ....................................................................................................  
P4-B7.H3-C12       T...................................................................................................  
P4-B7.B6-C8        ....................................................................................................  
P4-Plas.G12-A9     ....................................................................................................  
P4-Plas.C3-F3      ....................................................................................................  
P4-Plas.G7-C8      .....................................................................T..............................  
P4-Plas.D7-E2      ....................................................................................................  
P4-Plas.E6-G5      ....................................................................................................  
P4-Plas.H8-H10     ....................................................................................................  
P4-Plas.D10-B12    ....................................................................................................  
 
                           1810      1820      1830      1840      1850      1860      1870            
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|... 
P4-BCC        CCGCTGGTGACCTACGGCATGACGGGTCTTTGGTCCCTAGCTTTGCTCGTCCTCTTGCTCCCCCAGCGAGCGTAYGCT  
P4-B1.B11-A4       ..............................................................................  
P4-B1.C2-A6        ..............................................................................  
P4-B1.C4-G11       ..............................................................T...............  
P4-B1.C2-B7        ........................................................A.....................  
P4-B1.F5-D2        ..............................................................................  
P4-B1.E8-G2        ..............................................................................  
P4-B3.E9-B2        ..............................................................................  
P4-B3.E11-C3       ..............................................................................  
P4-B7.F3-E3        ..............................................................................  
P4-B7.F9-H6        ..............................................................................  
P4-B7.G7-E3        ..............A...............................................................  
P4-B7.H3-C12       ..............................................................................  
P4-B7.B6-C8        ..............................................................................  
P4-Plas.G12-A9     ..............................................................................  
P4-Plas.C3-F3      ..............................................................................  
P4-Plas.G7-C8      ..............................................................................  
P4-Plas.D7-E2      ..............................................................................  
P4-Plas.E6-G5      ..............................................................................  
P4-Plas.H8-H10     ..............................................................................  
P4-Plas.D10-B12    ..............................................................................  
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10.1.4 Patient 5 
Gene position: E1: 1 - 576nt, E2: 577 - 1693nt, p7: 1683-1872nt, HVR1: 577 – 657nt, HVR494: 913 - 933nt, HVR595: 1153 - 
1179nt. 
                          10        20        30        40        50        60        70        80        90        100                   
 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC             YTAGAGTGGCGGAATACGTCTGGCCTYTACATTCTTACCAACGACTGTTCTAATAGCAGTATTGTGTAYGAGGCCGACGATGTTATTCTGCACACACCYG  
P5-B1.C10-D9      ...................................C................................................................  
P5-B1.C9-C11      .....................................................C..............................................  
P5-B1.C2-B1       ..G.................................................................................................  
P5-B1.G7-C6       ..G..A..............................................................................................  
P5-B1.G4-E3       ....................................................................................................  
P5-B1.G9-A10      ....................................................................................................  
P5-B1.F4-C2       ....................C...............................................................................  
P5-B1.C8-D11      ............................................T........C..............................................  
P5-B1.D9-A12      .............................................................................T......................  
P5-B3.F5-C3       ....................................................................................................  
P5-B3.F11-F2      .....................................................C..............................................  
P5-B3.G2-G2       .....................................................C..............................................  
P5-B3.F3-B9       .............................................................................T......................  
P5-B6.D7-E5       ....................................................................................................  
P5-B6.1/125-4-D10 ....................................................................................................  
P5-B6.H6-H11      ....................................................................................................  
P5-B6.B7-G9       ..G.................................................................................................  
P5-B6.B2-H6       ....................................................................................................  
P5-B6.C12-E9      ....................................................................................................  
 
                         110       120       130       140        150      160       170       180       190        200          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC       GCTGCGTACCTTGTGTTCAGGACGGCAATAAATCYARGTGCTGGACCCCAGTGACACCTACAGTGGCAGTTAGGTACGTCGGAGCAACCACTGCTTCGAT  
P5-B1.C10-D9      ...................................................................G................................  
P5-B1.C9-C11      ....................................................................................................  
P5-B1.C2-B1       ....................................................................................................  
 361 
P5-B1.G7-C6       ....................................................................................................  
P5-B1.G4-E3       ............................C...........T...........................................................  
P5-B1.G9-A10      ...............................................T......................C.............................  
P5-B1.F4-C2       ....................................................................................................  
P5-B1.C8-D11      ....................................................................................................  
P5-B1.D9-A12      ................C...............A....T..............C.......................T.......................  
P5-B3.F5-C3       ....................................................................................................  
P5-B3.F11-F2      ....................................................................................................  
P5-B3.G2-G2       ....................................................................................................  
P5-B3.F3-B9       ................C...............A....T..............C...............................................  
P5-B6.D7-E5       ....................................................................................................  
P5-B6.1/125-4-D10 ....................................................................................................  
P5-B6.H6-H11      ...........................................................................................C........  
P5-B6.B7-G9       ....................................................................................................  
P5-B6.B2-H6       ....................................................................................................  
P5-B6.C12-E9      ..............................C.....................................................................  
 
                          210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        ACGCAGTCATGTGGACCTGCTAGTGGGCGCAGCCACTATGTGTTYTGCGCTYTACGTGGGTGATATGTGTGGGGCCGTCTTCCTCGTGGGACAAGCCTTC  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        .................................T..................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ......C.............................................................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ......C.............................................................................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       .......................................................................................A............  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        .....................G........G.....................................................................  
P5-B6.C12-E9       ...................T................................................................................  
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                          310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        ACGTTCAGACCCCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCTTTCAGGACATCGAATGGCTTGGGATATGATGATGA  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................G...............................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ........................................................G...........................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ....................................................................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ....................................................................................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ......................................C.............................................................  
P5-B6.B7-G9        ....................................................................G...............................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ..........................A.........................................................................  
 
                          410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        ATTGGTCCCCCGCTGTGGGTATGGTGGTAGCGCAYGTCCTGCGTCTGCCCCAGACYTTGTTTGACATATTGRCCGGGGCCCATTGGGGCATYATGGCAGG  
P5-B1.C10-D9       .............G......................................................................................  
P5-B1.C9-C11       ............................G.......................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ..........T.................G.......................................................................  
P5-B1.D9-A12       ............................................T.......................C...............................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ............................G......C................................................................  
P5-B3.G2-G2        ............................G.......................................................................  
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P5-B3.F3-B9        ............................................T.......................C...............................  
P5-B6.D7-E5        ..........T.........................................................................................  
P5-B6.1/125-4-D10  ............................G.......................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ..........T.........................................................................................  
P5-B6.C12-E9       ..........T.........................................................................................  
 
                          510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CCTAGCCTATTACTCCATGCAGGGCAACTGGGCCAAGGTCGCTATCATCATGGTTATGTTTTCAGGGGTCGACGCCACAACAYACRYCACTGGTGGCWCA  
P5-B1.C10-D9       T...................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ..............................................................................................A.....  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ........................T...............T...............................T...CA.....G..............GG  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ........................T..................G............................T...CA.....G..............GG  
P5-B6.D7-E5        ......T.............................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                          610       620       630       640       650       660       670       680       690       700          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        ATGGGCCGTACTGCCTTCACACTTACCAGTTTYTTWACTTCGGGCCCCAARCAGAACCTGCAACTGGTCAACACCAATGGCTCATGGCACATCAACAGAA  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ...............C....................................................................................  
P5-B1.G7-C6        .........G..........................................................................................  
P5-B1.G4-E3        .......................C............................................................................  
 364 
P5-B1.G9-A10       ............A....................C..................................................................  
P5-B1.F4-C2        ..A..............................C.C...........T....................................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ....CT.A....A....TGGT..C.....CC....CT..C....T...C.......A.....G.....T...............................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ....CT.A....A....TGGT..C.....CC....CT..C........C.......A.....G.....T...............................  
P5-B6.D7-E5        ...............C........................................T...........................................  
P5-B6.1/125-4-D10  ...A................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ...............C....................................................................................  
P5-B6.B2-H6        ..........................T..............A..........................................................  
P5-B6.C12-E9       ...............C....................................................................................  
 
                          710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CTGCCCTGAACTGCAATGATTCCCTAAACACAGGGTTTMTAGCTGGGTTGWTTTATYATCATAAGTTCAACTCTACTGGATGTCCTCAGAGGCTCAATAG  
P5-B1.C10-D9       .................................................A...........C......................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ...................................................................T................................  
P5-B1.G4-E3        .C....................................................................T.............................  
P5-B1.G9-A10       ............................T.......................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ....................A.TT.............C.........................G.................................C..  
P5-B3.F5-C3        ..........................................................C.........................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ....................A.TT.............C.........................G.................................C..  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  .......................T................................................................A...........  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                         
 365 
       810       820       830      840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC         CTGCAAACCCATTACCTTCTTCAGGCAGGGGTGGGGCTCCTTGACAGATGCTAACATCACCGGTCCCTCCAATGACAAACCGTACTGCTGGCACTACGCA  
P5-B1.C10-D9       ........................................................................C...........................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       .......................................................................................T............  
P5-B1.D9-A12       ......G........T.............................G.................CT.T................................G  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ......G........T...........A.................G.................CT.T.................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ...........................................T........................................................  
 
                          910       920       930       940       950       960       970       980       990      1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CCTAGACCTTGTGACACTGTCGAAGCATCACRTGTCTGCGGCCCTGTGTACTGYTTCACACCATCGCCAGTGGTTGTAGGCACTACTGATGYCAAGGGTG  
P5-B1.C10-D9       .............................T......................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        .....................A..............................................................................  
P5-B1.C8-D11       ...................................T................................................................  
P5-B1.D9-A12       .........................................T..........................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        .........................................T..........................................................  
 366 
P5-B6.D7-E5        ..................A.T...............................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
 
                         1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CCCCGACCTATACCTGGGGTGAGAATGAGACAGATGTGTTCCTGCTGAAGTCCCTGCGGCCTCCCAGTGGTCAGTGGTTCGGGTGTACGTGGATGAACTC  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ..........C.........................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       .....................G..................................................G.............G.............  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        .....................G..................................................G...........................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ...............................................................................T....................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ..............................................A.....................................................  
P5-B6.C12-E9       .................................................................................................T..  
 
                         1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CACRGGGTTTGTCAAGACGTGCGGAGCTCCCCCTTGTAAYATCTATGRGGGTGGGGGGGATCCCTCAAATGAGTCARACCTCTTCTGCCCCACCGAYTGT  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        .........C..........................................................................................  
 367 
P5-B1.G9-A10       T...................................................................................................  
P5-B1.F4-C2        ........................................................................................T...........  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ..........................................................AG........................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       .......G............................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ..........................................................AG........................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ..............................T.....................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                               
1210     1220     1230      1240       1250      1260      1270      1280      1290     1300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        TTCAGGAAACATCCTGAGGCCACATACAGCCGGTGTGGTGCGGGGCCCTGGTTAACACCTCGATGTATGGTCGACTATCCATACCGGCTTTGGCATTACC  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ...........................G........................................................................  
P5-B1.D9-A12       .....A........C.....T..................T............................................................  
P5-B3.F5-C3        ..T.................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        .....A.................................T............................................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       .....................................................G..............................................  
 
 368 
                          1310      1320     1330      1340      1350      1360      1370      1380      1390      1400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CATGTACAATTAATTTCACATTGTTCAAGGTGAGGATGTTTGTAGGCGGGTTTGAGCACCGGTTTACCGCCGCTTGCAACTGGACCAGGGGGGAGCGCTG  
P5-B1.C10-D9       .......G............................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        .......G............................................................................................  
P5-B1.G7-C6        .......G...........................................................T................................  
P5-B1.G4-E3        .......G............................................................................................  
P5-B1.G9-A10       .......G.......................A....................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ........G....C..T...................................................................................  
P5-B3.F5-C3        .......G............................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ........G....C..T...................................................................................  
P5-B6.D7-E5        .......G............................................................................................  
P5-B6.1/125-4-D10  ....C...............................................................................................  
P5-B6.H6-H11       .......G............................................................................................  
P5-B6.B7-G9        .......G............................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                               
1410     1420      1430      1440      1450      1460     1470      1480      1490      1500         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CGATATCGAGGATCGTGACCGCAGCGAGCAACATCCGCTGCTGCATTCAACAACTGAGYTTGCTATACTGCCTTGCTCCTTCACGCCCATGCCYGCATTG  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ....................................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ...........................................................................T........A...............  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       ...............C...........A............T...........................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ......T.............................................................................................  
 369 
P5-B3.F3-B9        ...........................A............T...........................................................  
P5-B6.D7-E5        ..................T.................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ....................................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                   
                         1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC         TCAACAGGYCTGATACACCTCCACCAAAATATCGTGGACGTCCAATACCTTTATGGCGTTGGATCTGGCATGGTGGGATGGGCGCTGAAATGGGAGTTCG  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ........G...........................................................................................  
P5-B1.G7-C6        ....................................................................................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        ....................................................................................................  
P5-B1.C8-D11       ....................T...............................................................................  
P5-B1.D9-A12       .............................C........T...........................................T......G..........  
P5-B3.F5-C3        .....G..............................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        .............................C........T...........................................T......G..........  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        ........G...........................................................................................  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       ....................................................................................................  
 
                         1610      1620      1630      1640      1650      1660      1670      1680      1690      1700         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        TWATCCTCGTGTTCCTTCTCCTAGCAGACGCACGCGTGTGCGTTGCTYTTTGGCTGATGCTGATGGTATCACAAACAGAAGCAGCCTTGGAGAACCTTGT  
P5-B1.C10-D9       ....................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        ...........................................C.........................................T..............  
P5-B1.G7-C6        ....................................................................................................  
 370 
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       ....................................................................................................  
P5-B1.F4-C2        .............T....................G......................................G..........................  
P5-B1.C8-D11       ....................................................................................................  
P5-B1.D9-A12       .C..................................................................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        .C..................................................................................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       .G..................................................................................................  
P5-B6.B7-G9        ...........................................C.........................................T..............  
P5-B6.B2-H6        ....................................................................................................  
P5-B6.C12-E9       .G.......................................................................G..........................  
 
                         1710      1720      1730      1740      1750      1760      1770      1780      1790      1800         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P5-BCC        CACGCTGAATGCCATCGCTGCTGCCGGGACACATGGTATCGGCTGGTACCTGGTGGCTTTTTGCGCRGCGTGGCACGTGCGGGGTAAACTTGTCCCGCTG  
P5-B1.C10-D9       ...A................................................................................................  
P5-B1.C9-C11       ....................................................................................................  
P5-B1.C2-B1        .....................A..............................................................................  
P5-B1.G7-C6        .............................................................-......................................  
P5-B1.G4-E3        ....................................................................................................  
P5-B1.G9-A10       .......................T............................................................................  
P5-B1.F4-C2        ..........................................................................................CT........  
P5-B1.C8-D11       ..................C.................................................................................  
P5-B1.D9-A12       ..T..........G.......C..............................................................................  
P5-B3.F5-C3        ....................................................................................................  
P5-B3.F11-F2       ....................................................................................................  
P5-B3.G2-G2        ....................................................................................................  
P5-B3.F3-B9        ..T..........G.......C..............................................................................  
P5-B6.D7-E5        ....................................................................................................  
P5-B6.1/125-4-D10  ....................................................................................................  
P5-B6.H6-H11       ....................................................................................................  
P5-B6.B7-G9        .....................A..............................................................................  
P5-B6.B2-H6        ........................T...........................................................................  
P5-B6.C12-E9       .....................................T..............................................................  
 
 371 
                               
1810     1820     1830      1840      1850      1860       1870      
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|.. 
P5-BCC        GTGACCTACAGCCTCACGGGTCTTTGGTCCCTAGCATTGCTCGTCCTCTTGCTCCCTCAACGGGCGTATGCT  
P5-B1.C10-D9       ........................................................................  
P5-B1.C9-C11       ........................................................................  
P5-B1.C2-B1        ........................................................................  
P5-B1.G7-C6        ........................................................................  
P5-B1.G4-E3        ........................................................................  
P5-B1.G9-A10       ....................................C...................................  
P5-B1.F4-C2        ........................................................................  
P5-B1.C8-D11       ........................................................................  
P5-B1.D9-A12       .................................................................A......  
P5-B3.F5-C3        ........................................................................  
P5-B3.F11-F2       ........................................................................  
P5-B3.G2-G2        .........G..............................................................  
P5-B3.F3-B9        ........A........................................................A......  
P5-B6.D7-E5        ........................................................................  
P5-B6.1/125-4-D10 ........................................................................  
P5-B6.H6-H11       .C......................................................................  
P5-B6.B7-G9        ........................................................................  
P5-B6.B2-H6        ........................................................................  






10.1.5 Patient 7 
Gene position: E1: 1 - 576nt, E2: 577 - 1665nt, HVR1: 577 – 657nt. 
 
 
                             10        20        30        40        50        60        70        80        90       100                   
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    TACCAAGTACGCAACTCCTCGGGCATCTACCATGTCACCAATGATTGCCCTAACTCGAGTATTGTGTACGAGACGGCCGATGCCATTCTRCACTCTCCGG  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ..................................................C.................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          .................T................................C.................................................  
P7-B1.F2-D11         ........G...........................................................................................  
P7-B1.F9-A8          .........................................C..........................................................  
P7-B6.C7-B8          ..................................................................................................A.  
P7-B6.B7-C9          ..................................................................................................A.  
P7-B6.F11-E11        ......................................................................................C.............  
P7-B6.A2-E8          ....................................................................................................  
P7-B6.F9-E6          ....................................................................................................  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        ....................................................................................................  
P7-Plas.A9-C6        ....................................................................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        .............................................C......................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ....................................................................................................  
 373 
P7-Plas.E2-A10       ......................................................................................C.............  
 
                             110       120       130       140       150       160       170       180       190       200          
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          GGTGTGTCCCTTGCGTTCGCGAGGGYAACAGCTCGAAGTGTTGGGTGGCGGTGGCCCCCACAGTCGCCACCAGGGACGGCARACTCCCCGCAACACAGCT  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ..............................................................................................G.....  
P7-B1.D9-D2          ........................................C...........................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ................C.............................................................................G.....  
P7-B1.F2-D11         .....................................C........................................................G.....  
P7-B1.F9-A8          .............................................................G.C..............................G.....  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ................G.............A...............A...............................................G.....  
P7-B6.F9-E6          ..............................A...............................................................G.....  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ........................................C.....................................................G.....  
P7-Plas.A2-G5        .............................................................G......................................  
P7-Plas.A9-C6        ................................................T...................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ..........C......................................................A..................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       .............T...................................A............................................G.....  
P7-Plas.E2-A10       ....................................................................................................  
 
                             210      220       230       240       250       260       270       280       290       300          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC         TCGACGTCACATCGATCTGCTTGTCGGGAGCGCCACCCTCTGTTCGGCCCTCTATGTGGGGGACTTATGCGGGTCTGTCTTTCTTGTCGGCCAACTGTTC  
P7-B1.C6-F3          .........T...........C..................................................................A...........  
P7-B1.C8-D4          ........................................................................................A...........  
P7-B1.C3-C11         ................................................T.................G.................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ....................................................................................C...............  
 374 
P7-B1.G7-F5          ....................................T..........................T....................................  
P7-B1.F5-B1          ....................................................................................C...............  
P7-B1.F2-D11         .........T...........C...............T.........................T........................A...........  
P7-B1.F9-A8          .........T...........C..................................................................A...........  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ................................................................C...................................  
P7-B6.F9-E6          ................................................................C...................................  
P7-Plas.E8-C12       .....................C......................................A.......................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ..............................................A.....................................C...............  
P7-Plas.A2-G5        ........................................................................................A...........  
P7-Plas.A9-C6        ......................................................C....................C........................  
P7-Plas.E7-B1        ..............................T.................................C....T..............................  
P7-Plas.B9-A4        ..........................................C.........................................................  
P7-Plas.A9-E3        ................T.......................................................................A...........  
P7-Plas.1/5-3-G4     ........................................................................................A...........  
P7-Plas.G7-F12       ................................................T.................G...........................T.....  






                            310       320       330       340       350       360       370       380       390       400          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          ACTTTCTCCCCCAGRCACCACTGGACRACGCAAGACTGCAACTGCTCCATCTACCCCGGCCATATAACGGGTCACCGCATGGCATGGGATATGATGATGA  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ..C..............T..............G...................................................................  
P7-B1.D9-D2          ..C...........................................................C.....................................  
P7-B1.F8-A5          ............................................T...........A...........................................  
P7-B1.G7-F5          ...................................................................................G................  
P7-B1.F5-B1          ....................................................................................................  
P7-B1.F2-D11         ..C.................................................................................................  
P7-B1.F9-A8          ....................................................................................................  
P7-B6.C7-B8          ...........................G........................................................................  
P7-B6.B7-C9          ....................................................................................................  
 375 
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          .............................................................................T......................  
P7-B6.F9-E6          ...........................................................................T.T......................  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        .............................................................................T......................  
P7-Plas.A9-C6        ..C.................................................................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ..C.............................G...................................................................  
P7-Plas.E2-A10       ..C.................................................................................................  
 
 
                            410       420       430       440       450       460       470       480       490       500          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          ATTGGTCCCCTACAACAGCGCTGGTAGTAGCTCAGCTGCTCAGGGTCCCGCAAGCCATCTTGGACATGATCGCTGGTGCCCACTGGGGAGTCCTAGCGGG  
P7-B1.C6-F3          .C..................................................................................................  
P7-B1.C8-D4          .C.............................C....................................................................  
P7-B1.C3-C11         ............................G.......................................................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ............................G.......................................................................  
P7-B1.G7-F5          ..........C.........................................................................................  
P7-B1.F5-B1          ....................................................................................................  
P7-B1.F2-D11         ............................................................................A.......................  
P7-B1.F9-A8          ............................................................................C.......................  
P7-B6.C7-B8          ................G...................................................................................  
P7-B6.B7-C9          ................G...................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          .............G..G..A................................................................................  
P7-B6.F9-E6          ................G..A................................................................................  
P7-Plas.E8-C12       ..............G.....................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        ..........C.................................................................................T.......  
P7-Plas.A9-C6        ....................................................................................................  
P7-Plas.E7-B1        ................G...................................................................................  
 376 
P7-Plas.B9-A4        ................G...................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ..........C.................G.......................................................................  
P7-Plas.E2-A10       ....................................................................................................  
 
                            510       520       530       540       550       560      570        580       590       600          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    CATAGCGTAYTTCTCCATGGTGGGGAACTGGGCGAAGGTCCTGGTGGTGCTGTTGCTGTTTGCCAGCGTCGATGCAGATACCTACACCACCGGGGGAACT  
P7-B1.C6-F3          ........................................................................C...........................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         .......................C............................................................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ....................................................C...............................................  
P7-B1.F5-B1          ....A........................................A.....A................................................  
P7-B1.F2-D11         ....................................................................................................  
P7-B1.F9-A8          ..........................................................................................T.........  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          .......................................................T.......T....................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          .................................................T........................................T.........  
P7-B6.F9-E6          ..........................................................................................T.........  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        .......................................................T............................................  
P7-Plas.A9-C6        ....................................................................................T...............  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ....................................................................................................  









                            610       620       630       640      650        660       670       680       690       700          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    GCCGCTAGGGGCGCGYTCGGGCTCGCCAACATCTTCAGTCCGGGCGCTAAGCAGAACATCCAGCTGATCAACACCAACGGCAGTTGGCACATCAATCGCA  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ........................................................T...........................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ....................................................................................................  
P7-B1.F2-D11         ..T..C..............................................................................................  
P7-B1.F9-A8          ..T.......................T.........................................................................  
P7-B6.C7-B8          ...........................................................T........T...............................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ..T.......................................................................T.....T...................  
P7-B6.F9-E6          ..T..............................................................A..............T...................  
P7-Plas.E8-C12       ..........................G.........................................................................  
P7-Plas.1/125-4-B11  .............................................................................T...........T..........  
P7-Plas.B8-C12       ...........................................A......................G.................................  
P7-Plas.A2-G5        ..................................................................................................T.  
P7-Plas.A9-C6        ....................................................................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ........................................................T...........................................  
P7-Plas.E2-A10       ....................................................................................................  
 
                            710       720       730       740       750       760       770       780       790       800          
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    CGGCCCTGAACTGYAATGCGAGTCTCGACACTGGCTGGGTGGCGGGGCTCCTCTATTACCACAAATTCAACTCTTCAGGCTGYACCGAGAGGATGGCCAG  
P7-B1.C6-F3          ................................................................G...................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          .....T..............................................................................................  
P7-B1.F8-A5          ....................................................................................................  
 378 
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          .....T..........C...................................................................................  
P7-B1.F2-D11         ...........................................A.................T........T.............................  
P7-B1.F9-A8          ....................................................................................................  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ...............................A....................................................................  
P7-B6.F9-E6          ....................................................................................................  
P7-Plas.E8-C12       ........................................A...........................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       .....T..............................................................................................  
P7-Plas.A2-G5        ....T..................................................C............................................  
P7-Plas.A9-C6        ....................................................................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       ................................................................G...................T...............  
 
 810        820       830       840       850       860       870       880       890       900                    
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    CTGTAGACCCCTTGCCGATTTCGATCAGGGCTGGGGCCCCATCAGCCACACCAACGGAAGCGGCCCCGAACACCGCCCTTACTGCTGGCACTACCCCCCA  
P7-B1.C6-F3          ................................................................................................T...  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          ................................................G...................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ............C.......................................................................................  
P7-B1.F5-B1          ..............................................................................G.....................  
P7-B1.F2-D11         ............C..........................T............................................................  
P7-B1.F9-A8          ......................................TT......................................C.....................  
P7-B6.C7-B8          ...............................................................T....................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ...C................................................................................................  
P7-B6.A2-E8          ........................C.................T.........................................................  
P7-B6.F9-E6          ........................C.................T.........................................................  
P7-Plas.E8-C12       ....................................................................................................  
 379 
P7-Plas.1/125-4-B11  .................................................G..................................................  
P7-Plas.B8-C12       .......................................T............................................................  
P7-Plas.A2-G5        ....................................................................................................  
P7-Plas.A9-C6        ......................A.............................................................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     .....................................................................G..............................  
P7-Plas.G7-F12       ....................................................................................................  









                            910       920       930       940       950       960       970       980       990      1000         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          AAGCCATGTGGCATCGTGCCAGCAAAGAGTGTATGTGGTCCAGTGTATTGCTTCACTCCTAGCCCCGTGGTGGTGGGAACGACCGACAAGTTGGGCGCGC  
P7-B1.C6-F3          .................................................................T..................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          .............................C...................................T..................................  
P7-B1.F8-A5          ........................................................C........T..................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          .................................................................T..................................  
P7-B1.F2-D11         .....T........A.....................................................................................  
P7-B1.F9-A8          .....C........A..A..................................................................................  
P7-B6.C7-B8          .................................................................T..................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ........................................................C...........................................  
P7-B6.A2-E8          .....C..............G...................................A....................G......................  
P7-B6.F9-E6          .....C..............G...................................A....................G......................  
P7-Plas.E8-C12       ........C...........................................................................................  
P7-Plas.1/125-4-B11  ..A.............................G...................................................................  
P7-Plas.B8-C12       .................................................................T..................................  
P7-Plas.A2-G5        ....................................................................................................  
 380 
P7-Plas.A9-C6        .................................................................T..................................  
P7-Plas.E7-B1        .................................................................T...........G......................  
P7-Plas.B9-A4        .................................................................T..................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ..................................................T.................................................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       .................................................................T..................................  
 
                           1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    CCACCTACAACTGGGGTAGCAATGACACGGACGTCTTCATCCTCAACAACACCAGGCCACCGTTGGGCAATTGGTTCGGCTGCACCTGGATGAATGCATC  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ......................................................T.............................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ....T...................................T...........................................................  
P7-B1.F2-D11         ....................................................................................................  
P7-B1.F9-A8          ....................................................................................................  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ..........T...................................................C.....................................  
P7-B6.F9-E6          ..............................................................C.....................................  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ....................................................................................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        .............................................................C......................................  
P7-Plas.A9-C6        ..............................................................C.....................................  
P7-Plas.E7-B1        ....................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     .............................................................C......................................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       ....................................................................................................  
 
                           1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
 381 
P7-BCC    TGGGTTTACCAAAGTGTGCGGAGCGCCCCCTTGTGTCATCGGGGGGGG~AGGCAACAACACATTGCACTGCCCCACTGACTGCTTCCGCAAACATCCGGA  
P7-B1.C6-F3          ................................................~...................................................  
P7-B1.C8-D4          ........................A.......................~...................................................  
P7-B1.C3-C11         ..........................................-.....~G.........................................G........  
P7-B1.D9-D2          ................................................~...................................................  
P7-B1.F8-A5          .................................C..............~...................................................  
P7-B1.G7-F5          ................................................~...................................................  
P7-B1.F5-B1          ................................................~...................................................  
P7-B1.F2-D11         ...............T................................~T..........T.......................................  
P7-B1.F9-A8          ................................................~T...........G......................................  
P7-B6.C7-B8          ................................................~...................................................  
P7-B6.B7-C9          ................................................~...................................................  
P7-B6.F11-E11        ................................................~...................................................  
P7-B6.A2-E8          ......C......................................A..~G..................................................  
P7-B6.F9-E6          ......C......................................A..~G..................................................  
P7-Plas.E8-C12       ................................................~...................................................  
P7-Plas.1/125-4-B11  ..............................C.................~...................................................  
P7-Plas.B8-C12       ................................................~...................................................  
P7-Plas.A2-G5        ................................................~.............C.....................................  
P7-Plas.A9-C6        ................................................~...................................................  
P7-Plas.E7-B1        ................................................~...................................................  
P7-Plas.B9-A4        ......C.........................................~...................................................  
P7-Plas.A9-E3        ................................................~...................................................  
P7-Plas.1/5-3-G4     ................................................~...................................................  
P7-Plas.G7-F12       ................................................~G.........................................G........  
P7-Plas.E2-A10       .........T......................................G...................C...............................  
 
                            1210     1220      1230      1240      1250      1260      1270      1280      1290      1300         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC    GGCCACATACTCTCGGTGTGGCTCCGGCCCCTGGGTCACGCCCAGGTGCCTGGTCCATTACTCTTACAGGCTTTGGCATTACCCTTGTACTGTCAACTAC  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ...........................A........................................................................  
P7-B1.C3-C11         ..............................................................................C.....................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ...................................................................................................T  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ....................................................................................................  
P7-B1.F2-D11         ..........................................T........C........T.......................................  
P7-B1.F9-A8          ..................................A................C........T.......................................  
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P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        .......................................................................C............................  
P7-B6.A2-E8          ....................................................................................................  
P7-B6.F9-E6          C...................................................................................................  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  ........................................................................C.................C.........  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        .......................................................................................C............  
P7-Plas.A9-C6        ....................................................................................................  
P7-Plas.E7-B1        C...................................................................................................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ................................................T...................................................  
P7-Plas.G7-F12       ................................................................................................T...  
P7-Plas.E2-A10       ....................................................................................................  
 
                           1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          ACCYTGTTCAAAGTCAGGATGTACGTGGGAGGGGTCGAGCACAGGCTGGAAGTTGCTTGCAACTGGACGCGGGGCGAGCGTTGCGATCTGGACGACAGGG  
P7-B1.C6-F3          .............................G........................................................C.............  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          ....................................................................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ........T...........................................................................................  
P7-B1.F2-D11         ............................................A.......................................................  
P7-B1.F9-A8          ....................................................................................................  
P7-B6.C7-B8          ...................................................................................T................  
P7-B6.B7-C9          ...................................................................................T................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          .......................T............................................................................  
P7-B6.F9-E6          .............................................T......................................................  
P7-Plas.E8-C12       ...................................................................................T................  
P7-Plas.1/125-4-B11  ..............................................................T.....................................  
P7-Plas.B8-C12       ....................................................................................................  
P7-Plas.A2-G5        ....................................................................................................  
P7-Plas.A9-C6        ....................................................................................................  
 383 
P7-Plas.E7-B1        .......................................................................A............................  
P7-Plas.B9-A4        ....................................................................................................  
P7-Plas.A9-E3        ...................................................................................T................  
P7-Plas.1/5-3-G4     ...................................................................................T................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       ....................................................................................................  
 
                           1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC       ACAGGTCCGAGCTCAGCCCGCTGCTGCTGTCCACCACACAGTGGCAGGTCCTTCCGTGTTCCTTCACRACCTTGCCAGCCTTGACCACCGGCCTCATCCA  
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ....................................................................................................  
P7-B1.C3-C11         ....................................................................................................  
P7-B1.D9-D2          ...................A................................................................................  
P7-B1.F8-A5          ...................A......................................C.........................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ...................A................................................................................  
P7-B1.F2-D11         .....................................G.................A........T......C............................  
P7-B1.F9-A8          .....................................G.................................C............................  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ................T.....................................................TC............................  
P7-B6.F9-E6          ................T.....................................................TC............................  
P7-Plas.E8-C12       .........................................................................A..........................  
P7-Plas.1/125-4-B11  .....................................G..............................................................  
P7-Plas.B8-C12       ...................A................................................................................  
P7-Plas.A2-G5        ....................................................................................................  
P7-Plas.A9-C6        ........................................A...........................................................  
P7-Plas.E7-B1        ...................A..A.............................................................................  
P7-Plas.B9-A4        ...................A................................................................................  
P7-Plas.A9-E3        ....................................................................................................  
P7-Plas.1/5-3-G4     ....................................................................................................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       ....................................................................................................  
 
                           1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P7-BCC          CCTCCACCAGAACATCGTGGACGTGCAATATTTGTACGGGGTGGGGTCAAGTATCGTATCCTGGGCCATCAAGTGGGAGTATGTCATYCTCTTGTTCCTC  
 384 
P7-B1.C6-F3          ....................................................................................................  
P7-B1.C8-D4          ............................................................T.......................................  
P7-B1.C3-C11         ......T.............................................................................................  
P7-B1.D9-D2          ....................................................................................................  
P7-B1.F8-A5          .............................................A......................................................  
P7-B1.G7-F5          ....................................................................................................  
P7-B1.F5-B1          ....................................................................................................  
P7-B1.F2-D11         ......................................................T.............................................  
P7-B1.F9-A8          ......................................................T.............................................  
P7-B6.C7-B8          ....................................................................................................  
P7-B6.B7-C9          ....................................................................................................  
P7-B6.F11-E11        ....................................................................................................  
P7-B6.A2-E8          ...................................................C................................................  
P7-B6.F9-E6          ...................................................C................................................  
P7-Plas.E8-C12       ....................................................................................................  
P7-Plas.1/125-4-B11  .........A......................................G...................................................  
P7-Plas.B8-C12       .........................................................G..........................................  
P7-Plas.A2-G5        ...............................C....................................................................  
P7-Plas.A9-C6        .....................T.....G.........................................T..............................  
P7-Plas.E7-B1        ...............T...........................................................................C........  
P7-Plas.B9-A4        ............................................................T....................C..................  
P7-Plas.A9-E3        ...........................................................................................C........  
P7-Plas.1/5-3-G4     ..................................................................T.................................  
P7-Plas.G7-F12       ....................................................................................................  
P7-Plas.E2-A10       .....................T.....G.........................................T..............................  
 
                           1610      1620      1630      1640      1650      1660           
                     ....|....|....|....|....|....|....|....|....|....|....|....|....|. 
P7-BCC       CTGCTTGCAGACGCGCGCATCTGCTCCTGCTTGTGGATGATGTTACTCATATCCCAAGCGGAGGCG  
P7-B1.C6-F3          ..................................................................  
P7-B1.C8-D4          ...........T......................................................  
P7-B1.C3-C11         ..................................................................  
P7-B1.D9-D2          ..................................................................  
P7-B1.F8-A5          ..................................................................  
P7-B1.G7-F5          ..................................................................  
P7-B1.F5-B1          ..................................................................  
P7-B1.F2-D11         ..................................................................  
P7-B1.F9-A8          .....C............................................................  
P7-B6.C7-B8          ..................................................................  
 385 
P7-B6.B7-C9          ..................................................................  
P7-B6.F11-E11        ................................................................AA  
P7-B6.A2-E8          ..................................................................  
P7-B6.F9-E6          ..................................................................  
P7-Plas.E8-C12       ...............................................................AA.  
P7-Plas.1/125-4-B11  ..................................................................  
P7-Plas.B8-C12       ..................................................................  
P7-Plas.A2-G5        ..................................................................  
P7-Plas.A9-C6        ..................................................................  
P7-Plas.E7-B1        ..................................................................  
P7-Plas.B9-A4        ............................A.....................................  
P7-Plas.A9-E3        ..................................................................  
P7-Plas.1/5-3-G4     ..................................................................  
P7-Plas.G7-F12       ..................................................................  
P7-Plas.E2-A10       ..................................................................  
 
 
10.1.6 Patient 9 
Gene position: E1: 1 - 576nt, E2: 577 - 1665nt, HVR1: 577 – 657nt. 
 
                           10        20        30        40        50        60        70        80        90       100                   
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC             TATCAAGTACGCAACTCCTCGGGCCTCTACCATGTCACCAATGATTGCCCTAACTCGAGTATTGTGTACGAGACGGCCGACACCATCCTACACTTTCCGG  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ..............................................................C.....................................  
P9-B1.G6-H8        ............................................................G.......................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ......................................A.............................................................  
 386 
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      .....G..............................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          110       120       130       140       150       160       170       180       190       200          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        GGTGTGTCCCTTGCGTTCGCGAGGRTAACGCCTCGAAATGTTGGGTGGCYGTGGCYCCCACAGTRGCCACCAGGGACGGCAAACTCCCCACAACGCAGCT  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        .....................................G..............................................................  
P9-B1.G6-H8        ........................................................................................T...........  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ....C................................G..............................................................  
P9-B6.C3-G10       ....................A.......T.......................................................................  
P9-Plas.B2-G3      .....................................G.......................G......................................  
P9-Plas.1/1-3-B12  .........................................................T..........................................  
P9-Plas.D7-D9      ..C..................................G..............................................................  
P9-Plas.A5-H6      .....................................G..............................................................  
P9-Plas.E8-H6      ....C...............................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
 
                          210       220       230       240       250       260       270       280       290       300          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC             TCGRCGTCACATCGACCTGCTTGTCGGGAGCGCCACCCTCTGCTCGGCCCTCTATGTGGGGGACTTGTGCGGGTCTGTCTTCCTTGTYGGTCARCTGTTY  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ...........................A...............................................C........................  
 387 
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ...........................................................................C........................  
P9-B6.C3-G10       ..................................G.................................................................  
P9-Plas.B2-G3      ...........................................................................C........................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ...........................................................................C........................  
P9-Plas.A5-H6      ...........................................................................C........................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ...........................................................................C........................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          310       320       330       340       350       360       370       380       390       400          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        ACCTTCTCCCCCAGGCGCCAYTGGACAACRCARGACTGCAACTGTTCTATCTACCCCGGCCATATAACGGGTCAYCGCATGGCATGGGACATGATGATGA  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ...................................................................................G................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ..................................................T.................................................  
P9-B6.C12-E4       ..................................................T.................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ...................................................................................G................  
P9-Plas.E8-H6      ..................................................T.................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          410       420       430       440       450       460       470       480       490       500          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        ACTGGTCCCCTACAGCAGCGCTGGTAGTAGCTCAGCTGCTYAGGGTCCCRCAAGCCATCTTGGACATGATCGCTGGTGCYCACTGGGGAGTCCTAGCGGG  
P9-B1.A10-F3       ....................................................................................................  
 388 
P9-B1.B9-C2        ..........................................................TC........................................  
P9-B1.C7-D5        ..................................A.................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       .......T............................................................................................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ............................G.......................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ................G...................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          510       520       530       540       550       560       570       580       590       600          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CATAGCGTATTTCTCCATGGTGGGGAAYTGGGCGAARGTCTTGGTGGTGCTGCTGCTGTTTGCCGGCGTCGATGCRCAAACCTATACCACCGGGGGGAGC  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        .............................................A......................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      .................................................T..................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................   
 
                          610       620       630       640       65        660       670       680       690       700          
 389 
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        GYTGCTCGGGSCGCGTCTGGAATCGCCRGTCTTTTYARTCCTGGCKCCAGGCAGAATATCCAGCTGRTCAACAGGAACGGCAGCTGGCACATCAAYAGCA  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        .................G.....................................................T............................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ...............................................T....................................................  
P9-B6.C12-E4       ...............................................T....................................................  
P9-B6.D10-G1       ...........T.........................................A..............................................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      .................C...........C......................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     .......................................................................T............................  
P9-Plas.1/1-2-C5   .........................................................................................T..........  
 
                          710       720       730       740       750       760       770       780       790       800          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CGGCCTTGAACTGTAATGCGAGCCTCGACACTGGATGGATAGCGGGGCTCTTCTAYCACCACAAATTCAACTCTTCAGGCTGTCCCGAGAGGATGGCCAG  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ................................................C...................................................  
P9-B1.C8-G8        ..........................A.........................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ...............................................................................T....................  
P9-B6.C12-E4       ...............................................................................T....................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       .........................T.........................................T............C...................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      .........................T..........................................................................  
P9-Plas.A5-H6      ..........................A.........................................................................  
P9-Plas.E8-H6      ............................................................................G.........A.............  
P9-Plas.F11-E4     ......................................................G.............................................  
 390 
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          810       820       830       840       850       860       870       880       890       900          
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CTGCAGACCCCTTGCCGAGTTCGACCAGGGTTGGGGCCCTATCAGCTACGCCAACGGAAGCGGCCCCGATCACCGCCCCTACTGCTGGCACTACCCCCCA  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ............................................................T.......................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ............................................................T.......................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ............................................................T.......................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ............................................................T.......................................  
P9-Plas.A5-H6      ............................................................T.......................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     .......................................C............................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                          910       920       930       940       950       960       970       980       990      1000         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        AAGCCTTGTGGTATCGTGCCGGCACAGAGTGTATGTGGCCCTGTGTATTGCTTCACTCCCAGTCCCGTGGTGGTGGGRACGACCAACARGTTGGGCGCGC  
P9-B1.A10-F3       ...........................................C........................................................  
P9-B1.B9-C2        ................................G...................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ...........C........................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ..............T.....................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
 391 
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                         1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CTACCTACAACTGGGGTAGCAATGACACGGACGTCCTCATCCTCAAYAACACCAGGCCRCCGTTGGGCAATTGGTTCGGGTGCACCTGGATGAACTCATC  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ........G..........................T................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ...................................T................................................................  
P9-Plas.A5-H6      ................C...................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
                         1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        TGGATTTACCAAAGTRTGCGGAGCGCCTCCTTGTGTCATCGGAGGGGCGGGCAACAACACCTTGTAYTGCCCTACTGACTGTTTCCGCAAGCATCCRGAW  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ...................................................................................................C  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       ...............C....................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
 392 
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ..........................A.........................................................................  
 
                         1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        GCCACATACTCTCGGTGTGGYTCTGGTCCCTGGATCACGCCCAGGTGTYTGGTYCACTATCCYTACAGGCTTTGGCAYTACCCTTGTACTGTCAACTACA  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ....................................................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
P9-B6.B12-B2       .....G..............................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ...........................................................C........................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      .....G..............................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ..........................................................................A.....................C...  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                         1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CCCTGTTTAAAGTCAGGATGTACGTGGGAGGGGTYGAGCAYAGGCTGGAAGTTGCTTGCAACTGGACGCGAGGCGAGCGTTGCGATCTGGACGACAGGGA  
P9-B1.A10-F3       ....................................................................................................  
P9-B1.B9-C2        ...................................................C.....................T..........................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        .........................................................................T..........................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       ....................................................................................................  
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P9-B6.B12-B2       ............................G.......................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      .......C............................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      T...................................................................................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ....................................................................................................  
 
                         1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CAGGTCCGAGCTCAGCCCGCTGCTGCTGTCTACCACACAGTGGCAGGTCCTTCCGTGTTCYTTCACGACYCTGCCAGCCTTGACTACYGGCCTCATCCAT  
P9-B1.A10-F3       ..................A.................................................................................  
P9-B1.B9-C2        .........................T..........................................................................  
P9-B1.C7-D5        ....................................................................................................  
P9-B1.C8-G8        ....................................................................................................  
P9-B1.G6-H8        ....................................................................................................  
P9-B6.G6-C12       ....................................................................................................  
P9-B6.C12-E4       ....................................................................................................  
P9-B6.D10-G1       .........................T..........................................................................  
P9-B6.B12-B2       .........................................................C..........................................  
P9-B6.C3-G10       ......................................................................A.............................  
P9-Plas.B2-G3      ...............T....................................................................................  
P9-Plas.1/1-3-B12  ....................................................................................................  
P9-Plas.D7-D9      .........................................................C..........................................  
P9-Plas.A5-H6      ....................................................................................................  
P9-Plas.E8-H6      .........................T..........................................................................  
P9-Plas.F11-E4     ....................................................................................................  
P9-Plas.1/1-2-C5   ...........................A........................................................................  
 
                         1510      1520      1530      1540      1550      1560      1570      1580      1590      1600         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC        CTCCACCAGAACATCGTGGACGTGCAATACTTGTACGGRGTGGGGTCAAGCATTGTGTCCTGGGCCATYAAGTGGGAGTAYGTCATCCTYYTGTTTCTCC  
P9-B1.A10-F3       ....................T...............................................................................  
P9-B1.B9-C2        ....................T...............................................................................  
P9-B1.C7-D5        ....................T...............................................................................  
P9-B1.C8-G8        ........................................................................................C...........  
P9-B1.G6-H8        ....................................................................................................  
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P9-B6.G6-C12       ....................T...............................................................................  
P9-B6.C12-E4       ....................T...............................................................................  
P9-B6.D10-G1       .................................................................................A..................  
P9-B6.B12-B2       ....................................................................................................  
P9-B6.C3-G10       ....................................................................................................  
P9-Plas.B2-G3      ....................................................................................................  
P9-Plas.1/1-3-B12  .........................................A..........................................................  
P9-Plas.D7-D9      ....................................................................................................  
P9-Plas.A5-H6      ..................................................T.................................................  
P9-Plas.E8-H6      ....................................................................................................  
P9-Plas.F11-E4     ....................T...............................................................................  
P9-Plas.1/1-2-C5   ....................T.......................................C.......................................  
 
                         1610      1620      1630      1640      1650      1660           
                   ....|....|....|....|....|....|....|....|....|....|....|....|....| 
P9-BCC             TGCTTGCAGAYGCGCGCATCTGCTCCTGCTTGTGGATGATGTTACTCATATCCCAAGCGGAGGCG  
P9-B1.A10-F3       .................................................................  
P9-B1.B9-C2        .................................................................  
P9-B1.C7-D5        .................................................................  
P9-B1.C8-G8        .................................................................  
P9-B1.G6-H8        .................................................................  
P9-B6.G6-C12       .................................................................  
P9-B6.C12-E4       .................................................................  
P9-B6.D10-G1       .................................................................  
P9-B6.B12-B2       .................................................................  
P9-B6.C3-G10       .................................................................  
P9-Plas.B2-G3      .................................................................  
P9-Plas.1/1-3-B12  .................................................................  
P9-Plas.D7-D9      ...........................................................A...GT  
P9-Plas.A5-H6      .................................................................  
P9-Plas.E8-H6      .................................................................  
P9-Plas.F11-E4     .................................................................  
P9-Plas.1/1-2-C5   .................................................................  
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10.2 Appendix 2 
 
Mean genetic distance between SGA-derived HCV sequences isolated from 
plasma and liver.  
 
STDEV: Standard Deviation. ND: Not Done, due to limited data.  
P-values are calculated by two-way unpaired t-test between the genetic 
distances of individual sequences.  
NS: non-statistical significant,  *: p<0.05, **: p<0.005, ***: p<0.001 
Table 10.1: Mean genetic distance (patient 1) 




Table 10.3: Mean genetic distance (patient 4) 
 
 
Table 10.4: Mean genetic distance (patient 5) 












10.3 Appendix 3 
Shannon entropy calculated for SGA-deriving sequences deriving from the same 
anatomical site and between sites. 
 
Two-tailed paired t-test: *: p < 0.05, **: p < 0.01  ***: p < 0.001, NS: Not Significant. 
r2: Pearson’s correlation coefficient. All correlation coefficients are significant (p > 
0.001) 
Table 10.7: Shannon entropy (patient 1) 








Table 10.9: Shannon entropy (patient 4)  
 
Table 10.10: Shannon entropy (patient 5) 
Table 10.11: Shannon entropy (patient 7) 
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10.4 Appendix 4 
BLOSUM62 similarity score for inferred HCV amino acid sequences isolated 
from plasma and liver collected from patient 1, 2, 4, 5, 7 and 9. 
 
STDV: Standard deviation. ND: Not Done, the analysis has not been possible 
due to limited samples.   
Table 10.13: Amino acid identity score by BLOSUM62  (patient 1) 




Table 10.15: Amino acid identity score by BLOSUM62  (patient 4) 
 
Table 10.16: Amino acid identity score by BLOSUM62  (patient 5) 




Table 10.18: Amino acid identity score by BLOSUM62  (patient 9) 
 
 
